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Abstract 
Methicillin resistant Staphylococcus aureus (MRSA) is a major pathogen in 
causing nosocomial infections in hospitals and recently also implicated in community 
outbreaks. MRSA causes a wide spectrum of infection including localized infections 
such as soft tissue, osteomyelitis, abscess, systemic sepsis and is associated with high 
morbidity. 
MRSA is endemic in Hong Kong hospitals. In this project, contemporary MRSA 
isolates causing bacteraemia from Hong Kong hospitals were characterized by 
phenotypic, molecular methods and the presence of virulence determinants. Two 
hundred single patient, non-duplicated isolates from Prince of Wales Hospitals (PWH), 
Princess Margaret Hospital (PMH), Pamela Youde Nethersole Hospital (PYNEH) and 
Tseung Kwan O Hospital (TKOH) from January, 2000 to April, 2002 were included. 
Four major Hong Kong clonal types (HKCT I-IV) have been identified using a 
combination of antibiotic resistance profile, phage typing, pulsed field gel 
electrophoresis (PFGE), PCR of SCCmec and agr, multi-locus sequencing and coa 
sequencing. The presence of enterotoxins, exfoliatin toxins, adhesins and other toxic 
genes were also characterized. 
The predominant clone, HK clonal type I (HKCT I) and its variants included 125 
pf the 200 MRSA isolates with PFGE types A-E and H and belonged to SCCmec type 
I 
Ill, agr group I, sequence type ST239 by MLST. These isolates have the resistance 
profile to tetracycline (T), erythromycin (E), clindamycin (D), gentamicin (G), 
tobramycin (T), ciprofloxacin (C) [TEDGToCi] and possess the virulence genes: lukE, 
cna,fib,fnbB, hla with/without sea. The enterotoxin gene sea was also present in 
isolates with PFGE types B，D and E but absent in types A, C and H. Variants of each 
HKCT differ by partial characteristic features, e.g. the addition or deletion of exotoxin 
gene(s) or/and the antibiogram. Isolates of HKCT I were present in all four hospitals 
studied and showed high similarity with the Brazilian clone, United Kingdom 
eMRSA-1, 4，7 and-11 as they carry the same SCCmec, agr, sequence type and similar 
set of virulence genes. They were also clustered into the phylogenetic tree of coa 
sequence. The isolates fell into the group of ST239-MRSA-III derived from the clonal 
complex CC8in the evolutionary model of emergence of MRS A. 
HK clonal type II and its variants included 35 isolates with PFGE type F, SCCmec 
type II, agr group II，sequence type ST 5 by MLST and virulence genes: sec, tsst-1, seg, 
sei, lukE and hla. The isolates of this clonal type were present in three of the four 
hospitals and showed the same characteristics of the New York/Japan clone with the 
clonal complex of CC5. HKCT III and its variants was another major type which 
included 10 isolates with PFGE type Q SCCmec I or II, agr IV, ST 45 and virulence 









親王醫院、瑪嘉原醫院、挪打素醫院、將軍澳醫院裏的病人血液感染的2 0 0 
MRSA菌株進行硏究 
本硏究應用藥敏測試、脈衝電游（PFGE)�phage typing (噬菌體分類）、 





A-E, H 型，狐mecin, agri, sequence type ST239 及致病基因：從c, Ust-1, seg, sei, lukE 
及 hla�有 Tetracycline (四環素)，Erythromycin (糸工黴素)，Clindamycin (氯林可黴素)， 
Gentamicin (慶大黴素),Tobramycin (妥布霉素),Ciprofloxacin(環丙沙星）的耐藥類型， 




部的四所醫院裏並與Brazilian clone,英國的eMRSA 1, 4, 7及 - 1 1高度相似。這個 
論點建基於牠們擁有相同的SCCmec, agr, sequence type及相似的致病基因組合。 
牠們亦於系統發育譜圖上聚集一塊。這些菌彳朱屬於clonal complex CC8衍生出的 
ST239-MRSAS-III 的類別。 
至今，發現35枚菌株屬於HKCTII及其變異體帶有PFGE F型,^CCmecIl 
agrll S T 5 及致病基因 : l u k E , cm, fib, fnbB, hla�牠們只存在於其中三所醫院 
裏並與歸類於clonal complex CC5的New York/Japan clone擁有相同的特性。HKCT 
III及其變異體有26枚帶有PFGE G型,SCCm^c I / II, agr IV, ST 45和致病基因:從g, 
sei, sej, cna及hla的菌株。HKCT IV只有3枚菌株並只存在於TKOH� 
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Chapter 1 Introdiiction 
Chapter 1 Introduction 
1.1. Methidllin-resistant Staphylococcus aureus 
Staphylococcus aureus {S. aureus) belongs to the Staphylococcus genus in the group of 
Bacillus/Clostridium. It is assigned in the Bacillus/Staphylococcus group 
phylogenetically and in the family of Staphylococcaceae (Kuroda et. al., 2001; 
Wilkinon, 1997) (http://www.ncbi.nlm.nili.gov/taxonomy). It was closely related to 
the Bacillus group as fondamental proteins of S. aureus strain N315 were 52% similar to 
those ofB. subtilis and B. halodurcms (Kuroda et. al., 2001). 
1.1.1. Definition and Identification 
The main distinctive diagnostic characteristic of S. aureus is the production of coagulase 
that converts plasma fibrinogen to fibrin. The other characteristics include nucleases 
degrading DNA and the presence of clumping factor that clots plasma (Humphreys, 
2002). 
Other than the conventional identification method, commercial kits API STAPH and ID 
32 STAPH (bioMerieux, France) are available to identify S. aureus. Selective media, 
such as mannitol salt agar, have also been used for screening for S. aureus (Blair et. al., 
1967). 
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1.1.2. Antibiotic resistance 
1.1.2.1. Methicillin/oxadllin resistance 
MRS A is defined as a S. aureus strain resistant to 1 |Lig of oxacillin disk on disk diffusion 
test (NCCLS, 2000). MRSA encodes a special penillicin-binding protein, PBP2a (or 
PBP2'), which has a low affinity for P-lactam antibiotics including methicillin. The 
PBP2a protein is a transpeptidase allowing formation of cross-bridges in bacterial cell 
wall peptidoglycan but cannot be inhibited by P-lactam antibiotics. 
1.1.2.2. Other antibiotic resistance 
MRSA are often multi-drug resistant. Many transposons (Tn) have been found in 
plasmids and antibiotic resistance island to encode antimicrobial resistance. Tn3853 
and Tn4002 encode p—lactamase resistance (Lyon and Skurray, 1987). Tn4001 and 
Tn3851 are responsible for the resistance to gentamycin, kanamycin and tobramycin 
(Byrne et al., 1990; B. R. Lyon and R. Skurrary, 1987). Tn554, which is the most 
common transposon, encodes spectinomycin and inducible resistance to erythromycin 
(Murphy et al., 1985). 
2 
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1.2. Evolution of MRS A 
The excellent environment adaptability of MRS A is due to the mobile elements within 
the genome or extra-chromosomal as the success of survival depends on the 
antimicrobial resistance and a wide range of virulence factors. These elements are 
plasmids, transposons, pathogenicity islands and SCCmec elements (Grubb, 1998; 
Novick, 2003; Ito et al., 2001; Ma et al., 2002). 
1.2.1. Staphylococcal Chromosome Cassette mec {^CCmec) 
In 1961, methicillin resistance in S. aureus was reported (Jevons, 1961). The 
antimicrobial resistance is encoded by the mecA gene that produces PBP2' or PBP2a ,a 
transpeptidase that catalyzes the formation of cell-wall and binds to all P-lactam 
antibiotics at low affinity to enable bacterial survival (Chambers and Sacheva, 1990; 
Hartman and Tomasz, 1984; Reynolds and Brown, 1985). 
The mecA gene was located in the Staphylococcal Chromosome Cassette mec (SCCmec) 
which is 21-67 kb in size (Ito et al., 1999; Katayama et al., 2000). Four types of 
SCCmec have been identified up to date and all four are constituted by ccr 
(chromosome cassette recombinase) complex and mec complex (Ito et al., 2001; Ma et 
al., 2002). The structure of the four SCCmec is shown in Fig. 1.1. 
3 
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The SCCmec/was identified in MRSANCTC 10442, which is known as the archaic 
clone and isolated in England in 1961. The SCCmec II was discovered from MRS A 
isolates N315 isolated in Japan. The SCCmec / //was firstly found from MRS A 
isolates 85/2082 isolated in New Zealand (Ito et al., 2001). The SCCmec IF was found 
in two MRSA isolates (CA05 and 8/6-3P) from a paediatric hospital in Chicago (Ma et 
al., 2002), and also in representative isolates from Poland and Portugal (Oliverira et al., 
2001). 
The ccr complex contains ccrA and ccrB for excision and integration at a unique 
location {attBscc) (Ito et al., 1999; Katayama et al., 2000). SCCmec I, -11, -IIIand -IV 
contains type 1, -2, -3 and -2 ccr complex, respectively (Hiramatsu et al., 2001). 
The mec complex contains at least mecl and mecRl genes. The gene mecRI encodes 
signal-transduction protein that senses the penicillin-binding domain and releases an 
active protease by autocatalytic cleavage. The protease then destroys the Mecl 
repressor encoded by mecl and leads to the expression of methicillin resistance (Zhang, 
2001; Sharma et al., 1998). 
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The four types of SCCmec differ from each other by the antibiotic resistance 
phenotypes located in the mec complex. SCCmec I and -IV, which both have a class B 
mec complex, only carry P-lactam resistance (Ito et al., 2001; Ma et al., 2002). 
SCCmec II carries Tn554 and linearised pUB 110. Tn554 carries ermA which 
encodes for erythromycin resistance and spc which encodes for spectinomycin 
resistance (Murphy et al., 1985). pUBllO carries aadD for resistance to kanamycin and 
tobramycin and ble for bleomycin resistance (Mckenzie et al., 1986). SCCmec III 
carries Tn554, \|/Tn553, linearised pT181 and mer. \j/Tn554 encodes for cadmium 
resistance (Hiramatsu et al., 2001). pT181 carries tet which encodes for tetracycline 
resistance and the mer gene encodes for mercury resistance (Dubin et al., 1992). In 
addition, insertion sequence, IS431, has been found in all four SCCmec, so it was 
thought to have involved in the transfer of resistance genes (Barber is-Maino et al., 
1987). 
Subgroups of SCCmec have also been described (Ito et al., 2001; Oliveira et al., 2001). 
SCCmec IVa and -IVb differ in the left extremity region (Ma et al., 2002). SCCmec lA 
differs from-/by the presence of pUBllO (Oliveira et al., 2001). SCCmec IIIA varies 
f rom-/ / /by lacking pT181 (Oliveira et al., 2002). 
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Fig. 1.1(a) Structure of four types of staphylococcal cassette chromosome mec 
(SCCmec). 
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indicated by asterisks of different size); Black regions: outside SCCmec element. Adopted from K. 
Hiramatsu et al. 2001. 
1.2.2. The origin of mec element 
The origin of MRSA SCCmec is not known. However, a gene found on the 
chromosome of S. sciuri encoding a PBP with 88% homology to PBP2a of MRSA has 
been identified (Wu et al.，1996). 
1.2.3. The acquisition of SCCmec: from MSSA to MRSA 
The acquisition of SCCmec is thought to be the event for methicillin-susceptible S. 
aureus (MSSA) to become MRSA (Hiramatsu et al., 2001; Ito and Hiramatsu, 1998; 
Oliveira et al., 2002). Early MSSA and MRSA isolates in Denmark between 1957 and 
1970 had been analyzed. Both of them were very similar in terms of phage group 
pattern (group III/ or 83A) and antibiotic profile (penicillin, streptomycin, tetracycline) 
except the methicillin resistance (lessen et al., 1969). Molecular typing (spa typing, 
MLST and PFGE) also confirmed their close relationship (Crisostomo et al., 2001). 
Early MRSA isolates in the UK had been shown to be very similar to the early Denmark 
MRSA isolates as both of them had the same phage group and antibiotic profile (Jevons, 
1961; Stewart and Holt, 1963). Therefore, early Denmark and UK MRSA isolates 
were thought to the archaic strains of MRSA in Europe (Crisostomo et al., 2001; de 
Lencastre et al., 2000; Oliveira et al., 2002). Those archaic clones have the common 
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molecular characteristics: 1) low methicillin minimum inhibition concentration (MIC) 
value (6-25 |ig/ml); 2) heterogeneous expression of the resistance; 3) Clal-mecA 
polymorphism II; 4) absence of mecl, the repressor of mecA; and 5) absence of Tn554 
(de Lencastre et al., 2000). 
The evolution of MRSA was recently found to involve multiple steps for successful 
MSSA lineages to become MRSA. Up to now, five major clonal lineages have been 
identified and they were CCS, CCS, CC22, CC30 and CC45 (Robinson and Enright, 
2003). Different mec elements (SCCmec I-IV) were acquired as the lineages evolved. 
For example, the Iberian clone (ST247, SCCmec I) was found to evolve from Archaic 
clone (ST250, SCCmec I) which in turn derived from ST250-MSSA. And the 
ST250-MSSA evolved from ST8-MSSA (Enright et al, 2002). 
1.2.4. Five pandemic clones 
In addition, based on MLST typing, five pandemic clones come from two distinct 
ancestors (Oliveira et al., 2001; Oliveira et al., 2002). Three of them, the Iberian, 
Brazilian and Hungarian clones were suggested to be derived from a common ancestor 
with a genotype similar to archaic clone in Europe. The other two pandemic clones, 
New York/Japan and Paediatric clones had a different genetic background. The 
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prevalent epidemic MRSA strains in UK, eMRSA-15 and eMRSA-16, that have unique 
MLST profiles, were also thought to be derived from a completely different genetic 
background. 
Hiramatsu and colleagues (Hiramatsu et al., 2001) have demonstrated that a few MRSA 
isolates recovered in 1980s have an intact mecl gene within its class A mec complex. 
These isolates were named "Pre-MRSA" as they had low methicillin MIC value (<8 
|Lig/ml). The Pre-MRSA and the clinical MRSA strains carrying SCCmec II or -III 
share the same mec complex, except that these clinical strains have mutation in the mecl 
gene or at the operator region of mecA (the binding site of Mecl repressor) (Hiramatsu 
et al., 2001). 
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1.3. Epidemiology of MRSA 
Since the emergence of methicillin-resistance in S. aureus in 1960 (Jevons, 1961) after 
the introduction of methicillin in 1959, the number of MRSA isolates declined in mid 
1970s but a dramatic increase in MRSA was reported in the late 1970s throughout the 
world, as in USA (Panlilio et al., 1992) and some European countries (France, Italy and 
Spain) (Voss et al., 1994). 
The usual antibiotics such as P-lactams, erythromycin, clindamycin, tetracycline and the 
aminoglycosides were often ineffective and consequently vancomycin was the only 
available drug for MRSA(Grubb, 1998; Hiramatsu et al, 2001; Wilma, 2001). 
However, vancomycin-resistant MRSA was isolated in 1996 in Japan (Hiramatsu, 
1998). 
The global spread of MRSA has resulted in five pandemic clones. The Iberain clone 
was reported in 1989 in Spain and later in Portugal, Belgium, Italy, Germany, the UK, 
Switzerland, France, Czech Republic, Poland and the USA (Mato et al., 1998; Oliveira 
et al., 1998, Oliveira et al., 2001; Santos Sanches et al., 1995). The Brazilian clone 
was identified in 1992 in Brazil and then in Portugal, Argentina, Uruguay, Chile, and the 
Czech Republic (Aires de Sousa et al., 2001; Aires de Sousa et al., 1998; Melter et al., 
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1999; Oliveira et al., 1998; Oliveira et al., 2001; Teixeira et al, 1995). The Hungarian 
clone was widely spread in Hungarian hospitals and later in Taiwan (de Lencastre et al., 
1997; Oliveira et al., 2001). The New York/Japan clone was found in New York, New 
Jersey, Pennsylvania, and Connecticut and one hospital in Tokyo, Japan. The 
Paediatric clone was described in 1992 in a paediatric hospital in Portugal and also in 
Poland, USA, Argentina, and Columbia (Aires de Sousa et al., 2000; de Lencastre et al., 
1996; Gomes et al.,, 2001; Oliveira et al., 2001; Sa-Leao et al., 1999). Table 1.1 shows 
the genetic backgrounds of the pandemic clones. 
Table 1.1 Genetic backgrounds of the pandemic clones 
Clonal Type spaA type motif MLST profile* SCCmec type 
Archaic MBQBLO 3-3-1-1/12-4-4-16 I 
Iberian MBQBLO 3-3-1-1/12-4-4-16 lA 
Brazilian KAOMQ 2-3-1-1-4-4-3 IIIA 
Hungarian KAOMQ 2-3-1-1-4-4-3 III 
NY/Japan DMGMK 1-4-1-4-12-1-10 II 
Paediatric DMGMK 1-4-1-4-12-1-10 IV 
Key: * sequence type of arc-aro-glp-gmk-pta-tpi-yqi 
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1.3.1. MRSA Infections 
S. aureus infections can be either categorized into community-acquired and 
hospital-acquired. Community-acquired infections cause deep and superficial skin 
infection, pneumonia, endocarditis, septic arthritis and oseteomyelitis. 
Hospital-acquired infections include wound infections of surgical sites, catheter-related 
septicaemia, prosthetic-valve endocarditis, and septic arthritis of prosthetic joints 
(Humphreys, 2002; Wilma, 2001). Hospital acquired MRSA were found to carry agr I 
and -II frequently. They are often characterized by multiple drug resistance and a 
common antibiotic resistance pattern was penicillin, erythromycin, clindamycin, 
chloramphenicol and sometimes gentamicin (Fey et al., 2003). The community-acquired 
MRSA will be discussed in section 1.3.2. 
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1.3.2. Community-acquired MRSA 
Community-acquired MRS A (C-MRSA) (Suggs et al., 1999; Chambers, 2001) is 
increasingly reported in a number of countries such as Australia, New Zealand, the UK, 
Canada, and the USA (Embil et al., 1994; Gross-Schulman et al., 1998; Herold et al., 
1998; Maguire et al., 1998; Nimmo et al., 2000; Rings et al, 1998; Stacey et al., 1998) 
in recent years. Analysis of the C-MRSA isolates in France, Australia and Japan has 
demonstrated that they carry SCCmec IV element and were genetically diverse (Ma et 
al., 2002). SCCmec IV has been found the element most frequently acquired by S. 
aureus (Robinson and Enright, 2003). Those C-MRSA were found to contain a 
combination of virulence and resistance genes distinct from the hospital-acquired 
MRSA (H-MRSA) (Baba et al., 2002; Vandenesch et al., 2003). Also, the C-MRSA in 
European countries, USA and New Zealand were found to contain mostly agr III 
(Vandenesch et al., 2003) 
SCCmec might have been widely distributed in S. epidermidis in healthy carriers and 
enable S. aureus to become MRSA (Wisplinghoff et al, 2003). 
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1.4. Staphylococcal Gene Regulators 
1.4.1. Accessory gene regulator {agr) 
The accessory gene regulator and staphylococcal accessory regulator have been 
identified as the global gene regulator in S. aureus (Morfeldt et al., 1988; Peng et al., 
1988; Cheung et al., 1992; Cheung and Projan, 1994). The virulence determinants were 
found to be under the control in terms of up-regulations and down-regulations by these 
two regulators in different phases of growth (Fig. 1.2). These virulence factors can be 
broadly subdivided into cell surface and secreted proteins. Cell surface proteins include 
microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) 
(Patti et al., 1994a), which help the bacteria to colonize the host tissues, and factors to 
evade the host immune system. Secreted proteins include enzymes degrading host 
components, exotoxins (such as TSST-1 and enterotoxins) and different hemolysins that 
damage host tissues (Projan and Novick, 1997). 
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1.4.1.1 Structure and functions of accessory gene regulator {agr) 
The agr was originally identified as a chromosomal Tn551 insertion (Morfeldt et al., 
1988) that consists of two transcriptional units, RNAII and RNAIII initiated from P2 
and P3 promoters, respectively. RNAII is encoded by four genes, agrB, D, C andv4, of 
which agrA and agrC constitute the response regulator and histidine kinase components, 
respectively, of a classical two-component signal transduction system (Novick et al., 
1995), while agrB and agrD together produce an autoinducing peptide (AIP) which is 
quorum-sensing (Balaban and Novick, 1995; Ji et al., 1995). 
RNAIII is the major effecter of agr operon (Janzon and Arvidson, 1990; Morfeldt et al., 
1995; Novick et al, 1993). In vitro studies have shown that activation of RNAII was 
followed by RNAIII activation implying that RNAII is required for RNAIII expression 
(Xiong et al., 2002). The molecule was capable to suppress expression of cell-surface 
proteins and promote the expression of secreted proteins (Cheung et al., 1992; Peng et 
al., 1988; Recsei, 1986; Regassa and Betley, 1992; Regassa et al., 1992; Vandenesch et 
al., 1991). 
The 5-hemolysin (hid) is also encoded from RNAIII. Although the secreted 5-toxin was 
not involved in the regulation of the virulence factors (Janzon and Arvidson, 1990; 
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Novick et al., 1993), its transcription affected the RNAIII to function (Balaban and 
Novick, 1995). 
1.4.1.2. Autoinducing Peptide (AIP) 
The AIP is a 7-9 amino acid internal cleavage product of AgrD. The AIP contains a 
thio lactone macro cycle followed by an exo cyclic tail. This macro cycle is required for 
agonist activity and for the activation ofArgC receptor (Lyon et al., 2002b). 
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Fig. 1.2 Differential expression of cell-associated proteins and exotoxins dependent on 
the growth phase. 
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The sequence of the AIP in S. aureus is variable, resulting in four specificity groups, 
AIP-I, -II, -III, and -IV. A group is meant that bacteria in the same group produce the 
same AIR This also results in four different receptors for the AIPs in S. aureus, 
designated AgrC-I, -II, -III, and -IV (Ji et al., 1997). AIPs activated their native 
receptors while competitively inhibiting non-native receptors (Ji et al., 1997) and the 
activation and inhibition were reversible (Lyon et al., 2002a). 
This inhibition was a form of bacterial interference that blocked the functions of the 
accessory gene regulator but did not inhibit growth. This enabled the strains to 
produce the most abundant or most potent AIP (Ji et al., 1997; Lyon, 2002b). This 
inhibitory property of AIPs suggested that they have potential to be a therapeutic agent. 
The idea was supported by an experiment that the virulence of S. aureus in a mouse was 
weakened after the simultaneous injection of inhibitory AIPs (Mayville et al., 1999). 
1.4.1.3. Implication of agr I-IV 
The agr groups may give the preliminary information to differentiate the community- or 
the hospital-acquired infection, as agr I and -//were predominantly distributed in the 
hospital-acquired MRSA while agr ///was found mostly in community- acquired MRSA 
(Vandenesch et al., 2003). Agr /Khas been shown to be associated with 
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exfoliatin-producing strains (S. Jarraud et al., 2000). Agr typing can also be used for 
epidemiology or evolutionary studies. 
1.4.2. Staphylococcal accessory regulator {sar) 
Besides the accessory gene regulator, another global gene regulator, staphylococcal 
accessory gene regulator {sar) in S. aureus was also found to affect the expression of 
RNAIII (Morfeldt et al., 1996). 
1.4.2.1 Structure and function of sar 
The staphylococcal accessory regulator was originally found in Tn917 insertion in 
chromosome of a S. aureus clinical isolate, strain DB, and resulted in a multiple effect 
on the expression of a number of exo- and cell-surface proteins (Cheung et al., 1992). In 
this particular strain, sar A inactivation led to decreased production of the 
cell-wall-associated protein and increased expression of extracellular protein. 
The sar locus is 1.2kb in size and encodes 3 different transcripts, sarA, sarB and sarC 
which were initiated from distinct promoters, PI, P2 and P3, respectively (Bayer et al., 
1996) (Fig. 1.3). Due to the overlapping nature of these transcripts, they all share the 
major 372bp open reading frame, sarA, which encodes for the 14.7kDa SarA protein (pi 
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=9.2). Two smaller upstream sequences, 0RF3 and 0RF4, which are located between 
PI and P3, and P2 and P3 respectively, were found to be able to modulate the 
expression of SarA (Chien and Cheung, 1998). 
The interaction between two gene regulators is based on the fact that the effector of agr, 
RNAIII, is transcriptionally controlled by SarA protein. Chien and his colleagues also 
found that the SarA protein level is required for the maximal RNAIII expression (Chien 
etal., 1998). 
1.4.3. Difference in Functions of sar and agr 
The function of agr locus is very clear that its effector, RNAIII, increases the expression 
of exoprotein (enterotoxins and hemolysin) and suppress the expression of cell-bound 
proteins (protein A and fibronectin-binding protein) during the post-exponential phase 
of growth. The sar locus also have the same effect on the enterotoxins, hemolysin and 
protein A but it acts differently on some virulence factors by up-regulating them which 
are downregulated by agr locus (P. M. Dunman et al., 2001). Examples are cna, fnbA, 
fnbB, lipase, and nuclease. The cna, fnbA midfnbB expression were suppressed by 
SarA while lipase and nuclease (exoproteins) expression are enhanced. 
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Fig. 1.3 Organization of the sar locus 
Schematic representation of the sar locus showing various transcripts, sarA, sarC, and 
sarB that originate from the PI, P3, and P2 promoters (arrows), respectively. The ORFs 
are indicated by boxes, promoters are indicated by vertical solid bars, and an inverted 
repeat (IRS) is indicated by a hairpin loop structure. Modified from A. C. Manna et al., 
1998. 
s 膽 I I ^ 
‘ . . .. . . / . \ 
Sar B ) 
P 2 ORH 鐘 ORF3 PI 严I 
^^ (f.o 0*3 0*6 O^ J 1,3^ 
21 
Chapter 1 Introdiiction 
1.4.4. Other sarA homologues, SarS, R，T，U，and other Gene 
Regulators 
Other sar homologues were later discovered subsequently and found to have different 
effect from sar and agr loci on the expression of target genes (Fig. 1.4) These may 
explain the differential effects on the gene expression (Arvidson and Tegmark, 2001; 
Manna and Cheung, 2001; Manna and Cheung, 2003; Schmidt et al., 2003). For 
example, SarS was shown to increase the transcription of spa in both agr, sar A double 
mutant cells, suggesting that SarS was the activator of spa (Recsei et al., 1986; Tegmark 
et al., 2000). On the other hand, the transcription of hla was decreased in sarA mutant 
which implied that SarS was the repressor of hla. As agr is the activator of hla, other 
gene regulators may exist to repress hla transcription and to counteract the function of 
agr, such as repressor of toxins (rot) (McNamara et al., 2000). The 498-bp rot 
down-regulates several known virulence genes such as hemolysins and protease and 
raises the expression of a number of cell-surface adhesins (Said-Salim et al., 2003). 
The protein encoded from rot may act as a repressor or activator to the rot-regulated 
genes. 
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Fig. 1.4 A schematic representation of agr/sarA regulatory network, involving 
sarA homologues 
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In a mutant strain, CYL5614, a multiple gene regulator, MgrA, was found to be a 
regulatory protein which represses hla, spa, protease and coagulase but up-regulates 
nuclease (Luong et al., 2003). The Helix-Tum-Helix (HTH) motif in MgrA suggested 
that it regulates its target genes by attaching to a specific DNA binding site. 
A complex virulence regulatory system network comprising several global regulators is 
being proposed in S. aureus (Arvidson and Tegmark, 2001; Schmidt et al., 2003). 
Those regulators interact with each other in order to make sure virulence factors 
expressed with fine adjustment at the right period of time. 
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1.5. Adhesin and toxin genes 
1.5.1. Adhesins 
Many cell-associated or MSCRAMMs (microbial surface components recognizing 
adhesive matrix molecules) and exotoxins genes have been identified and proved to 
contribute to the pathogenesis of S. aureus, such as endocarditis, meningitis and toxic 
shock syndrome Lowy, 1998; Banks et al., 2003; Ellis et al., 2003). The 
staphylococcal infections were found attenuated but not prevented when certain 
virulence factors were absent (Peacock et al., 2002; Rhem et al., 2000). The 
MSCRAMMs includes fibronectin-binding protein (fnbA,fnbB), fibrinogen-binding 
protein (fib), collagen-binding protein (cna) (Patti et al., 1994a). The distribution of 
those genes in S. aureus varied from strain to strain. The detection of those virulence 
factors is very important as it discloses the pathogenic capacity or virulence potential of 
different strains of aureus and predicts the symptom, severity and prognosis of the 
disease that these factors cause (Baba et al., 2002). 
For distributions of MSCRAMMSs, with the exception of cna and fbpA (one of the 
genes encoding fibrinogen-binding protein), all of the adhesin genes were found in 
every S. aureus strain (Smeltzer et al., 1997). 
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1.5.2. Exotoxins 
The exotoxins include pyrogenic toxin superantigens (PTSAgs), exfoliative toxins, 
hemolysins and leukocidins. The TSST-1 and staphylococcal enterotoxins were 
examples of PTSAgs (Banks et al., 2003; Dinges et al., 2000). Up to now, 15 
enterotoxins (A-0, except F) have been identified (Dinges et al., 2000; Jarraud et al., 
2001; Kuroda et al., 2001; Munson et al., 1998; Orwin et al., 2001; Ren et al., 1994; 
Zhang et al., 1998). 
Staphylococcal Pathogenicity Island (SaPI) is the chromosomal region for encoding 
exotoxin or superantigens (SAgs). There are seven pathogenicity islands (SaPI-1, 
SaPI-2, SaPI-3, SaPI-4, SaPI-ml,nl, SaPI-bov and SaPI-bap) (Novick, 2003) and their 
sequences have been determined (Kuroda et al., 2001; Yarwood et al., 2002; Fitzgerald 
et al., 2001, Cucarella et al., 2001). SaPI-1, the prototype of the pathogenicity island 
family, was found to have tst (gene for toxic shock syndrome toxin-1, TSST-1), sek and 
sel enterotoxin K and -L) (Novick, 2003; Kuroda et al., 2001; Ruzin et al., 2001). 
SaPI-2 contains tst (Chu, 1988; Kuroda et al., 2001) and SaPI-3 has tst and seb, sek and 
sel (Novick et al., 2001; Yarwood et al., 2002). SaPI-4 analysis is still in progress, but 
it has sec (in place of tst), sem, sel and sek (Novick, 2003). SaPI-ml, nl has sec and sel. 
SaPI-bov (Fitzgerald et al., 2001) has tst, sec and sek and SaPI-bap has bap (gene 
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encoding bio film associated protein) (Cucarella et al., 2001). They are all occupied at 
the same position, a t t c site (Ruzin et al., 2001). The acquisition of the virulence genes 
was thought to be aided by prophages. SaPI-1 has been excised and induced to replicate 
by (J)-13 or 80a, and then encapsidated into phage-like infections at high frequency 
(Ruzin et al, 2001). This demonstrated the spread of these mobile elements. In 
addition, enterotoxin A and —D {sea, sed) was encoded by prophages and plasmids, 
respectively. (Betley and Mekalanos, 1985; Bayles and landolo, 1989). 
In German hospitals, about 70% of blood and nosocomial isolates of aureus were 
enterotoxin positive (K. Becker et al., 2003). Among the classical enterotoxin gene，tst 
was the most abundant (-20%) followed by sea (--16%) and sec (-10%). Enterotoxins 
G and —I {seg and sei) (-55%) were the most common and were found in combination 
most frequently (-55%) among the newly identified toxins. Exfoliative toxins were 
less common and only found in about 2% of S. aureus (Becker et al., 2003). 
Hemolysins were also found in high frequency but leukocidins at only 2-4% of isolates 
(Dinges et al, 2000; Peacock et al., 2002). 
The distribution of PTSAgs also varied geographically in Europe and USA as the 
detection ranged from 2% (one isolate) of the Danish isolates to 65% (32 isolates) of the 
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Norwegian isolates in bovine mastitis (Larsen et al., 2002). 
Peacock and colleagues (Peacock et al., 2002) demonstrated that there were seven 
virulence genes significantly more common in invasive isolates than in carrier isolates. 
Those genes were fnbA, cna, sdrE (putative adhesin), sej, eta, hlg, and ica. No 
predominant gene was found and the effect of these factors on virulence was cumulative. 
There were various combinations and the most common were 1) fnbA, sdrE, sej, eta, hlg, 
ica and 2) fnbA, cna, hlg, and ica. The relationship with clonality was examined and 
factors including enterotoxins, tst, exfoliatins {eta and etb), hlb, hid, cna, ebpS were 
fixed in particular clonal complexes, but fnbA, clfA, coa, spa, hlg, hla, ica have spread 
through the clonal complexes. For enterotoxins, tst, exfoliatins, etc, a strong 
association with clonality was observed which implied that the horizontal transfer of 
genes helped to determine the distribution of genes in each clonal complex (Peacock et 
al., 2002). 
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1.6. Typing Methods 
Strain typing is to differentiate strains of the same species into different groups using a 
specific parameter or based on a biological characteristic. It is capable of detecting the 
incidence of outbreak and to watch over the distribution of strains in different clonal 
groups. It also allows differentiation of epidemic/endemic strains from the sporadic 
strains (Arbeit, 1997; Struelens et al., 1998; Zaidi et al., 2003). 
A favoured typing method would be one that is easy to use, with high discriminatory 
power, ease and convenience of interpretation (Arbeit, 1997; Tenover et al., 1994; 
Tenover et al., 1997). 
Table 1.2 summarizes some of the typing methods previously used for studying MRSA. 
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Table 1.2 Characteristics of frequently used strain typing method for MRSA* 
Typing Typability Reproducibility Discriminatory Ease of Ease of 
System** for MRSA Power Interpretation Performance 
Antibiogram All Fair Poor Excellent Excellent 
Phage typing Most Fair Fair Fair Fair 
PFGE All Excellent Excellent Fair Good 
AFLP All Excellent Good Good Fair 
PCR-RFLP All Excellent Good Excellent Excellent 
MecAyTn544 All Good Good Excellent Good 
Binary typing All Excellent Variable Excellent Good 
Spa-typing All Excellent Good Excellent Good 
MLST All Excellent Excellent Excellent Fair 
Plasmid analysis Mbst Good Fair Good Excellent 
^Modified from reference: R. D. Arbeit, 1997 
**Serotyping, Electrophoretic Protein Typing, Inmiiuioblotting, multilocus enzyme electrophoresis and 
ribotyping are not included 
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1.6.1. Phenotypic typing method 
1.6.1.1. Antibiotic-susceptibility Test 
The test measures the microbial resistance to a panel of antibiotics to obtain different 
antibiotic susceptiblity or resistance profiles to study relatedness among isolates. This 
test provides a quick and convenient way for clinical laboratories to determine whether 
an infection is likely to be due to the same strain. However, the accuracy is restricted 
by the hospital environment as antibiotic resistance is under highly unusual selective 
pressures (Zaidi et al., 2003). The susceptibility to one drug may be complemented by 
a mobile element and very genetically distinct strains may share the same profile, or 
isolates from the same strains may differ for one or more antibiotics (Mickelsen et al., 
1985). 
1.6.1.2. Bacteriophage Typing 
This method makes use of the bacteriophage to differentiate strains based on the 
susceptibility to the lytic action by a set of phages (Blair and Williams, 1961). A set of 
23 international phages which is currently used is assigned into five lytic groups (I, II, 
III, IV and V) (Parker, 1981). Phages 29, 52, 52A, 79, 80 belong to the lytic group I ； 
Phages 3A, 3C, 55, 71, 95 belong to group II ； Phages 6, 42E, 47, 53, 54 belongs to 
group m ； Phages 75, 77, 83A, 84 and 85 belong to group IV; Phages 81, 94 and 96 
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belong to group V. 
Although increasing the concentration of phage leads to the improvement of the 
typability of phage typing, the reproducibility will be reduced due to the confosion 
between inhibition and true lysis (Parker, 1972). Additional experimental phages 8 8A, 
90, 83A and 932 have been tested with the ability to distinguish different S. aureus 
strains in England, Spain and Thailand (O'Neill et al., 2001; Richardson et al., 1988). 
Phage typing requires both the phages and control strains to be biologically active, so it 
is time-consuming and labour-intensive to keep the phage system (Zaidi et al., 2003). 
Also, it requires skilled technicians to perform in order to minimize the variation in 
interpretation. 
1.6.1.3. Sero typing 
This technique is antibody-based and determines the relationship among isolates by 
identifying the antigenic determinants expressed on the cell surface. Cellular 
structures like capsule polysaccharides, flagella, and membrane proteins show antigenic 
variation (Zaidi et al., 2003). However, there are a limited number of antigenic 
variations in S. aureus as 80% of clinical isolates express only 2 of 8 capsular 
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polysaccharide serotypes (Karakawa et al., 1985). And some strains have unusual 
antigens which are non-typeable. This limits the potential for differentiation of strain 
types in MRSA. 
1.6.1.4. Electrophoretic Protein Typing and Immunoblotting 
The electrophoretic protein typing analyzes the protein expressed by studying the gel 
pattern after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A target 
protein is radiolabelled before electrophoresis and pattern detected by autoradiography. 
For immunoblotting, the electrophoresed proteins are fixed on a nitrocellulose 
membrane and are followed by exposure to antibodies. The antibodies that recognize 
specific antigens are detected by the enzyme-linked anti-immunoglobulins (Arbeit, 
1995) 
The method has been effective in studies of S. aureus (Mulligan et al., 1988). 
However, the patterns obtained may be difficult to resolve and difficult for strain 
comparison. 
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1.6.1.5. Multilocus Enzyme Electrophoresis 
This method studies a set of proteins, typically 10 common housekeeping enzymes by 
measuring the migration rates of these enzymes (Selander et al., 1986) as the migration 
rate of an enzyme is affected by the altered charge of the protein due to amino acid 
substitution. Allelic variations are indirectly detected by different electrophoresis 
variants, electromorphs. The different combinations of the electromorphs give rise to 
the electrophoretic types (Zaidi et al., 2003). 
However, the method is time-consuming and the method can only offer moderate 
discriminatory power for epidemiology (Zaidi et al., 2003). 
1.6.1.6. Limitations of phenotyping 
Phenotyping depends strongly on the gene expression which has great tendency to vary 
when there are changes in different growth conditions, different growth phase and even 
mutation (Zaidi et al., 2003). Isolates that are almost indistinguishable genetically 
can be considered as different strains due to variation in the phenotype detected. In 
addition, non-typable isolates could be obtained with the phenotypic approach, such as 
in bacteriophage typing (Tenover et al., 1994). 
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1.6.2. Genotyping methods 
1.6.2.1. PGR Assays 
It is the most widely used detection method for diagnosis (Naber, 1994; Fredricks and 
Relman, 1999). Rapid detection method for toxin genes in S. aureus has been 
developed using PGR (Becker et al., 1998; Ladhani et al., 2001; Monday and Bohach, 
1999). The nature of this method is the amplification of specific DNA sequences 
through many cycles of denaturation, annealing, and extension in the thermocycler. 
The advantage of this method is the sensitivity as it requires very small amount of DNA 
as a template (Zaidi et al., 2003). Also, the purity of DNA does not have to be very 
high, and even the template can be partially degraded as long as the target sequence is 
intact. PGR can detect RNA transcribed by a micro-organism (Zaidi et al., 2003). 
The detectable amount of amplified fragment from target sequence only takes a few 
hours. The PGR product may then undergo probe hybridization or restriction cutting 
for restriction fragment length polymorphism (RFLP). 
The major error of PCR is the occurrence of false-positive result (Zaidi et al., 2003). 
Contaminating DNA fragment from previous PCR products can act as a template for 
amplification and false-positive results may follow and thus need to be guarded 
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cautiously with controls. 
1.6.2.2. Pulsed-Field Gel Electrophoresis (PFGE) 
PFGE has been recognized as the "gold-standard" for typing MRSA due to its high 
discriminatory power. For conventional electrophoresis, DNA molecules larger than 
50 kb remain non-separated. PFGE is better than conventional electrophoresis as it is 
capable of resolving large DNA fragments from 50 to 700 kb 
(http://www.nal.usda.gov/pgdic/Probe/v2n3/puls.html). The resolution is increased as 
the DNA move in a zig-zag pattern down the agarose gel. The re-orientation angle 
responsible for the zig-zag pattern is generally between 96-120�. Pulse-time, voltage 
applied and run time also play important roles in controlling the resolution. Lower 
voltage, longer pulse time and longer run time are required for the separation of larger 
DNA molecules. 
One of the most common examples of PFGE is the Contour-clamped homogeneous 
electric field (CHEF) which has the electrodes in a hexagonal contour that offers 
reorientation angles of 60�or 120�. 
The PFGE involves three steps: (1) DNA isolation, (2) restriction enzyme digestion, and 
36 
Chapter 1 Introdiiction 
(3) electrophoresis (Laboratory of Hospital Infection, 1999). In the first step, 
chromosomal DNAwas extracted in agarose plugs and then digested by a rare 
restriction cutter followed by electrophoresis which separates the DNA fragments. 
Clamped homogeneous field electrophoresis has emerged as the one of extensively used 
method for hospital epidemic investigations. However, the lack of standardization 
between laboratories makes the data comparison between laboratories difficult to 
analyze (Shopsin and Kreiswirth, 2001). 
1.6.2.3. Multi-Locus Sequence Typing (MLST) 
The method accesses the alleles of several housekeeping genes by nucleotide 
sequencing of a particular organism (Maiden et al., 1998). The combination of each 
unique allele determines the sequence type of the isolate. The sequencing data 
generated are unambiguous, easy to standardize, and electronically portable. For 
MLST, a global database was set up to allow exchange of sequence data through 
internet (Enright and Spratt, 1999). For MRSA, it has been proven that the allelic 
profile is compatible with the Smal-?FGE pattern (Enright et al., 2000). 
This method is extremely useful in global epidemiological study and can also be a 
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reference tool for comparing isolates between laboratories or different geographic areas 
(Zaidi et al., 2003). However, it is labour intensive and time consuming (Zaidi et al., 
2003). 
1.6.2.4. Amplified Fragment Length Polymorphism (AFLP) 
This method is based on fluorescent analysis of an amplified subset of restriction 
fragments. The restriction fragments are generated by restriction digestion by two 
restriction enzymes, one rare cutter and one frequent cutter followed by pre-selective 
amplification and the selective amplification (Grady et al., 2001; Zaidi et al., 2003). 
The method shows good reproducibility and typabilty but requires advanced equipment 
and multiple steps of procedures resulting only moderate discriminatory power (Grady 
et al., 2001). 
1.6.2.5. Ribotyping 
Ribotyping involves the probing of the 16S ribosomal RNA with the endonuclease-
digested chromosomal DNA. This technique can differentiate strains as the random 
fragment polymorphic patterns generated by endonuclease digestion usually vary from 
strain to strain (Zaidi et al., 2003). It is useful in typing Haemophilus influenza, 
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Pseudomonas capacia, E coli，Salmonella typhi, and Providencia stuartii but has little 
discriminatory power in S. aureus (Tompkins, 1992; Tenover, 1991). 
1.6.2.6. Plasmid Typing 
Bacterial plasmid analysis was the first molecular method to be used as a typing tool 
and can type both gram-positive and gram-negative bacteria (Tenover et al., 1997). 
The technique mainly involved DNA isolation, restriction enzyme digestion, and gel 
electrophoresis. The method helps to determine the spread of antibiotic resistance 
within hospitals and distinguished endemic strains within hospitals during a specific 
period. 
The main disadvantage of plasmid typing is the biological properties of the plasmids. 
Plasmids are extra-chromosomal, transferable and self-replicating, so that bacterial 
strains can gain or lose plasmids. The variation in structure (gain or loss of mobile 
element, such as transposons) also makes plasmid analysis a less desirable method 
(Zaidi et al., 2003). 
1.6.2.7. Restriction Fragment Length Polymorphism (RFLP) 
The method basically involves gel electrophoresis of digested DNA fragments using 
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restriction enzymes. Different RFLP patterns are obtained when there are differences 
in size and number of the fragment. Examples are PCR-RFLP in coa and spa as both 
of them contain many alleles (Frenay et al., 1996; Lawrence et al., 1996; Walker et al., 
1998). The PGR product within coa hypervariable and spa repeat regions is digested 
hy Alul and Rsal, respectively. 
The PCR-RFLP is easy to perform and cost-effective and for studying epidemiology 
and evolution of S. aureus. (Carter et al., 2003) 
1.6.2.8. Nucleic Acid Hybridization 
This method involves probing of CM-digested genomic DNA with a labeled DNA 
fragment, the probe. For studying MRSA, the probe is either recognizing mecA or 
Tn554 (Leski et al., 1998). The C/al-mecA polymorphism and Clal-Tn55A insertion 
pattern, together with Smal-?VGE have shown their success in analyzing epidemiology 
of MRSA in many countries (Aires de Sousa et al., 1996; de Lencastre et al., 1994; 1996; 
1997; Dominguez et al., 1994; Santos Sanches et al., 1995; 1995a; Teixeira et al., 1995) 
and tracking the global dissemination of some MRSA clones (Aires de Sousa et al., 
1998; de Lencastre et al., 1994; Oliveira et al., 1998; Santos Sanches et al., 1995). 
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1.7. Objectives of the project 
The objectives of the project are: 
1) To type contemporary MRSA causing bacteraemia in Hong Kong Hospitals for 
the years 2000 — 2002 using typing methods: antibiotic susceptibility test, phage 
typing, pulsed-field gel electrophoresis, multi-locus sequence typing, coa 
sequence typing; 
2) To characterize the MRSA by their genotypic characteristics, including virulence 
genes detection using PCR. 
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Chapter 2 Materials and Methods 
2.1. Bacterial Isolates & Culture conditions 
2.1.1. Bacterial Isolates 
Isolates from MRSA bacteraemia from Jan 2000 to April 2002 at four hospitals, Prince 
of Wales Hospital (PWH), Princess Margaret Hospital (PMH), Pamela Youde 
Nethersole Eastern Hospital (PYNEH), Tseung Kwan O Hospital (TKOH) in Hong 
Kong were studied. Only single patient isolates were examined. These isolates were 
stored on nutrient agar slopes at room temperature. The number of isolates chosen 
from different hospitals is shown in Table 2A 
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Table 2.1 Number of MRSA isolates in four hospitals 
No. of Isolates in Hospital 
No. of Isolates Prince of Wales Princess Pamela Youde Tseung Kwan 
Hospital Margaret Nethersole O Hospital 
(PWH) Hospital Eastern (TKOH) 
(PMH) Hospital 
(PYNEH)  
200 56 70 66 8 
2.1.2. Reference Strains 
Thirty-three reference MRSA strains were included in this study. They were 
Staphylococcus aureus ATCC 25923, epidemic MRSA 1-16 (eMRSA 1-16) from the 
United Kingdom (gifts of Dr. Enright, Department of Biology and Biochemistry, 
University of Bath, UK), representatives of the four international MRSA clones: 
Brazilian clone (HSJ216), Iberian clone (HPV107), New York/Tokyo clone (BK2464), 
Pediatric clone (HDE288) (gifts of Dr. H. de Lencastre and Dr. A. Tomasz, Laboratory 
of Microbiology, The Rockefeller University, New York, USA) and 12 isolates with 
PFGE types A-E and their subtypes, representative of the predominant types from 
PWH during 1989-2000 (Chio, 2002). The S. aureus ATCC 25923 served as a control 
for the susceptibility test and an internal standard in pulsed-field gel electrophoresis 
(PFGE). 
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2.1.3. Identification of MRSA 
The MRSA strains were identified by routine methods for identification of iS. aureus 
which included a combination of gram stain, colonial morphology, tube coagulase test, 
and DNase test. Methicillin-susceptibility was tested by the disk diffusion method 
according to NCCLS (NCCLS, 2000). A 1 \ig oxacillin disk was placed on a 
Mueller-Hinton agar plate after bacterial inoculation. The agar plate was then read 
after 24hr and 48hr incubation at 30°C. Isolates which gave a clear zone of diameter 
< 10mm were consider as resistant (NCCLS, 2000) 
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2.2. Antibiotic Susceptibility Test 
A total of 233 MRSA strains, including 200 from four hospitals (section 2.1.1) and 33 
reference strains (refer to section 2.1.2) were tested for antimicrobial susceptibility to 
13 antibiotics using disk diffusion method. These antibiotics were tetracycline (T), 
mupirocin (M), netilmicin (N), ciprofloxacin (Ci), gentamicin (G), fusidic acid (F), 
tobramycin (T), co-trimoxazole (C), erythromycin (E), chloramphenicol (C), 
rifampicin (R), clindamycin (D) and oxacillin (O). The disc contents of the 
antimicrobial agents and the interpretive standards are shown in Table 2.2 and were 
based on the guidelines of NCCLS (NCCLS, 2000) and BSAC for disc susceptibility 
testing (J. M. Andrews, 2001). 
The susceptibility test was performed according to the guidelines of NCCLS. (NCCLS, 
2000) MRSA isolates were grown overnight and isolated colonies were suspended in 
0.85% saline to a density equivalent to the McFarland standard 0.5. The suspension 
was inoculated onto two Mueller Hinton agar plates with a sterile cotton swab and 6 
anti-microbial disks placed onto each plate. The plates were incubated overnight at 
370C in air. Methicillin/oxacilllin susceptibility was performed as in section 2.1.3. 
The ATCC 25923 strain was used as control for each run. 
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Table 2.2 Antibiotic dosage used & zone diameter interpretive standards 
, . 1 . . , … X _ , \ Zone Diameter (mm) 
Antibiotics (Abbrev.) Dosage (|ig) r-^   
R I S 
Tetracycline (T) 30 < 14 15-18 > 19 
*Mupirocin (M) 5 <21 >22 
Netilmicin (N) 30 < 12 13-14 > 15 
Ciprofloxacin (Ci) 5 < 15 16-20 >21 
Gentamincin (G) 10 < 12 13-14 > 15 
Fusidic acid (F) 10 < 19 20 >21 
Tobramycin (To) 10 < 12 13-14 > 15 
Co-trimoxazole (S) < 10 11-15 > 16 
Erythromycin (E) < 13 14-22 >23 
Chloramphenicol (C) 30 < 12 13-17 > 18 
Rifampicin (R) 5 < 16 17-19 >20 
Clindamycin (D) 2 < 14 15-20 >21 
"oxacillin (0) 1 | < 10 11-12 > 13 — 
Key: R: resistant area 
I: intermediate area 
S: susceptible area 
The NCCLS interpretive standards for all antibiotics except mupirocin are followed 
(NCCLS, 2000). 
*BSAC interpretive standards for mupirocin (Andrews, 2001) 
46 
Chapter 2 Materials and Methods 
2.3. Pulsed-Field Gel Electrophoresis (PFGE) 
All 233 MRSA strains were typed by pulsed-field gel electrophoresis (PFGE). The 
PFGE protocol was based on Laboratory of Hospital Infection in Central Public 
Laboratory, Colindale, Standard Operating Procedure for PFGE with modifications 
(Laboratory of Hospital Infection, 1999). 
2.3.1. DNA preparation 
Colonies of fresh, overnight cultures of MRSA grown on blood agar plates were 
suspended into 500)il of SE buffer (Appendix II) to turbidity equivalent to McFarland 
standard No. 6. Equal volume of the suspended bacterial cells was mixed with 2% 
low melting agarose (Seaplaque GTG agarose, FMC bioproducts) (Appendix II) and 
dispensed in the mould to allow the agarose plugs to set at room temperature. The 
plugs were placed in bijoux containing 1 ml of gram-positive lysis buffer (Appendix II) 
containing 30 U/ml of lysostaphin (Sigma) and 500)ig/nil lysozyme (Sigma) and 
incubated overnight at ？) TC. The buffer was replaced with 1ml of proteolysis buffer 
containing 60mg/ml of Proteinase K (Sigma) and incubated overnight at 56�C. Plugs 
were washed three times in TE buffer for 30 min at 4T . 
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2.3.2. Restriction digestion 
A portion (approx. 2mm x 3mm) of plug for each isolate was sliced and equilibrated 
with 100|il restriction buffer for 30mins prior to restriction digestion. The 
lOOiLil Smal buffer containing 20U Smalrestriction enzyme (Amersham Biosciences, 
USA) was then added and incubated overnight at C in water bath. 
2.3.3. PFGE 
The digested DNA in agarose plugs were loaded into 1% Seakem Gold agarose gel 
(FMC Bioproducts, USA) (Appendix II). Pieces of X-DNA markers (Amersham 
Biosciences, USA) were placed in every or lanes from samples for inter- and 
intra-gel alignment. ATCC 25923 was included in every gel as a control. The wells 
were sealed with molten agarose. The gel was then placed in the gel tank of the Chef 
MapperTM (BioRad, USA) with �2 L of 0.5X TBE buffer (Appendix) and run at the 
following parameters: running temperature - M '^C; initial switch time - 5sec; final 
switch time - 35sec; run time - 24hr; voltage - 6V/cm; ramping factor - linear, 120�(F. 
Olio, 2002) 
2.3.4. Analysis of band patterns 
The gel images were analyzed by BioNumerics 2.5 (Applied Maths, Belgium). After 
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normalization, bands were manually assigned and comparison of the band patterns was 
performed by selecting Dice band-based similarity coefficients with 1% optimization 
and 1% positive tolerance in band matching. Unweighted pair-group method by 
using average linkages (UPGMA) was chosen to construct the dendrogram. The 
grouping of the PFGE types was determined visually based on Tenover's rule (Tenover 
etal., 1995). 
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2.4. Phage Typing 
The phage typing protocol was based on the Laboratory of Hospital Infection in 
Central Public Laboratory, Colindale, Standard Operating Procedure for phage typing 
with modifications (Laboratory of Hospital Infection, 1995) and a protocol by 
Aucken and Westwell (Aucken and Westwell, 2002). 
2.4.1. Source of Phages & Propagating Strains 
A set of twenty-three international phages (Parker, 1981) in liquid suspension at 
Routine Test Dilution (RTD) lOOOx and twenty-two propagating strains in freeze-dried 
ampoules were obtained (gift of Dr. Tyrone Pitt, CPHLS, Colindale, UK). The phage 
concentration was diluted to RTD lOOx as a working solution. The phage dilution at 
RTD lOOOx and lOOx were kept at 4�C. Phage dilution at RTD lOOx were kept for two 
weeks and discarded. Their propagating strains were kept on nutrient agar slope at 
room temperature. Table 2.3 shows a list of phages and their propagating strains. 
2.4.2. Procedures of phage typing 
A colony from each MRSA strain grown on blood agar plate overnight was inoculated 
in 3ml Brain/Heart Infosion (BHI) broth and incubated at 37°C for 16 hours. The 
culture was then flooded onto a soft nutrient agar plate containing calcium chloride 
( s e e plate) (Appendix). The plate was air-dried at room temperature for � 2 hr. 5jil 
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of each phage at RTD lOOx were applied to the agar plate using an automatic pipette, 
air-dried and incubated at 30�C overnight. The plate was read visually the next day 
and the reaction pattern was interpreted according to table 2.4. Any sample that was 
unable to be typed at RTD lOOx (i.e. no reaction in all phages) was repeated at RTD 
lOOOx. Representative strain of eMRSA 2 was included as a control for every batch 
of phage reactions. 
2.4.3. Routine check of the lytic strength of phages 
To confirm the activity of the phages, each phage lysate was checked weekly by adding 
20|il of the phage suspension at RTD lOOx to the corresponding propagating strain that 
has been inoculated on the SCC plate. Strong lytic reaction should be observed at 
each phage dilution, otherwise fresh suspension would be prepared and the old 
preparation discarded. 
2.4.4 Evaluation of the reproducibility of phage typing 
Five MRS A isolates: eMRSA 2, eMRSA 4, eMRSA 10, eMRSA 13, eMRSA 15 were 
phage typed under three situations so that the phage typing was proved to be 
reproducible. 
These situations are listed as follows (R Chio, 2002): 
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1. Inoculate duplicate grown culture of each isolate on two different SCC plates; 
2. Inoculate one grown culture of each isolate on two different SCC plates; 
3. Inoculate grown culture of each isolate on a SCC plate and repeat the step on 
different day. 
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Table 2.3 23 International phages and their propagating strains 
Phage no. Propagating Strain 
29 NCTC 8331 
NCTC 8507 
52A NCTC 8363 
79 NCTC 8363 
80 NCTC 9789 
3A NCTC 8319 
3C NCTC 8327 
55 NCTC 8358 
71 NCTC 9315 
95 NCTC 10971 
6 NCTC 8509 
42E NCTC 8357 
47 NCTC 8325 
53 NCTC 8511 
^ NCTC 8329 
75 NCTC 8354/eMRSA 12* 
77 NCTC 8356 
83A NCTC 10039 
84 NCTC 10455 
NCTC 10457 
81 NCTC 9717 
94 NCTC 10970 
96 NCTC 10972 
*NCTC 8354 was unable to be revived after shipping and representative of eMRSA 12 
which gave confluent lysis reaction by phage 75 was used as replacement. 
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Table 2.4 Interpretation of lysis reaction 
No. of plaques Grading (lOOx or lOOOx) Interpretation 
Inhibition 0 * Inhibition reaction 
1 - 5 1 Weak reaction 
6 - 9 2 Weak reaction 
20 -49 3 Weak reaction 
> 50 8 * Strong reaction 
Confluent Lysis 9 Strong reaction 
* Inhibition reaction - 0 and Strong reaction - 8 may be ambiguous, but grading by 
visual interpretation was kept consistent by one reader (the investigator) throughout. 
The phage types were determined according to the three-reaction-difference rule (H. M 
Aucken and K. Westwell, 2002). 
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2.5. Detection of SCCmec and mec Genes by Polymerase 
Chain Reaction (PCR) 
2.5.1. DNA preparation for PCR 
DNA templates of the isolates were either obtained from molten plugs prepared for 
PFGE (refer to section 2.3.1) or from overnight broth culture using an extraction kit, 
Nucleospin® Tissue (Machery Nagel, Germany) as per manufacturer's instructions and 
kept at 4�C. Briefly, a slice of plug is molten at 75�C for 15min in 200|LI1 ddH20 in an 
eppendorf and stored at until use. An extraction kit was used as the quality of 
some DNA samples may decrease due to long term storage. For these isolates, 1 ml 
fresh overnight culture was used for DNA extraction. 
2.5.2. Master mix preparation and PCR conditions 
The PCR reaction-mix for each isolate contained 2 fil of DNA template, 1 of each of 
the forward [10pmol/(al] and reverse [10pmol/|il] primer, l\i\ of dNTP mix[5mM], lU 
of Taq polymerase (Qiagen, USA), 2.5|il of lOX PCR buffer and 17.3^1 of ddHzO in a 
total volume of 25|il. 
2.5.3. Electrophoresis of DNA Amplicors (PCR products) 
After PCR, 3.5|il of PCR product and 2.5|il of size marker (50ng/|Lil), $-174 
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DNA/Haelll Marker (Promega, USA) were loaded on a 1% agarose gel (Seakem LE 
agarose, BMA, USA) in 1% TBE buffer for electrophoresis and run at 120V for 1 hour 
in an electrophoresis gel tank (Amersham Biosciences). The gel was stained with 
ethidium bromide (1 |Lig/ml) and visualized by a UV transillumination and image 
system, Thermal Imaging System CTI-500 (Perkin Elmer, Applied Biosystem, USA) 
and recorded as digital image. 
2.5.4. Detection of mecA gene by PCR 
The detection of mec A gene was performed to confirm the identity of the MRSA 
strains. The sequences of forward and reverse primers and PCR conditions are listed 
in Table 2.5. All PCRs (sections 2.5, 2.6, 2.7, 2.8) were done in GeneAmp PCR 
System 9700 (Perkin Elmer, Aplplied Biosystem, USA) 
One positive control, eMRSA-1, containing mecA gene and one negative control ATCC 
25923 (MSSA), were included in each batch of PCR. Internal negative controls 
containing only master mix reagent and water without addition of DNA template were 
also included in each PCR run. 
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Table 2.10 Primers and PCR conditions for eta，eth and tsst-1 genes 
Forward primer (F) and reverse primer PCR conditions** Gene Bank Product 
(R) (performed in GeneAmp PCR Accession no. Size 
System 9700) (seq. region) (bp) 
MecA-F*: Initial denaturation - X52593 
5 ‘-TGGCTATCGTGTCACAATCG-3 ‘ 95°C(15miii); 30 cycles of (1025-1044) 
denaturation - 95�C(45sec)， 
304 bp 
MecA-R*: annealing - 56°C(45 sec), X52593 
5'-CTGGAACTTGTTGAGCAGAG-3' extension - 72°C(45 sec); final (1328-1309) 
extension - 72°C(7 min) 
* Reference: PVannufFel et al., 1995 
** Reference: F. Chio, 2002 
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2.5.5. Detection of SCCmec I-IVhy PGR 
Eight oligonucleotides were chosen for amplification of part of SCCmec I，11,-111 IVa， 
and IVb genes (H. Wisplinghoff et al., 2003) and the respective PGR conditions used 
are listed in Table 2.6. 
Table 2.6 Primers and PCR conditions for SCCmec 
Forward primer (F) and reverse primer (R) Gene Bank PCR PCR conditions 
Accession no. Product 
(seq. region) (fragment 
size, bp) 
al(F)i: AB033763 Initial denaturation -
5‘-AACCTATATCATCAATCAGTACGT-3‘ (24845-24868) SCCmecI 95°C(15mm); 30 
Pc(R)i: (695 bp) cycles of 
5‘-ATTGCCTTGATAATAGCCITCT-3‘ (25539-25522) denaturation -
a2(F)i: D86934 SCCmecII 94°C(45s), annealing 
TAAAGGCATCAATGCACAAACACT (26325-26348) (937 bp) _ 58�C(45s)， 
Pc(R) 1 (27261 -27243 extension -
a3(F)i: AB037671 SCCmec III 72°C(45s); final 
5 ‘-AGCTCAAAAGCAAGCAATAGAAT-3 ‘ (5486-5508) (1791 bp) extension - 72�C(7 
Pc(R)i (7276-7258) min) 
IVal(F)i: AB063172 SCCmec IVa The same except 
5‘-TTTGAATGCCCTCCATGAATAAAAT-3‘ (4726-4750) (455 bp) annealing 
IVa2(R) 1: temperature = 53�C 
5，-AGAAAGATAGAAGTTCGAAAGA-3， (5180-5161) 
IVbl(R)^: AB063173 SCCmec IVb 
5,-AGTACATTTTATCTTTGCGTA-3 ’ (2266-2286) (994 bp) 
IVb2(F)i: 
5 ‘ - AGTCATCTTCAATATCGAGAAAGTA-3， (3259-3235) 
^Reference: H. Wisplinghoff et al., 2003 
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The Iberian clone, New York/Japan clone, Brazilian clone and Paediatric clone were 
the positive controls in each batch of PGR of SCCmec I, II, III and IV, respectively. 
One negative control ATCC 25923 (MSSA), was also included in each batch of PGR. 
Internal negative controls which contained only master mix reagent and water but no 
DNA template were also included in each PCR run. 
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2.6. Multiplex Polymerase Chain Reaction 
2.6.1 Detection of agr I-IV 
Nine oligonucleotides were designed for amplification of part of agr I，II，III，/F genes 
(B. Shopsin et al., 2003) and are listed in Table 2.7. Two separate multiplex PCRs were 
optimized to detect agr I or II and agr III or IV respectively. 
Table 2.7 Primer sequences for agr I-IV 
Forward primer (F) and reverse primer (R) Gene Bank Product PCR conditions 
Accession no. (fragment 
(seq. region) size) 
pan-agr(F)i: 5‘-ATGCACATGGTGCACATGC -3， X52543 agr I (439 initial 
(1990-2008) bp) denaturation -
agr-I(R)i: 5‘-GTCACAAGTACTATAAGCTGCGAT-3‘ (2428-2405) 95�C(15min); 30 
pan-agr(F)i AF001782 agr II cycles of 
(215-233) (573 bp) denaturation -
agr-II(R)i: 94�C(30sec), 
5 ‘ -GTATTACTAATTGAAAAGTGCCATAGC-S ‘ (787-761) aimealing -
pan-agr(F)^ AF001783 agr III 58°C(30 sec), 
(215-233) (406 bp) extension - 72°C 
agr-III(R)i: (Imin); final 
5‘-CTGTTGAAAAAGTCAACTAAAAGCTC-3‘ (620-595) extension -
pan-agr(F)i AF288215 agr IV 72°C(10min) 
(932-950) (657 bp) 
agr-IV(R)i: 5‘-CGATAATGCCGTAATACCCG-S‘ (1588-1569) 
^Reference: B. Shopsin et al., 2003 
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The PCR reaction-mix for agr I and agr II was made with 2\i\ of DNA template, 1 |li1 of 
each of the following primers [10 pmol/|il]: pan-<3gr(F), flgr-I(R),以gr-II(R), l|il of 
dNTP mix[5mM], lU of Taqpolymerase (Qiagen, USA), 2.5 of lOX PCR buffer 
and 16.3)il of dcfflbO to make up a total volume of 25 |LI1. 
For agr III and agr IV, 2 |LI1 of DNA template, 1 |xl of each of the following primers 
[10pmol/|il]: pan-agr(F), agr-in(R), «gr-IV(R), l^il of dNTP mix[5mM], 1 U of Taq 
polymerase (Qiagen, USA), 2.5 |LI1 of lOX PCR buffer and 16.3^1 of ddlfcO were 
added to make up a total volume of 25 [il. 
Two positive controls, the Brazilian clone, containing agr I and the New York/Japan 
clone, containing agr II, and one negative control, eMRSA-16, were included in each 
batch of PCR for agr I & agr 11. And eMRSA 16, containing agr III, and MRSA #33, 
containing agr IV, and one negative control, Brazilian clone, were included in each 
batch of PCR for agr III & agr IV. The positive controls were sent to Macrogen, 
Korea for sequencing to confirm. Internal negative controls that contained only 
master mix reagent and water without DNA template were also included in each run of 
PCR. The PCR products were run on 1 % gel for 1 hour in 100 volts or as according 
to section 2.5.3. 
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2.6.2. Detection of Pyrogenic Toxin Genes 
Twelve pairs of oligonucleotides were designed for amplification of part of enterotoxin 
^-E, G-J {sea-SQe, seg-SQj), exfoliative toxin A 8c B [eta, etb), Toxic Shock Syndrome 
Toxin-1 (tsst-1) (K. Becker et al., 1998; S. R. Monday and G. A. Bohach, 1999) and are 
listed in Table 2.8, 2.9 and 2.10. The multiplex PGR conditions and the primer mix 
preparations (section 2.6.2.1) were based on that of the PHLS protocol (SOP No. 
L-4334/02-00) with modifications. 
Three separate multiplex PCRs were performed to amplify three groups of enterotoxin 
genes, as listed in Tables 2.8, 2.9 and 2.10 respectively. 
62 
Chapter 2 Materials and Methods 
Table 2.10 Primers and PCR conditions for eta，eth and tsst-1 genes 
Forward primer (F) and reverse primer (R) Gene Bank Product PCR conditions 
Accession (fragment 
no. (seq. size，bp) 
region) 
SEA(F)i: Ml8970 sea initial denaturation 
5 ‘-CCTTTGGAAACGGTTAAAACG-3 ‘ (487-507) (127 bp) - 95°C(15mm); 30 
SEA(R)i: cycles of 
5 ‘-TCTGAACCTTCCCATCAAAAA-3‘ (613-592) denaturation -
SEB(F)i: M11118 seb 94°C(lmin), 
5，-TCGCATCAAACTGACAAACG-3， (634-653) (477 bp) annealing -
SEB(R)i: 55�C(lmin), 
5‘-GCAGGTACTCTATAAGTGCCTGC-3 ‘ (1110-1088) extension -
SEC(F)i: AB084256 sec 72°C(2mm); final 
5‘-CTCAAGAACTAGACATAAAAGCTAGG-3‘ (555-580) (271 bp) extension at 
SEC(R)i: 72T(lQmm) 
5 '-TCAAAATCGGATTAACATTATCC-3 ‘ (825-803) 
SED(F)i: M28521 sed 
5 ‘ -CTAGTTTGGTAATATCTCCTTTAAACG-3 ‘ (332-358) (319 bp) 
SED(R)i: 
5，-TTAATGCTATATCTTATAGGGTAAACATC-3， (650-622) 
SEE(F)i: M21319 舰 
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Table 2.10 Primers and PCR conditions for eta，eth and tsst-1 genes 
Forward primer (F) and reverse primer (R) Gene Bank Product PCR conditions 
Accession (product size, 
no. (seq. bp) 
region) 
SEG(F)': AF064773 seg initial denaturation-
5 ‘-CGTCTCCACCTGTTGAAGG-3 ‘ (317-335) (328 bp) 95�C(15min); 30 cycles of 
SEG(R)2: denaturation -
5'-CCAAGTGATTGTCTATTGTCG-3， (644-624) 94°C(lmm), annealing -
SEH(F)2: U11702 seh 55°C(lmm), extension -
5 ‘-CAACTGCTGATTTAGCTCAG-3 ‘ (452-471) (359 bp) 72�C(2min); final 
SEH(R)2: extension at 72°C(10mm) 
5，-GTCGAATGAGTAATCTCTAGG-3， (810-790) 
SEI(F)^: AF064774 sei 
5'-CAACTCGAArTTTCAACAGGTAC-3' (325-347) (466 bp) 
SEI(R)': 
5'-CAGGCAGTCCATCTCCTG-3' (790-773) 
SEJ(F)2: AF053140 sej 
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Table 2.10 Primers and PCR conditions for eta，eth and tsst-1 genes 
Forward primer (F) and reverse primer (R) Gene Bank Product PCR conditions 
Accession no. (product (performed in 
(seq. region) size) GeneAmp PCR 
System 9700) 
eta(F)i: M17347 eta initial denaturation -
5‘-CTAGTGCATTTGTTATTCAAGACG-3‘ (374-397) (119 bp) 95°C(15mm); 30 
eta(R)i: cycles of 
5,-TGCATTGACACCArAGTATTATTC-3， (492-475) denaturation -
etb(F)i: M17348 etb 94°C(lmin)， 
5，-ACGGCTArATACATTCAATTCAATG-3 ’ (51 -75) (261 bp aimealing -
etb(R)i: 55°C(lmin), 
5 ‘ -AAGTTATTCArTTAATGCACTGTCTC-3 ‘ (311-286) extension -
Tsst-l(F)i: J02615 tsst-1 72°C(2mm); final 
5,-AAGCCCTTTGTTGCTTGCG-3， (51 -69) (445 bp) extension at 
Tsst-l(R)': 72°C(10miii) 
5，-ATCGAACTTTGGCCCATACTTT-3 ’ （495-474) 
^Reference: K. Becker et al., 1998 ^Reference: S. R. Monday and G. A. Bohach, 1999 
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2.6.2.1. Primer Mix Preparation for Multiplex PCR 
2.6.2.1.1. Sea-see Multiplex PCR 
2.5|il of each of the following stock primers [lOOOpmol/jil] was added to a sterile 
1.5ml eppendorf tube: SEA(F), SEA(R), SED(F), and SED(R). of each of the 
following stock primers [1000pmol/|il] was added to the same tube: SEB(F), SEB(R), 
SEE(F), and SEE(R). 7.5|ilof each of the following stock primers [ 1 OOOpmol/jil]: 
SEC(F), SEC(R) was then added. 955[il sterile double-distilled water was mixed with 
the primer mix thoroughly. 200(il of the primer mix was aliquot to 0.5ml eppendorf 
tubes and store them at -20''C. 
2.6.2.1.2. Seg-sej Multiplex PCR 
2.5|il of each of the following stock primers [1000pmol/|il] was added to a sterile 
1.5ml eppendorf tube: SEG(F), SEG(R), SEH(F), SEH(R), SEI(F), SEI(R), SEJ(F) and 
SEJ(R). 918|il sterile double-distilled water was mixed with the primer mix 
thoroughly. 200|il of the primer mix was aliquot to 0.5ml eppendorf tubes and store 
them at -20T. 
2.6.2.1.3. Eta，etb，tsst-1 for multiplex PCR 
2.5jil of each of the following stock primers [lOOOpmol/jil] was added to a sterile 
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1.5ml eppendorftube: eta(F), eta(R), etb(F), etb(R), TSST-l(F) and TSST-l(R). 
918s t e r i l e double-distilled water was mixed with the primer mix thoroughly. 200|il 
of the primer mix was aliquot to 0.5ml eppendorf tubes and store them at -lO '^C. 
2.6.2.2. Multiplex Master Mix Preparation 
The PGR reaction-mix for the multiplex PGR for sea-see for each isolate contained 2 
fxl of DNA template, l|il of enterotoxin A-E primer mix, 4|LI1 ofdNTP mix [5mM], 3|il 
ofMgCl2 [25mM], lU of Tag polymerase (Qiagen, USA), 5|LI1 of lOX PGR buffer and 
34.8^1 of ddH20 in total volume of SOjul. The PGR reaction-mix for the multiplex 
PCRs for seg-sej and eta, etb, tsst-1 genes were the same, but with their respective 
enterotoxin G-J and eta/etb/tsst-1 primer mix. 
2.6.2.3. PCR controls for pyrogenic toxins (sea-sej, eta-b, tsst-1) 
Two positive controls, MRSA (#92), MRSA (#91), contains sea, sec, respectively, and 
one negative control, NY/Japan clone, were included in each batch of PCR for sea-see. 
A positive control, eMRSA 3, containing sei and seg, and a negative control, Brazilian 
clone, were included in each batch of PCR for seg-sej as a positive control. A 
positive control, eMRSA 16 containing tsst-1, and a negative control, Brazilian clone, 
were included in each batch of PCR for eta, etb, TSST-1. Internal negative control 
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which contained only master mix reagent and water instead of DNA template was also 
included in each run of PCR. These PCR products used for controls were sequenced 
to confirm their identities. 
Procedures were followed in section 2.5.3 with modifications: 2% agarose gel was 
used and the electrophoresis was run at lOOV for 1.5hr. 
2.6.2.4. Sequencing of PCR products 
For every gene found by PCR, the amplified DNA fragment was purified by 
Micro Spin™ Columns (Amersham Biosciences, USA) and sent to Macrogen, Korea 
for DNA sequencing with BigDye terminator sequencing method with an ABB700 
automatic DNA sequencer to confirm the identity of the genes. 
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2.6.3. PCR for adhesin and toxin genes 
Nine pairs of oligonucleotides were designed for amplification of part of adhesin and 
toxin genes: leukocidin E {lukE), collagen binding protein (cna), fibrinogen binding 
protein (fib), intercellular adhesin A & D {icaA and icaD),fibronectin binding protein 
A 8cB (fnbA & fnbB), hemolysin A &B (hla and hlb) and are shown in Table 2.11. 
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Table 2.11 PCR design for adhesin and toxin genes 
Forward primer (F) and reverse primer (R) Gene Bank PCR PCR conditions 
Accession no. Product 
(seq. region) (fragment 
size.，bp) 
lukE(F)3: 5‘-GACTGATTGCACCTTTAGC-3‘ Y13225 lukE initial 
(551-569) (953 bp) denaturation -
liikE(R)^: 5'-GCAATTGATGAAGCAACTGATG-3' (1503-1482) 95°C(15niin); 32 
cna(F)': 5'-AAGCATTTGCAGCACGAG-3' M81736 cna cycles of 
(227-244) (740 bp) denaturation -
ciia(R)5: 5'-ATATGACCCATAGCCTTGTGG-3, (966-946) 94�C(30sec), 
fib(F)': 5'-AACATTAGCGGCAATAGG-3' X72014 fib annealing -
(158-175) (432 bp) 57�C(30sec), 
fib(R)': 5'-ATTCGCTCTTGTAAGACC-3' (589-572) extension -
icaD(F)i: 5‘-ATGGTCAAGCCCAGACAGAG-3‘ U43366 icaD 72°C(90sec); 
(1963-1982) (198 bp) final extension -
icaD(R)i: '-CGTGTTTTCAACATTTAATGCAA-3' (2160-2138) 72°C(5mm) 
fiibA(F): 5'-CACAAACTGCACAACCAGC-3‘ J04151 fnbA 
(422-440) (1522 bp) 
fiibA(R): 5 ‘-GGATTTGATTCCTCAGAGGAC-3， (1943-1923) 
hlb(F)^: 5'-AGTTGGTGCACTTACTGAC-3' S72497 hlb 
(261-279) (920bp) 
hlb(R)^: 5，-TACTATAGGCTTTGATTGGG-3， (1180-1161) 
fiibB(F): 5 ‘ -GCTCAACCAAGTAACGTCTC-3 ‘ X62992 fnbB 
(904-923) (524 bp) 
fiibB(R): 5'-TTGCTAACCGTAGTCTCACC-3' (1427-1408) 
hla(F)4: 5'-AATTGGCGGCCTTATTGGTG-3' X01645 hla 
(801-820) (299 bp) 
hla(R)4： 5，-CTGTAGCGAAGTCTGGTGAA-3， (1099-1080) 
icaA(F)i: 5‘-TCTCTTGCAGGAGCAATCAA-3‘ U43366 icoA 
(1337-1356) (188 bp) 
icaA(R)i: 5'-TCAGGCACTAACArCCAGCA-3， (1524-1505) 
^Reference: C. R. Arciola et al., 2001; ^Reference: P. Colque-Navarro et al., 2000; ^Reference: A. Gravet 
et al., 1998; ^Reference: G. S. Gray and M. Kehoe, 1984; ^Reference: J. M. Patti et al., 1994; ^Reference: 
S. J. Projan et al., 1989 
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2.6.3.1. Multiplex Master mix preparation for lukE,fib, cna, icaD 
The PCR reaction-mix for each isolate was made when 2 of DNA template, of 
each of the following primers [lOpmol/^il]: lukE(F), lukE(R), fib(F), fib(R)，cna(F), 
cna(R), icaD(F) and icaD(R), 2|LI1 ofdNTP mix [5mM], 2|il of MgCl2 [25mM], lU of 
Taq polymerase (Qiagen, USA), 2.5|xl of lOX PCR buffer and 8.3(il of ddHzO were 
added together. The total volume was 25|LI1. 
2.6.3.2. Multiplex Master mix preparation for fnbA,fnbB, hla, hlb, 
icaA 
The PCR reaction-mix for each isolate was made when 2 |il of DNA template, 0.1|LI1 of 
each of the following primers [10pmol/|il]: fnbA(F) & fnbA(R), 0.5|il of the following 
primers [10pmol/|il]: fnbB(F) & fhbB(Il), l.Sjil of the following primers [10pmol/|il]: 
hla(F) & hla(R), Ijil of the following primers [10pmol/|il]: hlb(F), hlb(R), icaA(F) and 
icaA(R), 2 III ofdNTP mix [5mM], 2|il of MgCl� [25mM], lU of Taq polymerase 
(Qiagen, USA), 2.5^1 of lOX PCR buffer and S.ljil of ddl^O were added together. 
The total volume was 25|LI1. 
2.6.3.3. PCR controls for adhesin and toxin genes 
A positive control, Brazilian clone, contains lukE，cna and fib, and a negative control, 
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eMRSA-9 were included in each batch of PCR of lukE, cna，fib, icaD. A positive 
control, MRSA (#0060, 1993), contains hlbJnbB & hla and a negative control, 
eMRSA-16, were included in each batch of PCR offnbAJnbB, hla, hlb, icaA. 
Internal negative control which contains only master mix reagent and water instead of 
DNA template was also included in each time of PCR 
2.6.3.4. Size of PCR products resolved by gel electrophoresis 
Procedures were followed in section 2.5.3 with modifications: 2% agarose gel was 
used and the electrophoresis was run at lOOV for 1.5hr. 
2.6.3.5. Sequencing of PCR products 
For every gene found by PCR, the amplified DNA fragment was purified by 
Micro Spin™ Colunms (Amersham Biosciences, USA) and sent to Macrogen, Korea 
for DNA sequencing with BigDye terminator sequencing method with an ABB700 
automatic DNA sequencer to confirm the identity of the genes. 
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2.7. Multi-locus Sequence Typing 
2.7.1. Bacterial Isolates 
Representative strains of MRSA strains with PFGE pattern B, C，D ,E, F, Q H, I were 
selected for MLST (#149, #46, #137, #88, #36, #61，#71, #234, #238, #132, #150, 
#175, 176). The sequence type of PFGE type A isolates was obtained in previous 
research (F. Chio, 2002) and that of the international clones was obtained from 
publications (M. C. Enright et al., 2002). 
2.7.2. Primer design 
The sequences of the primers were obtained from MLST website 
(http: / /www. mist. net). 
Table 2.12 shows a list of these primers. 
2.7.3. PCR Master mix preparation 
The master mix for one reaction for the PCR contained 2 jul of DNA template, 1 |LI1 of 
each of the forward [10pmol/|il] and reverse [lOpmol/jil] primer, 1 |il of dNTP 
mix[5mM], lU of Taq polymerase (Qiagen, USA), 5\il of lOX PCR buffer and 37.8|LI1 
of ddHiO, in a total volume of 50|il 
73 
Chapter 2 Materials and Methods 
Table 2.12 PCR/Sequendng Primers for MLST 
Genes Primers Product 
Size (bp) 
arc-F: 5' TTG ATT CAC CAG CGC GTA TTG TC -3' 
arc (Carbamate kinase) 456 
arc-R: 5' AGG TAT CTG CTT CAA TCA GCG -3’ 
aro-F: 5' ATC GGAAAT CCT ATT TCA CAT TC -3’ 
aro (Shikimate dehydrogenase) 456 
aro-R: 5' GGT GTT GTA TTAATAACG ATA TC -3' 
gip (Glycerol kinase) 
gIp-F: 5' CTAGGAACT GCAATC TTAATC C -3’ 
465 
gIp-R: 5, TGG TAAAAT CGC ATG TCC AAT TC -3' 
gmk (Guanylate kinase) gmk-F: 5'ATC GTT TTATCG GGACCATC -3' 
429 
gmk-R: 5' TCATTAACT ACAACG TAATCG TA-3' 
pta (Phosphate pta-F: 5' GTT AAA ATC GTA TTA CCT GAA GG -3' 
474 
acetyltransferase) pta-R: 5' GAC CCT TTT GTT GAAAAG CTTAA-3' 
tpi (Triosephosphate isomerase) 
tpi-F: 5' TCG TTC ATT CTG AAC GTC GTG AA -3' 
402 
tpi-R: 5' TTT GCA CCT TCTAAC AAT TGTAC -3' 
yqi (Acetyl coenzyme A yqi-F: 5' CAG CAT ACA GGA CAC CTA TTG GC -3' 516 
acetyltransferase) yqi-R: 5' CGT TGA GGA ATC GAT ACT GGA AC -3' 
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2.7.4. PCR for MLST gene 
The PCR was performed with the GeneAmp PCR System 9700 (Perkin Elmer, Applied 
Biosystem, USA). The reaction began with initial denaturation at 95°C for 15min, 
followed by 34 cycles of denaturation at 95�C for 30sec, annealing at 55�C for 30sec, 
extension at 72�C for Imin, followed by final extension at 72�C for lOmin. The PCR 
product was resolved by gel electrophoresis, as for section 2.5.2.3. 
2.7.5. Sequencing of PCR products 
The PCR products were sent to Macrogen, Korea for purification and DNA sequencing 
with BigDye terminator sequencing method with an ABB700 automatic DNA 
sequencer. 
2.7.6. Data Analysis 
The sequences of the PCR products were compared with the existing sequences 
available in the MLST website (http://www.mlst.net) for S. aureus and the allelic 
number determined for each sequence. A unique sequence would be assigned a new 
allelic number, and for each isolate, the alleles at each of the seven loci define the 
allelic profile that corresponds to the sequence type (ST). 
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2.8. Sequence typing of Coa gene 
2.8.1. Bacterial Isolates 
MRSA strains representing PFGE pattern F, Q H, I were selected (#36, #61, #71, #234, 
#238, #132, #150, #175, 176) for coa gene sequencing. DNA templates preparation 
was performed as for section 2.5.1. The sequences for representative PFGE patterns 
A-E and of the international clones were previously obtained (Chio F, 2002 ) and used 
for phylogenetic analysis. 
2.8.2. Amplification of Coa Gene by PCR 
A pair of oligonucleotides was used for amplification of part of coa gene (GeneBank 
accession: D00184, X17679, XI6457) (S. Kaida et al., 1989; S. Kaida et al., 1987; P. 
Phonimdaeng et al., 1990) as follows: 
coa(F): 5'-TATAGAGATGCTGGTACAGG-3' (1574-1593, D00184; 1545-1564, 
X17679; 1512-1531, X16457) 
coa(R): 5'-CTGTATGTCTWTGGATAGAG-3 ‘ (2324-2305, D00184; 2052-2033, 
X17679; 2100-2081, XI6457) 
The primer pair amplifies 507，588 or 750 bp fragment of coa gene. "W" stands for 
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A/T variation. 
The PCR reaction-mix for each isolate contained 2 \il of DNA template, l|il of each of 
the forward [10pmol/|il] and reverse [lOpmol/^1] primer each, 1|LI1 ofdNTP mix[5mM], 
lU of Tag polymerase (Qiagen, USA), 5|il of lOX PCR buffer and 37.8)LI1 of diffibO in 
a total volume of 50|li1. 
The PCR was performed in a GeneAmp PCR System 9700 (Perkin Elmer, Applied 
Biosystem, USA). The reaction began with initial denaturation at 95°C for 15min, 
followed by 30 cycles of denaturation at 95°C for 45sec, annealing at 55�C for 45sec, 
extension at 竹C for 45sec, followed by final extension at for 7min 
2.8.3. coa sequencing 
Gel electrophoresis of the PCR products was followed in section 2.5.4. The PCR 
products were sent to Macrogen, Korea for purification and DNA sequencing with 
BigDye terminator sequencing method with an ABB700 automatic DNA sequencer. 
2.8.4. Sequence Analysis 
The sequence results were analyzed by ClustalW Analysis vl.82 from the EMBL 
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Bioinformatics website (http://www.ebi.ac.uk) and the phylogenetic tree was drawn 
with TreeView vl.6.6 (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). 
Sequence similarity would then be observed based on the phylogenetic tree. 
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Chapter 3 Results 
3.1. Bacterial Isolates 
Two-hundred single patient MRSA isolates from bacteremic patients from four hospitals 
were examined. These four hospitals included the major acute hospitals within four of 
the five clusters of hospitals within the Hospital Authority in Hong Kong. 
Staphylococcus aureus, ATCC25923, eMRSA 1-16 from Britain and representatives of the 
four international clones，Brazilian, Iberian, New York/Tokyo, Paediatric clones, 12 
representative MRSA isolates (PFGE type Al, 2, B — E) from PWH for years 1988 — 1999 
previously characterized were also included in this project. 
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3.2. PCR for mecA gene 
The presence of mecA gene by PCR was confirmed in all 200 Hong Kong MRSA isolates 
examined. The reference strains (eMRSA 1-16, Brazilian, Iberian, New York/Tokyo, 
Paediatric clones) (Figure 3.1) were previously confirmed to be MRSA (Chio, 2002). 
However, during this study, the mecA gene was lost in the eMRSA 14 strain and the isolate 
became susceptible to oxacillin and was negative to mecA gene by PCR. 
Figure 3.1 Gel photo showing PCR product of mecA gene 
no. of bp 
1358 bp 
310-^  304 bp 
lane 1: 0-174 DNA/Hae III Marker; lane 2: eMRSA 1; lane 3: eMRSA2; lane 4: eMRSA3; 
lane 5: eMRSA4; lane 6: eMRSA 5; lane 7: ATCC25923(negative control); lane 8: water 
control; lane 9: reagent control 
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3.3. Antibiotics Susceptibility Test 
Table 3.1 shows the number and percentage of MRSA isolates that were resistant to each of 
the antibiotics tested. More than 90% of MRSA isolates were resistant to tetracycline, 
erythromycin, and ciprofloxacin. The resistance rates to netilmicin, mupirocin, fusidic 
acid, rifampicin, cotrimoxazole and chloramphenicol remained low (2-7%) 
Table 3.1 Percentage (%) of the isolates resistant to antibiotics 
Antibiotic resistance 
% of T |e |d G I T O I Ci I N I M I F R S C~~ 
MRSA 
isolates 91 95 55 78 82 95 4 7 4 2 7 2 
(n=200) 
Key: T (tetracycline); E (erythromycin); D (clindamycin); G (gentamicin); 
To (tobramycin); Ci (ciprofloxacin); N (netilmicin); M (mupirocin); 
F (fusidic acid); R (rifampicin); S (co-trimoxazole); C (chloramphenicol) 
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3.3.1. Antibiotic Resistance Profiles of MRSA 
Thirty-three different resistance profiles were obtained among the 200 MRSA isolates 
examined (Table 3.2). Eighteen profiles were present in two or more MRSA isolates and 
fifteen isolates showed unique resistance profiles, U. The predominant resistance profile I, 
TEDGToCi was found in 41% of isolates (Table 3.2). The five major profiles, patterns 
I-V, made up 75% of all the isolates. The antibiotic resistance profiles of the representative 
isolates from United Kingdom (eMRSAl-16) and Brazilian, Iberian, Pediatric and 
NY/Tokyo clones are listed in Table 3.3. 
MRSA with resistance profiles I (TEDGToCi) and III (TECi) were present in all four 
hospitals. MRSA with resistance profiles II, FV, V and VI were present in PWH, PYNEH 
and PMH but absent in TKOH. 
The unique resistance profile is shown in Appendix V - Table 4 
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Table 3.2 Antibiotic Resistance Profiles of MRSA isolates in Four hospitals 
Resistance tvo. of % PWH PYNEH PMH TKOH 
profile isolates (n=56) (N=66) (n 二 70) (n=8)  
(N=200) 
I TEDGToCi 82 41% n ^ ^ 2 
II TEGToCi 27 14% 8 6 13 
m TECi 21 11% 4 6 10 1 
IV TEDCi 9 5% 3 1 5 
V TEGToCiNS 7 4% 2 3 2 
VI TEDGToCiM 5 3% 2 2 1 
VII TEDGToCiF 4 2% 3 1 
VIII TEGToCiS 4 ^ 4 
I X _ E T o C i 2% 4 
X GToCi 4 2% 3 1 
XI TEDGTo 3 1.5% 3 
XII Ci 3 1% 1 2 
XIII TEDGToCiN 2 1% 1 1 
XIV TEDGToCiR 2 1% 2 
XV TEGToCiM 2 1% 1 1 
XVI TEGToCiMC 2 1% 2 
XVII ToCi 2 m 1 1 
XVIII Fd 2 1% 2 
U Unique (single 15 7.5% 7 6 2 
isolates) 
Key: T (tetracycline); E (erythromycin); D (clindamycin); G (gentamicin); 
To (tobramycin); Ci (ciprofloxacin); N (netilmicin); M (mupirocin); 
F (fusidic acid); R (rifampicin); S (co-trimoxazole); C (chloramphenicol) 
Abbrev: PWH, Prince of Wales Hospital; PYNEH, Pamela Youde Nethersole Eastern 
Hospital; PMH, Princess Margaret Hospital; TKOH, Tseung Kwan O Hospital 
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Table 3.3 Antibiotic Resistance profile of UK eMRSA 1-16 and four international 
clones 
Strain Resistance profile 
eMRSA 1 TEDGToSC 
eMRSA 2 ~E ~ 
eMRSA 3 EGTo 
eMRSA 4 TES 
eMRSA 5 TEDGToCiS 
eMRSA 6 ^ 
eMRSA 7 TE 
eMRSA 8 T 
eMRSA 9 TEGToSC 
eMRSA 10 TESC 
eMRSA 11 TEGTo 
eMRSA 12 TEF 
eMRSA 13 TGToF 
eMRSA 14 TEGToCi 
eMRSA 15* 
eMRSA 16 EDToCi 
Brazilian clone TEDGToCiNRSC 
Iberian clone TEDGToCi 
New York/Japan clone EDCi 
Paediatric clone F 
*eMRSA 15 is sensitive to all ten antibiotics 
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3.4. Pulsed-field Gel Electrophoresis 
3.4.1. Optimization of PFGE and Inter-gel Variation 
The PFGE methodology was previously optimized (F. Chio, 2002) for MRSA and the 
control strain, ATCC25923, was included in each batch of PFGE in order to evaluate the 
inter-gel variation. A dendrogram of the pulsotypes from different PFGE runs were 
generated by unweighted pair-group method by using average linkages (UPGMA) (Figure 
3.2). Almost 100% similarity on the pulsotypes of the control was obtained, indicating that 
variation in band patterns between gels was minimized. 
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Figure 3.2 Dendrogram of the pulsotypes of ATCC25923 from different PFGE 
runs 
Dice (0pt:1.00%) (Tol 1.0%-1.0%) (H>0.0% S>0.0%) [0.0%-100.0%] 
PFGE PFGE  
o O) o O) T -
I I I . I I 




I 179/#4ATCC 25923 
179/#5ATCC 25923 
179/#7ATCC 25923 
I 179/#8ATCC 25923 
I I 179/#6ATCC 25923 
Cluster analysis by Dice-band based similarity coefficient, 1% optimization & 1% 
positive tolerance; dendrogram generated by UPGMA 
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3.4.2. Analysis of PFGE profiles 
Of the 200 MRSA isolates studied, nine PFGE types and subtypes, A-I, based on the 
interpretations ofTenover (Tenover et al., 1995) were obtained (Fig 3.3). A dendrogram 
of the representative isolates of different PFGE types and of the reference strains was also 
drawn (Fig. 3.5). PFGE types, A-E, were previously identified to be the predominant types 
at the PWH during the period of 1988-2000 (Figure 3.4) (Ip et al, 2003). Representative of 
these types were also included in this study. Other PFGE types, F-I, were new patterns 
present in this study in MRSA from bacteraemia in four Hong Kong hospitals during the 
period 2000 to 2002. 
The number of MRSA isolates belonging to the PFGE types and their distribution in the 
four Hong Kong hospitals is listed in Table 3.4 PFGE type A is the predominant type and 
constituted 50% (99/200) of all isolates and present in all four hospitals. Among the PFGE 
type A, 5 and 89 isolates belonged to the previously identified subtypes Al and A2 
respectively. The next commonest PFGE types were types F and G, and representing 
17.5% and 13% of all isolates. PFGE type B was the second dominant type present at 
PWH previously (Ip et al., 2003) but only found at one hospital at PMH in this study. 
PFGE types C - G were also present in three of the four hospitals, at PWH, PYNEH and 
PMH. PFGE type H were only present in two hospitals, PWH and PMH, whereas PFGE 
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type I included only 3 isolates and present at TKOH only. 
Cluster analysis using Dice-band based similarity coefficient at 1% optimization and 1% 
positive tolerance was performed and a dendrogram of the PFGE profiles is generated by 
UPGMA and shown in Figure 3.3. PFGE types A-E fell into a cluster 79.42% whilst 
several small clusters were obtained and correlated to PFGE types F-I. 
From the dendrogram shown in Figure 3.5, the band pattern of type A isolate (#203) was 
indistinguishable from that of eMRSA 1. The newly discovered PFGE types (F, G, H, I) 
were not found related with the reference strains. 
Representative strains of PFGE types B-I were selected for further analysis by MLST, type 
F-I strains were chosen for coa sequencing typing. This is because PFGE has a high 
discriminatory power. The corresponding results for PFGE types A - E previously 
obtained (F. Chio, 2002) will also be compared. 
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Table 3.4 Number of MRSA isolates in different PFGE types 
PFGE No. of PWH PYNEH PMH TKOH 
types isolates N=56 N=66 N=70 N=8  
(N = 200) 
^ ^ 30 31 34 4 
B 1 - — 丁 一 
_C 3 1 1 1 
^ 9 2 1 6 
E 5 2 3 
F 35 11 14 10 
^ ^ 5 9 11 1 
J I 8 4 4 
J 3 1 
Unique 11 | 3 8 [ 
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Figure 3.3 Dendrogram of PFGE profiles of MRSA isolates including eM RSA, 
four international clones 
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Cluster analysis by Dice-band based similarity coefficient, 1 % optimization & 1 0/0 
positive tolerance; dendrogram generated by UPGMA 
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Figure 3.4 PFGE dendrogram comparing previously identified PWH pattern with 
pattern A-I 
Dee (Ql:CO%) (Td I.CP/rl .0/。）(H>0%S>Q CJ/o) [OOy.rlCO.0%] 
FFGE PFGE  
8 R S 8 § 
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厂 i I I I I II I I I I I 203 PYNEH A1 
_j I I I I 11 I I I I I I  132 01MB 00033 15/01/01 PMH H 
‘ I I I I I II I I I III 150 01MB00 2577 1 5/03/01 PMH H 
� I I I I I j I M j l 141 01MB000咖 29/01/01 PMH A2 
1 I I II III I I I II K@Phil. F2436 2000 PWH PWH Patern A2 
II II II I I II I I  182 eMRSA-1 A2 
- I ~ I I II I I I I I I I I I I K@Phili. F0060 1 993 PWH PWH Pattern A2 
r M l I I I I I I I II 152 01MB 002655 14/03/01 PMH E 
I I I I I I  I I I I II K@Phil. F5406 1 997 PWH PWH Patern E 
- J- III I I I  I I I II 092 00MB0073U 06^07/00 PMH D1 
^ I I I I I II I I I I II K©Phili. F0556 1 993 PWH PWH Pattern D1 
J - I I I I I I I I I I I 046 296 03/02/01 PWH C1a 
P- II II I I I I II I K@Phil. F4027 1 999 PWH PWH Patern C1a 
I ~ I I I j I I i j j | K@Phili. F 0 7 7 1 1997 P W H P W H Pattern C l b 
I II II I I I I III K@PhiI. FO^O 1995 PWH PWH Patern E 
H I I I I I I I  I I III K©Phjli. F1063 2000 PWH PWH Patern B 
. II I I I I I  I I I  I K@PNIi. F5136 1995 PWH PWH Patern B 
I I~ I II I I I II I I III K@PNIi. F8015 1 996 PWH PWH Patern B 
I II I I I I I I I II I 149 01MB002360 0M)3/01 PMH B 
I I I II III I I II I 036 929 14/03/01 PWH F 
I I I II I I I j I I I I 071 A9212 PYNEH F 
I I I I II I I I III i INI 175 T-235 TKOH I 
I I I II I III II I 丨III 176 T-252 TKOH I 
I I I I II III III 234 G 
I I I I 丨 I 丨丨 11 I I 233 PYNEH G 
Cluster analysis by Dice-band based similarity coefficient, 1% optimization & lo/o 
positive tolerance; dendrogram generated by UPGMA 
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Figure 3.5 PFGE dendrogram (pattern A-I + 16 eMRSAs + 4 international clones) 
Dice (Opt 1.00%) (Tol 1.0%-1.0%) (H>0.0% S>0.0%) [0.0%-100.0%] 
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厂 J I I I I I II I I I I II 150 01MB 002 577 H 
_ i l l I I I I I II 152 01MB 002655 E 
J - I I I I I I I I I II 141 01MB 0008 38 A2 
厂 1 I I I II I I III II 182 eMRSA-1 A2 
—— II I I I II I I I I I 203 A1 
II I I I I I I I I I I I 190 eMRSA-9 
149 01MB 0023 60 B 
J I I I I I I I I III II I 188 eMRSA-7 
fl I I I I 11 I I I I II II K@. NY/Japan 
L II III III I I II I 192 eMRSA-11 
I I I I III II II II 195 eMRSA-14 
j K@. Iberian 
J II II I I I II I II II K@. Pediatric 
I I I I I I I I 11 11 I 036 929 F 
I I I I I I III I 071 A9212 F 
I I I I I I I I I I I I 175 T-235 I 
M I I I I I II I I I I I II 176 T-252 I  
I l l I I I 197 eMRSA-16 
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Cluster analysis by Dice-band based similarity coefficient, 1% optimization & 1% 
positive tolerance; dendrogram generated by UPGMA 
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3.4.3. PFGE patterns and antibiotic profiles 
72% of MRSA isolates with PFGE type A had the major antibiotic resistance profile I 
(TEDGToCi) (Table 3.5). A further 12% of these isolates had the addition of one other 
antibiotic resistance, such as netilmicin, mupirocin or fusidic acid. The remaining 
resistance profile in type A isolates is shown in Appendix V-table 1. 
PFGE pattern B had a resistance profile of TEGToCiNM. PFGE type C isolates had the 
same resistance profile, TEDGToCi, as that of PFGE type A (Table 3.5). 44% of type D 
strains had the resistance pattern V (TEGToCiNS), 33% had pattern VIII (TEGToCiS), and 
also profile VII (TEDGToCiF) and TEGToCiNMS. 40% of type E strains (2/5) had the 
resistance profile V (TEGToCiNS), while the other three isolates had profile VIII, -II 
(TEGToCi) and -IV (TEDCi). 
62.9% of type F strains (22/35) had the resistance profile II (TEGToCi). 61.5% of type 
G strains (16/26) had the resistance profile III (TECi). 75% of type H isolates (6/8) were 
found to have profile IV (TEDCi) and the remaining two isolates had the profile I and -III. 
Clindamycin resistance was found in major resistance profiles of the type A, C and H 
strains but absent in those of the B, D, E, F, G and I strains. 
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The remaining resistance profiles in type F and G isolates are shown in Appendix V - Table 
2 and -3, respectively. 
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Table 3.5 Different PFGE types and their key antibiotic resistance profiles 
PFGE patterns Resistance profile Percentage 
(no. of isolates/total number of (profile no.) (%) of isolates 
isolates in each PFGE pattern) 
A (71/99) TEDGToCi (I) 72 
B (1/1) TEGToCiNM 100 
C (3/3) TEDGToCi (I) 100 
D (4/9) TEGToCiNS (V) 44 
E (2/5) TEGToCiNS (V) 40 
F (22/35) TEGToCi (II) 62.9 
G (15/26) TECi (in) 61.5 
H (6/8) TEDCi (IV) 75 
I (2/3) F (XVni) 66.6 
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3.5. Phage Typing 
The phage patterns for the individual isolates according to PFGE types are shown in the 
appendix (Appendix V-table 6). Overall, a trend may be observed on the phage types 
among these PFGE types. In type A isolates, the majority had inhibition reactions in 
group III phages (6, 47, 54) and some other also had inhibition in group I phages (52, 52A, 
79, 80). Previously, the inhibition in group I and III phages have been regarded as Phage 
Type I (PTl) (F. Chio, 2002) among the PFGE A, C, E isolates. PFGE type B had strong 
reactions to group III phages, and previously named Phage Type II (PT 2) (Chio, 2002). 
In type C isolates, one of them had PT2 pattern but the other two have PT 1 pattern. In 
type D isolates, the pattern was much uniform. They mostly carried PTl pattern though 
one isolate had extra inhibition to group I and II phages. 
Type E and F isolates showed PTl pattern. In type F isolates, strong reactions to phages 
42E and 81 were observed but three of them showed PT2 with a strong reaction to phage 
81. Type G isolates showed strong reactions to phage 42E and 81 which are designated 
as PT3. Type H isolates generally showed PTl but one showed strong reactions to group 
I and III phages. Type I isolates showed strong reactions to phages 6, 47 and 81. 
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Overall, the results for phage typing were inconclusive. Difficulties were also 
encountered when interpreting the results at the volume (5 |al) of phage at RTD x 100 for 
inoculation used, and the method may not have been well optimized for use. Due to 
insufficient supply of phages, these data were not repeated. 
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3.6. ^CCmec Typing 
3.6.1. PCR Optimization 
Two annealing temperatures for PCR had been examined for the reference strains (Figure 
3.6). It was found that 58°C was suitable for amplification of ^CCmec I, -II and -III 
while 53�C was the annealing temperature for PCR of SCCmec IVa. Nonspecific 
amplification was found at for SCCmecI (lane 5; Figure 3.7a) but was eliminated at 
annealing temperature. For SCCmec IVa, was found to be a suitable annealing 
temperature and a weak or even no band was observed in eMRSA-6 and Paedeiatric clone 
when the annealing temperature was 58°C. SCC mec IVb could not be optimized as there 
was no such element in the reference strains, its annealing temperature is estimated as 53^C 
as the calculated melting temperature of the primers are 54°C and Figure 3.7 shows 
the sizes of PCR products of SCCmec I-IV in one gel. 
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Figure 3.6 PCR products of SCCmec I-IV at different annealing temperature 
a) PCR of SCCmec I b) PCR SCCmec II 
(annealing temperature = 53�C) (annealing temperature = 53'C) 
no. of bp 
no. of bp 
1358 bp 
1358 hn 二 
1078 ^ ^ B ^ H M i i l i i i i i l i l i l i l 
I I i n — i 
c) PCR of SCCmec/ d) PCR oi SCCmec II 
(annealing temperature = 58�G) (annealing temperature = 58�G) 
no. of bp 
no. of bp 
1358 bp 
hn I 
i i i l i l l l ^ ^ M M i l l — — 1078 l i i l i i i i i i ^ M M B a a i — — 
603 ^ ^ ^ g j n 
船 ^ ^ H H 3 i �i — I 
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e) PCR of SCCmec III f) PCR of SCCmec IVa 
(annealing temperature = 53V) (annealing temperature = 53"C) 
no. ofbp no. of bp 
1358 bp 1358 bp 
g) PCR of SCCmec III"^ h) PCR of SCCmec IVa 
(annealing temperature = 58�G) (annealing temperature = 58°C) 
no. ofbp no. ofbp 
1358 1358 ^ V m g g g g g g g g ^ g ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
1078 1078 
872 ^ C ^ ^ ^ ^ J I M 872 _ _ _ 圓 
603 603 i i l l l i i i l i i i i i — M 
310-> J l l l l l l l l l l l l l l l J I 
i _ ^ i i i i i i m m m i i i i 
a) & c) lane 1: 0-174 DNA/Hae III Marker; lane 2: eMRSA 5; lane 3: Iberian clone; lane 4: New 
York/Japan clone; lane 5: eMRSA 2; lane 6: ATCC25923(negative control; lane 7: water control; lane 8: 
reagent control 
b) & d) lane 1: <I)-174 DNA/Hae III Marker; lane 2: eMRSA 16; lane 3: New York/Japan clone; lane 4: 
eMRSA 2; lane 5: ATCC25923(negative control; lane 6: water control; lane 7: reagent control 
e) lane 1: <D-174 DNA/Hae III Marker; lane 2: eMRSA 1; lane 3: eMRSA 4; lane 4: eMRSA 7; lane 5: 
Brazilian clone; lane 6: ATCC25923(negative control; lane 7: water control; lane 8: reagent control 
g) lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: eMRSA 1; lane 3: eMRSA4; lane 4: eMRSA7; lane 5: 
ATCC25923(negative control; lane 6: water control; lane 7: reagent control 
f) & li) lane 1: 0-174 DNA/Hae III Marker; lane 2; Iberian clone; lane 3: Brazilian clone; lane 4: eMRSA 
6; lane 5: Paediatric clone; lane 6: ATCC25923(negative control; lane 7: water control; lane 8; reagent 
control 
* The Brazilian clone was not included in the optimization at 58°C 
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3.6.2. PCR and distribution of SCCmec types 
All four types of SCCmec were found among Hong Kong MRSA isolates (Table 3.6). 
Most of the isolates were SCCmec III (60%) and II (25.5%). 10% of isolates belonged to 
unidentified group. 
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Table 3.6 Frequency of SCCmec group in MRSA isolates 
Number (percentage) Reference Strains 
Total = 200 
SCCmecI 12 (6%) eMRSA3,-5, -8,-12, 
Iberian clone 
SCCmec II 52 (26.5%) eMRSA 2, -10, -13, -15, 
-16, New York/Japan clone 
SCCmec III 120 (60%) eMRSA 1，-4, -7，-9,-11, 
Brazilian clone 
SCCmec IV 6 (3%) eMRSA 6, Paediatric clone 
Unidentified 10 (5%) eMRSA 14 (mecA lost) 
Figure 3.7 PCR product of SCCmec I-IV 
R79 I � . ^ ^ ^ B M M I M B I I I — 
603 • 圓 丨 丨 画 隱 画 I I I • 画 • 画 圓 ^ 
^ B 瞧:i:丨::::::::::丨丨:::::::::::::丨:丨；丨ililiipMMMMllMMli 
lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: Brazilian clone(SCCmec III, 1791 bp); lane 3: Iberian 
clone(SCCmecI, 695 bp) ； lane 4: New York/Tokyo(SCCmec II, 937 bp); lane 5: Paediatric clone(SCCm沈 
IVa, 455 bp); lane 6: ATCC25923(negeative control); lane 7: water control; lane 8: reagent control 
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3.6.3. PFGE patterns and SCCmec types 
In PFGE type A, most of the isolates (90%) were SCCmec III (Table 3.7). In PFGE type 
F, 80% were SCCmec II. In PFGE type Q half were SCCmec I and 34.6% were SCCmec 
II. For the isolates with PFGE type B, D, E and H, they were all SCCmec III. And more 
than a half (66.7%) were SCCmec IVm type I strains. 
For the reference strains, the SCCmec are shown in Table 3.6 eMRSA 1 had type A 
PFGE pattern and type III SCCmec whilst eMRSA 9 had type E PFGE pattern and type III 
SCCmec. 
Table 3.7 Distribution of different SCCmec types in isolates with different PFGE 
patterns 
PFGE type 
SCCmec I {Vo) SCCmec II {%) SCCmec III (%) SCCmec IV(%) UID* (%) 
N=200 
A (99) 3 (4.0%) 90 (90.0%) 2 (2.0%) 4 (4.0%) 
B (1) 1 (100%) 
C (3) 1 (33.3%) 2 (66.7%) 
D (9) 9 (100%) 
E (5) 5 (100%) 
F (35) 3 (8.6%) 28 (80%) 3 (8.6%) 1 (2.9%) 
G(26) 9(34.6%) 13 (50%) 1 (3.8%) 1 (3.8%) 2 (7.7%) 
H (8) 8 (100%) 
1(3) 1 (33.3%) 2 (66.7%) 
Unique(ll) 7 (64%) 2(18%) 2(18%) 
Key: * unidentified type 
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3.7. agr Typing 
3.7.1. Optimization of PCR 
Multiplex PCRs of agr I/II and agr III/IV at 58�C annealing temperature were performed in 
reference strains (Figure 3.8a and -b). Optimized PCR conditions for both multiplex PCR 
were found to be identical (refer to table 2.7). Although agr IV could be found in 
reference strains, it could be found among the Hong Kong isolates (Figure 3.8 c). 
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Figure 3.8 PCR of agr I-IV 
a) Multiplex PCR of agr I/II (annealing temperature = 58®C) 
1358 bp 
872 agr II，573bp 
lane 1& 14: <I>-174 DNA/Hae III Marker; lane 2-11: eMRSA 1-10; lane 12: water control; lane 13: 
reagent control 
b) Multiplex PCR of agr III/IV (annealing temperature = 58^C) 
1358 bp 
1078 
agr III, 406 bp 
lane 1& 14: €>-174 DNA/Hae III Marker; lane 2-8: eMRSA 10-16; lane 9: water control; lane 10: 
reagent control 
c) Another multiplex PCR of agr III/IV (annealing temperature = 58®C) ； ― — 
； i :、：、；：僵 
lane 1& 14: <I)-174 DNA/Hae III Marker; lane 2: MRSA#33; lane 3-11: MRSA#202-#210; lane 
12: water control; lane 13: reagent control 
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3.7.2. PCR and Distribution of agr groups 
Figure 3.9 shows the sizes of agr I-IV PCR products in one gel. Four groups of agr were 
found in the isolates (Table 3.8). The majority of isolates were (2gr/which made up 
65.5%. The second major group was agr II (20%). 
For the reference strains, eMRSA 1 and eMRSA 9 had group I agr with type III SCCmec 
(Table 3.5 and 3.8). 
Table 3.8 Frequency of agr group in MRSA isolates 
Number (percentage) Reference Strains 
Total = 200 
agr I 131 (65.5%) EMRSA 1-2, -4-15, Iberian 
clone and Brazilian clone 
agr II 40 (20%) eMRSA 3，New York/Japan 
clone and Paediatric clone, 
agr III 2(1%) eMRSA 16 
agr IV 27 (13.5%) 
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Figure 3.9 PCR product of agr LU and agr III/IV 
1358 
1078 F • • • m m J B B ^ ^ ^ ^ ^ ^ ^ ^ B 
lane 1&13:�-174 DNA/Hae III Marker; lane 2: Brazilian clone(agr I, 439 bp); lane 3: Iberian clone(agr I, 
439 bp); lane 4: New York/Japan(agr II, 573 bp); lane 5: eMRSA 16 clone(agr III，406 bp); lane 6: MRSA 
#33(agr IV, 657 bp); lane 7: eMRSA 16(negative control for agr ////; lane 8: water control for agr I/II; lane 9: 
reagent control for agr ////; lane 10: Brazilian clone(negative control for agr III/IV); lane 11: water control 
for agr III/IV; lane 12: reagent control for agr III/IV. 
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3.7.3. PFGE patterns and agr groups 
From Table 3.9, in PFGE type A, most of the isolates (96%) were agr I. In PFGE type F, 
88.6% were SCCmec II. In type G strains, most (92.3%) were agr IV. For the isolates 
with PFGE type B, C, D, E and H, they were all agr I. And 66.7% of type I strains were 
agr I. 
Table 3.9 Distribution of different agr types in isolates with different PFGE 
patterns 
PFGE type (quantity) 
agrl(%) agr II (%) agr III (%) agrIV{%) 
N=200 
A (99) 96 (96.0%) 3 (4.0%) 
B (1) 1 (100%) 
C (3) 3 (100%) 
D (9) 9 (100%) 
E (5) 5 (100%) 
F (35) 2 (8.57%) 32 (88.6%) 1 (2.86%) 
G(26) 1 (3.8%) 1 (3.8%) 24 (92.3%) 
H (8) 8 (100%) 
1(3) 2 (66.7%) 1 (33.3%) 
Unique (11) 4 (36.4%) 4 (36.4%) 2 (18.2%) 1 (9.1%) 
3.7.4. SCCmec types and agr groups 
A good relationship was found between SCCmec and agr (Table 3.10). It was found that 
90.8% of isolates with agr I carried SCCmec III., 82.5% with agr II and SCCmec //; all of 
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agr HI isolates had SCCmec II. It seems that there was an exception in agr IV isolates as 
more than half had SCCmec II, but 33.3% carrying SCCmec I. 
Table 3.10 Distribution of different SCCmec types in ALL isolates with different 
agr types 
agr type 
/(%) //(%) ///(%) IV(%) UID* 
N=200 
agr I (131) 4(3.1%) 119(90.8%) 5 (3.8%) 3 (2.3%) 
agr II {AO) 3 (7.5%) 33 (82.5%) 2 (5%) 2 (5%) 
agr III {2) 2(100%) 
agr IV {21) 9 (33.3%) 15 (55.6%) 1 (3.7%) 2 (7.4%) 
Key: * Unidentified type 
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3.8. PCR for adhesin, pyrogenic and other toxin genes 
3.8.1. Optimization of PCR 
The first trial was run according to protocol in CPHLS (SOP No. L-433402-00) and the 
PCR conditions were found to be compatible with our experimental settings. Gels showing 
the amplicors of multiplex PCR of sea-see, seg-sej and tsst-l/eta/etb are demonstrated in 
Figures 3.10, 3.11 and 3.12, respectively. 
For optimization of multiplex PCR of lukE, cna，fib and icaD, reference strains, such as 
Brazilian, Iberian, New York/Japan and Paediatric clone, were firstly tested for the 
presence of these genes by individual amplification. Four of them were found containing 
at least one of those genes (Figure 3.13 a-d). Multiplex PCR at 5TC (annealing 
temperature) with equal ratio of primer sets ([0.4 pmol/|il] each) was then tested (see 
section 2.6.3.1) and the same result was obtained (Figure 3.13e). The icaD was later found 
absent in all reference strains by PCR. 
For optimization of multiplex PCR of fnbA, hlb, fnbB, hla and icaA, reference strains such 
as MRSA #0060(1993), MRSA #0750(1995), MRSA# 1063(2000) and MRSA#1602(1999), 
were run in separate reactions with annealing temperature = Those four isolates are 
the representatives of the previously identified PFGE pattern A2, E, B and Al, respectively. 
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The hlbJnhB, hla were found in all four isolates except MRSA# 1063(2000) (Figure 3.14) 
but fnbA and icaA were not found (gel not shown). Multiplex PCR was then tested using 
these four isolates with equal ratio of primer sets ([0.4 pmol/jil] each), but a weak 
non-specific band in the location o f f n b A PCR product was observed in MRSA# 1602(1999) 
(Figure 3.15 a) as fnbA did not exist in MRS A# 1602(1999) (gel not shown). The quantity 
of fnbA primers were halved (referred to primer set ratio [1], Table 3.12) to eliminate the 
weak band (Figure 3.15b). 
However, when the sample isolates were undergoing multiplex PCR, MRSA#28(lane7), 
#31(lane 10), #36(lane 13), #38(lane 15) were found with the weak bands showing 
probable amplification of fnbA (Figure 3.15c). Individual amplification offnbA of these 
isolates was tested mdfnbA was found absent (gel not shown). The quantities of 
different primers were adjusted and primer set ratio [2] (Table 3.11) was determined to 
further eliminate the non-specific amplification o f f nbA (Figure 3.15 d). 
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Table 3.11 Quantities of different primers for multiplex PCR of fnbA, hlb, fnbB, 
hla and icaA 
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lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: MRSA #91; lane 3: MRSA#13; lane 4: MRSA #92; lane 5: 
MRSA #114; lane 6: New York/Japan clone(negative control for sea-see); lane 7: water control; lane 8: 
reagent control 
Figure 3.11 Multiplex PCR of seg-sej 
1358 bp 
1078 5 6 
872 
-- ��� sei, 466 bp 
603 今 國圓••___ 
310 � seg, 328 bp 
281 




lane 1: 0-174 DNA/Hae III Marker; lane 2: MRSA#146; lane 3: eMRSA-3; lane 4: Brazilian clone(negative 
control for sea-see); lane 5: water control; lane 6: reagent control 
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Figure 3.12 Multiplex PCR of tsst-l/eta/etb 
1078 
872 




lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: MRSA#134; lane 3: eMRSA 16; lane 4: Brazilian 
clone(negative control for tsst-l/eta/etb); lane 5: water control; lane 6: reagent control 
Figure 3.13 PCR of lukE，cna，fib，icaD 
a) PCR of/M/^^ for trial 
1358 bp 
ESIHl^Hj^Hi^PpPi^^l^^HI lukE, 953 bp 
3 1 � 
lane 1: 0-174 DNA/Hae III Marker; lane 2: Brazilian clone; lane 3: Iberian clone; lane 4: New York/Japan 
clone; lane 5: Paediatric clone; lane 6: water control; lane 7: reagent control 
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lane 1 :�-174 DNA/Hae III Marker; lane 2: Brazilian clone; lane 3: Iberian clone; lane 4: New York/Japan 
clone; lane 5: Paediatric clone; lane 6: water control; lane 7: reagent control 





lane 1 :�-174 DNA/Hae III Marker; lane 2: Brazilian clone; lane 3: Iberian clone; lane 4: New York/Japan 
clone; lane 5: Paediatric clone; lane 6: water control; lane 7: reagent control 
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d) PCR of/ca/) for trial 






lane 1 :�-174 DNA/Hae III Marker; lane 2: Brazilian clone; lane 3: Iberian clone; lane 4: New York/Japan 
clone; lane 5: Paediatric clone; lane 6: water control; lane 7: reagent control 
e) Multiplex PCR of lukE，cna，fib，icaD for trial 
1358 lukE, 953 bp 
1078 cna, bp 
310 432 bp 
lane 1: 0-174 DNA/Hae III Marker; lane 2: Brazilian clone; lane 3: Iberian clone; lane 4: New York/Japan 
clone; lane 5: Paediatric clone; lane 6: eMRSA-9 (negative control); lane 7: water control; lane 8: reagent 
control 
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Figure 3.14 PCR offnbA, hlbJnbB, hla and icaA 
Stock number and the collection year is shown within the bracket 
a) PCR of MZ^  for trial 
1358 bp  
• • • • H H ^ H H H H I 
310 
lane 1: 0-174 DNA/Hae III Marker; lane 2: MRSA (#0060, 1993); lane 3: MRSA (#0750, 1995); lane 4: 
MRSA (#1063, 2000) lane 5: MRSA (#1602, 1999); lane 6: water control; lane 7: reagent control 
b) PCR offnbB for trial 
1358 
1078 
603 今 ^ ^ ^ P m ^ P I ^ ^ B i l W ^ W ^ W M B M W I B W I I fribB, 524 bp 
lane 1 :�-174 DNA/Hae III Marker; lane 2: MRSA (#0060, 1993); lane 3: MRSA (#0750’ 1995); lane 4: 
MRSA (#1063, 2000) lane 5: MRSA (#1602, 1999); lane 6: water control; lane 7: reagent control 
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c) PCR of Ma for trial 
1358 bp 
603 
310 hla^ 299 bp 
lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: MRSA (#0060,1993); lane 3: MRSA (#0750, 1995); lane 4: 
MRSA (#1063, 2000) lane 5: MRSA (#1602, 1999); lane 6: water control; lane 7: reagent control 
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Figure 3.15 
a) Multiplex PCR offnbA, hlb,fnbB, hla, icaA with equal ratio of primer sets for 
trial 
. A weak band, non-specifc 
1358 bp丨^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^丨丨丨丨,丨丨丨丨丨丨丨丨丨丨丨丨丨丨||丨丨丨丨川丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨 fnbA amplication 
1078 h]h 0 9 0 b p 
872 
603 今 fnbB. 524 bp 
299 bp 
lane 1 : � - 1 7 4 DNA/Hae III Marker; lane 2: MRSA (#0060,1993); lane 3: MRSA (#0750, 1995); lane 4: 
MRSA (#1063, 2000) lane 5: MRSA (#1602, 1999); lane 6: eMRSA-16 (negative control); lane 7: water 
control; lane 8: reagent control 
b) Multiplex PCR of fnbA，hlb, fnbB，hla, icaA (with primer set ratio [1]) for trial 
1358 bp 
1078 
：二+ N�n-spec i fc /— 
310 amplification eliminated 
lane 1: 0-174 DNA/Hae III Marker; lane 2: MRSA (#0060，1993); lane 3: MRSA (#0750, 1995); lane 4: 
MRSA (#1063, 2000) lane 5: MRSA (#1602, 1999); lane 6: eMRSA-16 (negative control); lane 7: water 
control; lane 8: reagent control 
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3.8.2. Distribution of adhesin，pyrogenic and other toxin genes 
From table 3.13, most of the type A (88/99, 89%) isolates carried the lukE, cna,fib,fnbB 
and hla genes though 11 out of the 88 isolates carried more genes such as hlb{S), tsst-l(^�, 
sea{ 1), sec{ 1) and seg/sei/sej{ 1). For the remaining 11 type A isolates, almost all (10/11) 
carried hla and are listed in Appendix V - Table 5. Type C isolates were indistinguishable 
from type A in genetic characteristics. For type B(100%), -D(78%) and -E(60%) isolates, 
they mostly carried sea, lukE, cna, fib, fnbB and hla. sea gene was "popular" only in type 
B, -D and -E isolates. Within 22% of type D isolates (2/9), they both had similar genetic 
profile to type B, -D and -E isolates but one lacked sea and the other one did not have lukE. 
The rest of type E isolates (2/5，40%), carried lukE/cna/fib/fnbB/hla, but one lacked sea 
and the other one carried one more gene, hlb. Type B and C isolates were very similar as 
they carried lukE, cna, fib, fnbB and hla genes, though type isolates did not have sea gene. 
Isolates of type F differed from those of type A, D and E as more than half of them (63%) 
carried sec, tsst-1, seg, sei but few carried cna, fib and fnbB genes. Type G isolates 
mostly (77%) carried seg, sei, sej, cna and hla. All type H isolates had lukE, cna, fib, 
fnbB and hla which is similar to type A, -D and -E isolates. The major gene profiles of all 
PFGE patterns are shown in Table 3.13. For those genes not included in Table 3.12, they 
were not found in this study. 
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Table 3.12 Distribution of adhesin, pyrogenic and other toxin genes in PFGE 
patterns 
PFGE type 
sea sec tsst-1 seg sei sei lukE cna fib hlb fnbB hla 
N=200 J J 
A (99) 3 3 5 3 3 1 93 93 91 5 91 98 
B ( l ) 1 1 1 1 1 1 
C (3) 3 3 3 3 3 
D (9) 8 1 8 9 9 9 9 
E (5) 3 1 5 5 5 1 5 5 
F(35) 1 27 26 31 31 1 31 6 3 1 3 35 
G (26) 2 1 24 24 23 3 24 1 1 24 
H (8) 1 8 8 8 8 8 
1(3) 1 2 1 3 
1 2 3 7 7 1 6 6 3 2 10 
(11) 
rw^ J I 
0 a 17 34 38 65 65 26 159 157 125 7 123 196 
(200) 
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Table 3.13 PFGE patterns with their gene profiles 
PFGE pattern (no. of isolates/total number of Gene profiles 
isolates in each PFGE pattern) (%) 
A (88/99) (89%) lukE. cna. fib. fnbB, hla 
B (1/1) (100%) sea, lukE，cna, fib’ fnbB, hla 
C (3/3) (100%) lukE. cna, fib�fnbB, hla 
D (7/9) (78%) sea, lukE, cna, fib, fnbB, hla 
E (3/5) (60%) sea, lukE, cna, fib, fnbB, hla 
F (22/35) (63%) 從c, tsst-1, seg, sei, lukE, hla 
(7/35) (20%) 從容 sei, lukE, hla 
G (22/26) (77%) seg, sei, sej, cna, hla 
(4/26) (15%) sei 
H (8/8) (100%) lukE. cna, fib’ fnbB�hla 
I (2/3) (67%) cna, hla 
(1/3) (33%) lukE, fib, hla  
eMRS A-1 sea，lukE, cna，fib，fnbB, hla 
eMRSA-2 sea, lukE, fib, fnbB, hla 
eMRSA-3 seg, sei, lukE, hla 
eMRSA-4 sea，lukE，cna，fib，fnbB，hla 
eMRSA-5 sea, lukE，fib, fnbB，hla 
eMRSA-6 sea，lukE, fib, fnbB, hla 
eMRSA-7 sea，lukE，cna，fib，fnbB，hla 
eMRSA-8 lukE’ fib, fnbB, hla 
eMRSA-9 fnbB, hla 
eMRS A-10 sea, lukE，fib, fnbB’ hla 
eMRS A-11 sea, lukE, cna, fib, fnbB，hla 
eMRSA-12 lukE, fib, fnbB, hla 
eMRS A-13 lukE’ fib’ fnbB, hla 
eMRSA-14 lukE, fib, fnbB, hla 
eMRSA-15 seg, sei, cna, hla  
eMRS A-16 sea, tsst-1, seg, cna 
Brazilian clone lukE, cna, fib, fnbB, hla 
Iberian clone sea, lukE, fib, fnbB, hla 
New York/ Japan clone •seg，sei, lukE, hla * 
Paediatric clone seg, sej lukE, hla  
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Key: bold letteres: profile identical to PFGE type B, -D and -E isolates 
underline: profile identical to type A isolates 
*: profile similar to type F isolates 
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3.9. Multi-Locus Sequence Typing 
Representatives of PFGE types B-I strains with corresponding sample number shown in 
Table 3.14 were selected for MLST. PCR of seven housekeeping genes (listed in Table 
2.12) were performed and the PCR products were sent to Macrogen, Korea for DNA 
sequencing by BigDye terminator sequencing method with an ABB700 automatic DNA 
sequencer. Isolates for PFGE pattern B, C, D, E and H had the same sequence type 
(ST239) (Table 3.14) whilst pattern F and G isolates had ST5 and ST45 respectively. PFGE 
type I isolates had the new sequence type (3-35-19-2-20-26-39). 
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Table 3.14 PFGE patterns and Sequence Types 
PFGE pattern Allele no. Sequence Type (ST) 
(Sample no.) (arc-aro-glp-gmk-pta-tpi-yqi) 
B (#149) 2-3-1-1-4-4-3 ST 239 
C (#46) 2-3-1-1-4-4-3 ST 239 
D (#137) 2-3-1-1-4-4-3 ST 239 
E (#88) 2-3-1-1-4-4-3 ST 239 
F (#36) 1-4-1-4-12-1-10 ST 5 
¥ (#61) 1-4-1-4-12-1-10 ST 5 
F (#71) 1-4-1-4-12-1-10 ST 5 
F (#227) 1-4-1-4-12-1-10 ST 5 
G (#234) 10-14-8-6-10-3-2 ST 45 
G (#238) 10-14-8-6-10-3-2 ST 45 
H(#132) 2-3-1-1-4-4-3 ST 239 
H(#150) 2-3-1-1-4-4-3 ST 239 
I (#175) 3-35-19-2-20-26-39 New ST 
I (#176) 3-35-19-2-20-26-39 New ST 
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3.10 coa Sequence Typing 
The coa sequences between 1500-2300bp (the hypervariable region) of PFGE type A-E 
isolates and of international clones were obtained from previous work (Chio, 2002). The 
eMRSA coa sequences were obtained from GenBank. The coa sequences within the 
mentioned region of PFGE type F-I isolates were amplified by PCR and then sent to 
Macrogen, Korea for DNA sequencing by BigDye terminator sequencing method with an 
ABI3700 automatic DNA sequencer. All obtained coa sequences were analyzed to obtain 
the phylogenetic tree. 
Several findings were obtained from figure 3.16. PFGE type A, B, C, D and H isolates 
and Brazilian clone were closely related. Type G and I isolates were distinct from the 
reference strains and other PFGE type isolates. PFGE F isolates were very closely related 
to New York/Tokyo clone. 
The typing patterns and the characteristics of PFGE type isolates in Hong Kong hospitals 
are listed in Appendix VI. 
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Chapter 4 Discussion 
4.1 • Evaluation of the Typing methods for MRSA 
4.1.1. Antibiotic Susceptibility Test 
Overall, only two major resistance profiles I (TEDGToCi) and III (TECi) were present 
among MRSA in all four hospitals. Four other profiles (II, IV, V and VI) were present in 
three of the four hospitals. If a clone is classified as two or more isolates of the same 
pattern and present in two or more hospitals in Hong Kong, a total of six predominant 
clones will be present. However, profile I and II only differ by one antibiotic, 
clindamycin, and III and IV by also the aminoglycoside, gentamicin/tobramycin. Hence, 
antibiotic profiles alone may not adequately type these isolates. Most MRSA isolates 
showed susceptible to a number of antibiotics and they were netilmicin, mupirocin, 
fusidic acid, rifampicin, co-trimoxazole and chloramphenicol (>90% isolates 
susceptible) 
4.1.2. PFGE 
Nine PFGE patterns were identified using this method. Five profiles (A-E) were 
previously identified at PWH during 1989-2000 (M. Ip et al., 2003). PFGE type A 
remain the most prevalent type in this study and present in about 50% all isolates from 
these Hong Kong hospitals presently (Table 3.12). eMRSA-1 was indistinguishable 
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from PFGE type A subtype2 isolates whilst PFGE A- E were closely related and fell 
within the cluster of British eMRSA-1, -4, -7,-11 byAFLP (F. Chio, 2002). 
Interestingly, PFGE type B was present in PMH only in this study but was the second 
most common type identified at PWH previously. The PFGE type B is closely related to 
the British eMRSA-9. The PFGE types A-E were consistent with the results of 
previous study and using the reference isolates from PWH for comparisons (M. Ip et al., 
2003). 
Four PFGE patterns (F-I) were newly identified between 2000 and 2002. Type H 
pattern was similar to type A pattern by 4 bands difference. MRSA with PFGE type G 
and H showed distinctive antibiotic patterns. For type G clones, they could be picked 
up by the combination of tetracycline, erythromycin, ciprofloxacin. Type H clones 
could be discriminated by the combination of tetracycline, erythromycin, clindamycin, 
ciprofloxacin. 
The results of this method were reproducible and the method has a high discriminatory 
power to distinguish isolates with different PFGE patterns. And the new PFGE 
patterns, except pattern H，were found easily distinguishable from the PFGE type A-E. 
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4.1.3. Phage Typing 
Using this method, two previously identified phage types, type 1 and 2, have been found. 
PTl was found in most isolates and was the majority of PFGE type A, C, D，E, F, H 
isolates while PT2 was only found in one type B isolate. Anew phage type, PT3, was 
proposed (strong reaction to 42E and 81) in majority of type G isolates. 
The phage typing was found to be poor in discriminatory power and time-comsuming in 
this project. Therefore, it as not suggested to be included one of the methods in typing 
MRSA. 
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4.1.4. PFGE, SCCmec typing and agr typing 
The majority of PFGE A-E, and H isolates carried the SCCmec///gene. This inferred 
that these are likely to be closely related in origin to that of the eMRSA 1, 4, 7，9, 11 
that also carried the SCCmecIII gene and consistent with previously finding using the 
AFLP (Chio,2002). These isolates also belong to agr I group, except for 1 isolate. A 
linkage between agr I and SCCmec///was inferred. These isolates are often multidrug 
resistant as most numerous resistance genes are located in SCCmec III. The majority 
of PFGE type F isolates (31/35) carried the SCCmec// gene whilst PFGE type G isolates 
carried SCCmec/ or II genes. The PFGE type F isolates belong to agr II group and a 
close relationship between agr II and SCCmec //were also seen as 82.5% of agr II 
isolates carried SCCmecII. Agr group 2 isolates include also the representatives of the 
New York/Japan and that of the Paediatric clones. Interestingly, almost all PFGE type 
G isolates belong to agr group IV. 
In the SCCmec typing, there were 10 isolates non-typable but they were confirmed to 
carry mecA gene. Other novel type of SCCmec may exist or the primers could not 
anneal with the template DNA for an unknown reason. 
The significance of SCCmec and agr were that they provide evidence for evolution at 
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the molecular level (M. C. Enright et al., 2002; F. Vandenesch et al., 2003) and it is 
likely that the same type of SCCmec and agr might be carried during clonal expansion 
of particular clone of MRSA. Both of them also can act as epidemiology marker. 
4.1.5. MLST 
Four ST types (ST 5, 45, 239 and unspecified ST) were identified among the 
predominant PFGE types. Representatives of our PFGE types A - E isolates have 
identical sequence type (ST239) that is also the same for representatives of the eMRSA 
1, -4, -7 and —11 and the Brazilian clone. MRSA with ST239 had been suggested to be 
derived from an ancestor with ST 8 (M. C. Enright et al., 2002) and carry the SCCmec 
type III gene. MRSA isolates with ST 239 have also been found in other countries such 
as Australia, Brazil, China, Finland, Greece, Holland, Hungary, Ireland, Poland, 
Portugal, Scotland, Slovenia, Spain, Taiwan, Thailand, USA (http://www.mist.net; M. C. 
Enright et al., 2002). PFGE type F isolates have a ST 5 which was the same as 
eMRSA 3, New York/Tokyo clone and Padiatric clone. MRSA belonging to ST5 spread 
to European countries such as Belgium, Canada, Columbia, Denmark, France, Finland, 
Holland, Ireland, Poland, Portugal, Scotland, Slovenia, Thailand (http://www.mist.net; 
M. C. Enright et al., 2002). PFGE type G isolates have identical sequence type (ST45) 
to the isolates in Belgium, Finland, Germany, Sweden and USA and previously found to 
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belong to an ancestral genotype found by Dr. Enright and colleagues (M. C. Enright et 
al., 2002). 
4.1.6. Sequencing typing of coa gene 
PFGE types A-E, -H, Brazilian clone and UK eMRSAl, 4 and 7 were closely related 
whilst type F isolates have close lineage with the New York/Japan clone and the 
representative of Paediatric clone. The coa sequencing typing within the PFGE types 
examined were identical for the strains examined and was found to be a useful, 
reproducible and objective method in investigating clonal relationship of predominant 
MRSA clones. 
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4.2. Characteristics of MRSA 
4.2.1. PCR for adhesin and toxin genes 
Almost all PFGE type A-E and -H isolates carried the genes encoding leukocidin E 
{lukE), collagen binding protein (cna), fibrinogen-binding protein (fib), 
fibronectin-binding protein B (fnbB), and a-haemolysin (hla) gene and those isolates 
carry almost the same set of genes. Interestingly, only 2 isolates belonging to PFGE type 
A (Sample no. 096, 106) carried multiple enterotoxin genes, sec, seg, sei, and the toxin 
shock syndrome toxin, TSST-I. These two isolates also had unique agr (group 2) and 
SCCmec (type II) types to that of PFGE type A isolates. Only seven PFGE type A 
isolates carried one or more of these enterotoxin genes or TSST. When comparing 
with the reference strains (Table 4.1), PFGE types A and C isolates carried the same 
adhesin genes as that of the Brazilian clone, whilst PFGE type B, -D and -E isolates 
carried an additional enterotoxin gene, sea, identical to the toxin/adhesions gene profile 
of eMRSA-1, -4, -7,-11. 
For PFGE type F, -G and -I isolates, they showed distinctive toxin/adhesions gene 
profiles. In PFGE type F, majority of isolates carried the enterotoxin genes, sec, TSST-1, 
seg and see but only few (Sample no. 97, 107, 225, 228) carried adhesin genes (cna and 
fib). This is similar to that of the eMRSA 3, representatives of NY/Japan and 
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Paediatric clones, except with the addition of the enterotoxin C and TSST-1 genes. 
Also, the NY/Japan strain did not encode the collagen binding protein, cna, but carried 
the lukE. 
For PFGE type G isolates, the isolates predominantly carry the enterotoxin genes, seg, 
sei, sej, and seh, exotoxin gene, a-haemolysin (hla), and adhesin gene, cna. Two 
isolates (Lab no. 094 and 091) in this group that did not belong to agr group 4 (but with 
groups 1 and 2 respectively) also had unique gene profiles with the former strain with 
no detectable enterotoxin genes but exotoxin genes, lukE and hla and adhesin genes, 
cna, fib mdfnbB present. The latter strain encodes enterotoxins, sec, TSST-1, seg, sei, 
and exotoxin genes, lukE and hla. 
PFGE type I only included three isolates and again did not encode enterotoxin genes, 
but were unique isolates when in combination with the patterns of adhesin genes, agr 
and SCCmec and the antibiogram. 
The genes encoding enterotoxin B, -D, -E, -G {seb, sed, see, seg), exfoliative toxins {eta, 
eth), intercellular adhesins (icaA, icaD) were not detected by PCR in all the MRSA 
isolates examined. The enterotoxin H {seh) gene was only found in one isolate which 
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have a unique PFGE pattern (Sample no. 233). 
Although PCR is effective on the detection of genes, there are some limitations. The 
first one is that the detection of genes cannot represent gene expression since there are 
factors such as regulation and mutations affecting the expression. The second one is 
that there may be false negative or false positive result and these have to e\be graded by 
positive and negative controls in each PCR run, and taking all measures to avoid 
contamination in the procedures. 
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4.3. Key Characteristics of Hong Kong isolates 
The MRSA isolates in Hong Kong between 2000 and 2002 have been characterized and 
categorized into four major Hong Kong clonal types (see Table 4.1) The first HK 
clonal type I (HKCT I) and its variants include 125 isolates with PFGE types A-E, and 
H, and belong to SCCmec type III, agr group I, ST239, mainly PTl, with virulence 
factors: {sea), lukE, cna,fib,fnbB, hla, antibiogram, TE(DGTo)Ci. Variants of each 
HKCT differ by partial characteristic features, e.g. addition or deletion of exotoxin 
gene(s) or/and antibiogram. The sea gene may be the extra-chromosomal material 
carried by prophages, and are present in MRSA isolates of PFGE types B, D, and E but 
not in A, C and H. MRSA belonging to HKCT I show high similarity with the Brazilian 
clone, eMRSA-1, -4, -7 and-11 as they carry the same SCCmec, agr, sequence type and 
similar set of virulence genes. They are also clustered together in the phylogenetic tree 
of coa sequence. These isolates fall into the group of ST239-MRSA-III that represents a 
distinct branch within clonal complexes CCS in the evolutionary model of emergence of 
MRSA (D. Ashley Robinson and M. C. Enright, 2003). This lineage includes numerous 
clones of the epidemic MRSA (eMRSAl,-4,-7,-9,-ll), Brazilian, Portuguese, and 
Vienna clones (D. Ashley Robinson & M. C. Enright, 2003). 
HK clonal types II-IV (HKCT II-IV) are also distinct and were not identified in the 
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previous study of MRSA at PWH. HKCT II and its variants include 35 isolates with 
PFGE type F, SCCmec type 2, agr group 2, ST5, with virulence genes sec, TSST, seg, 
sei, lukE, hla and are present in three of the four major hospitals. These isolates show 
the same properties with NY/Japan clone based on SCCmec typing, agr typing, MLST 
and coa sequence typing. It was suggested that these isolates fall to the group 
ST5-MRSA-II that were derived from the same ancestor with NY/Japan clone within 
the clonal complex of CCS (D. Ashley Robinson & M. C. Enright, 2003). 
Twenty-six isolates were included in HKCT III and its variants. They were also 
present in three of the four hospitals and belong to PFGE type G, with SCCmec types 1 
or 2, agr group 4, ST45, with virulence genes seg, sei, sej, cna and hla. Similar isolates 
belonging to ST34-MRSA-II have been documented in USA and Berlin, and belong to 
the clonal complex of CC45 (D. Ashley Robinson & M. C. Enright, 2003). However, 
strains with SCCmec type 1 will require further delineation as to its origin. 
There are only 3 MRSA isolates of HKCT IV and they are all from Tseung Kwan O 
Hospital，hence are not a HK-wide clonal type, particularly only 2 of the 3 isolates 
belong to SCCmec type 4, agr group 2, and encode the virulence genes, cna and hla 
only. These isolates have a unique MLST allele number of 3-35-19-2-20-26-39 for 
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housekeeping genes arc-aro-glp-gmk-pta-tpi-yqi, and do not have an assigned known 
sequence type, as yet. The acquisition of SCCmec IV in methicillin-sensitive strains is 
known to be more common than the replacement of another SCCmec and is commonly 
found in clones from patients with community-acquired MRSA disease (D. Ashley 
Robinson & M. C. Enright, 2003). One needs to relate clinically if these cases may be 
associated, and further surveillance and SCCmec typing may elucidate further the 
importance of this ‘clonal type' in Hong Kong. 
The detection of the virulence genes helps to identify the pathogenicity of the MRSA 
present in Hong Kong. As the predominant types of MRSA also carry unique profiles 
of toxin and adhesin genes, these may also be used as a rapid typing method in 
combination to the agr and SCCmec types to identify the particular clonal type present 
in the hospital setting. Clinical correlations and retrospective case-controlled studies 
of the patients with these isolates may help to determine the significance of the toxins 
production and possible differences in their pathogencity potential. The presence of 
multiple adhesin genes in the predominant PFGE type A isolates may also explain the 
propensity for colonization and to become a predominant clone in our hospital setting in 
Hong Kong. 
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Table 4.1 Characteristics of Hong Kong Clonal Types of MRSA 
Common Features 
Clonal No. PFGE SCC- agr Surface protein genes or Antibiogram ST Phage 
Type mec exotoxin genes Type^ 
1 76 A 3 1 lukE, cna, fib, fnbB, hla TEDGToCi 239 PTl 
B sea, lukE, cna, fib, fnbB, hla TEGToCiNM PT2 
C lukE, cna, flb, fnbB, hla TEDGToCi PTl 
D sea, lukE, cna, fib, fnbB, hla TEGToCi(N)S 
E sea, lukE, cna, fib, fnbB, hla TEGToCi(N)S 
H lukE, cna, fib, fnbB, hla TEDCi 
Variants 3 A 3 1 lukE, cna, fib, fnbB, hla TEDGToCiF 
of Type 3 TEDGToCiM 







1 lukE, cna, fib 
1 sec, lukE, cna, fib, fnbB, hla 
TEDGToCi 
3 lukE, cna, fib, fnbB, hla, hlb 
1 fnbB, hla 
1 fnbB, hla TEGToCiNF 
1 lukE, cna, fib, fnbB, hla, hlb TEDGToCiNM 
1 lukE, fnbB, hla TEDGToCiM 
1 seg, sei，sej, lukE, cna, fib, TEGToCi 
fnbB, hla 
1 lukE, cna, fib, fnbB, hla, hlb GToCi 
1 tsst-1, lukE, cna, fib, fnbB, TEDGToCiM 
hla 
1 tsst-1, lukE, cna, fib, fnbB, TEGToCiNS 
hla 
1 tsst-1, lukE, cna, fib, fnbB, TEGToCi 
hla 
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Table 4.1 Characteristics of Hong Kong Clonal Types of MRSA (Cont'd^) 
Common Features 
Clonal No. PFGE SCC- agr Surface protein genes or Antibiogram ST Phage 
Type mec exotoxin genes Type^ 
Variants 1 GToCi 239 PTl 
UID 1 sea, cna, hla 
of Type 1 EGToCi 
I I UID 1 lukE, cna, fib, fnbB, hla TEDGToCiN 
2 A 4 1 cna, hla TEDGToCi 
1 2 1 lukE, cna, fib, fnbB, hla TEGToCi 
1 UID 2 lukE，fib, hla 
1 sec, tsst-1，sez sei, lukE, hla 
TEDGToCi 
1 2 2 sec, tsst-1, seg’ sei, lukE, fib, 
hla 
1 C 2 1 lukE, ma, fib, fnbB, hla TEDGToCi 
1 D 3 1 sea, lukE, cna, fib, fnbB, hla TEDGToCiF 
1 D sea, lukE, cna, fib, fnbB, hla TEGToCiNMS 
1 D sea, cna, fib, fnbB, hla TEGToCiS 
2 D, E 3 1 sea, tsst-l, lukE, cna, fib, TEGToCiNS 
fnbB，hla 
2 A，E lukE, ma，fib, fnbB, hla TEDCi 
1 E 3 1 lukE, cna, fib, fnbB, hla, hlb TEGToCi 
1 lukE, cna, fib, fnbB, hla TEDGToCi 
1 tsst-l lukE, cna, fib，fnbB, TEDCi 
H 3 1 
hla 
1 lukE，cna, fib, fnbB, hla TECi 
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Table 4.1 Characteristics of Hong Kong Clonal Types of MRSA (Cont'd^) 
Common Features 
Clonal No. PFGE SCC- agr Surface protein genes or Antibiogram ST Phage 
Type mec exotoxin genes Type^  
2 12 F 2 2 sec, tsst-1, seg, sei, lukE, hla TEGToCi 5 PTl 
Variant 3 sec，tsst-1, seg, sei, lukE, hla TEDGToCi 
oftype 1 TEDGToCiM 
2 1 TEGToCiMC 
(11=23) 1 TEDGToCiR 
1 sec’ tsst-1, seg, sei, cna, hla TEGToCi 
1 tsst-1，seg, sei, lukE, hla 
3 sec, seg, sei, lukE, hla 
1 tsst-1 ’ seg, sei, lukE, hla TEGTo 
1 sec, tsst-1, seg, sei, hla TEGToCiM 
1 seg, sei, lukE, hla TECi 
1 sec, tsst-1, seg, sei，lukE, TEToCi 
hla, hlb 
3 3 2 lukE, cna，fib, fnbB, hla TEDGToCi 
3 1 2 sec, tsst-1，seg, sei, lukE，hla TEGToCi 
1 2 4 seg, sei, sej, cna, hla EToCi 
1 4 1 sea, cna, hla GToCi 
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Table 4.1 Characteristics of Hong Kong Clonal Types of MRSA (Cont'd^) 
Common Features 
Clonal No. PFGE SCC- agr Surface protein genes or Antibiogram ST Phage 
Type mec exotoxin genes Type^ 
3 10 G 1(2) 4 seg, sei, sej, cna, hla TECi 45 42E, 
Variant 1 2 4 seg, sei, sej, cna, hla TCi 81 
of type 2 ToCi 
3 1 TEDCi 
(n=16) 2 Ci 
1 EToCi 
1 1 4 sec, seg, sei, sej, cna, hla TECi 
1 1 4 seg, sei, sej, can 
1 2 4 cna, hla 
1 2 4 sez sei, sej, cna 
TEDGToCi 
1 2 2 sec, tsst-1, seg, sei, lukE, hla 
2 UID 4 seg, sei, sej, cna, hla TECi 
1 3 1 lukE, cna，fib，fnbB, hla TECi 
1 4 4 seg，sei，sej, lukE, hla Ci 
4 I I 4 1 cna, hla F New* 6,47, 
1 2 1 cna, hla 81 
1 4 1 lukE, fib, hla TEDGTo 
*Tlie allele immbers are in the order of arc-aro-glp-gmk-pta-tpi-yqi which are 3-35-19-2-20-26-39 
#UID= unidentified SCCmec group 
1 The name of phage shows strong reaction to corresponding phage 
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4.4. Conclusion 
Four Hong Kong clonal types (HKCT) have been identified and each clonal group can 
be distinguished by SCCmec, agr typing, MLST and its virulence determinants. The 
predominant clone, HKCT I, was highly similar to the Brazilian clone with ST 239 and 
may be derived from clonal complex CCS. The isolates in HKCT II may be derived 
from the same ancestor with NY/Japan clone within the clonal complex of CC5. A 
linkage between agr I and SCCmecIII was inferred. A rapid typing method based on 
the SCCmec, agr typing and detection of adhesin and toxin genes may be developed to 
detect the particular clonal type present in the hospital setting. 
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4.5. Future Research 
In this project, only MRSA isolates from blood culture were collected. Future research 
may focus on the isolates from the non-blood culture to investigate whether distinct 
features could be observed. Also, isolates from other regions such as Macau, 
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Appendix I (Al) - Materials/Reagents for Methods 
(I)Identification 
Material/Reagent Source 




Mannitol Oxacillin salt 
agar 
(II) Antibiotic Susceptibility Test 
Material/Reagent Source  
Oxacillin Oxoid, UK 
Tetracycline (T) Oxoid, UK 
Erthromycin (E) Oxoid, UK 
Clindamycin (D) Oxoid, UK 
Gentamicin (G) Oxoid, UK 
Tobramycin (To) Oxoid，UK 
Ciprofloxacin (Ci) Oxoid, UK 
Netilmicin (N) Oxoid, UK 
Mupirocin (M) Oxoid，UK 
Fusidic acid (F) Oxoid, UK 
Rifampicin (R) Oxoid, UK 
Co-trimoxazole (S) Oxoid, UK 
Chloramphenicol (C) Oxoid, UK 
Antibiotic disk dispenser Oxoid, UK  
McFarland Standard bioMerieux, France  
Blood agar 
Mueller Hinton agar  
BioNumerics 2.50 Applied Maths, Belgium  
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(III) PCR for mecA gene 
Material/Reagent Source 
GeneAmp PCR System 9700 Perkin Elmer, Applied Biosystem, USA 
Thermal Imaging System CTI-500 Amersham Biosciences, USA 
Gel Electrophoresis Tank Amersham Biosciences, USA 
MecA(F): GIBCOBRL, Life technologies, USA 
5, -TGGCTATCGTGTC AC AATCG-3, 
MecA(R): GIBCOBRL, Life technologies, USA 
5, -CTGGAACTTGTTGAGC AGAG-3, 
Taq DNA polymerase Qiagen, USA 
1 OX PCR buffer Qiagen, USA 
DNA polymerization mix (dNTP) Amersham Biosciences, USA 
[20mM]  
Seakem LE agarose BMA, USA 
4)-174 YmkJHaelll Marker Promega, USA  
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(IV) Pulsed-field Gel Electrophoresis 
Material/Reagent Source 
Sea Plague GTG agarose (Low melting agarose) FMC BioProducts, USA 
Seakem Gold agarose (PFGE agarose) FMC BioProducts, USA 
Boric Acid Merk, UK 
Brij 58 (w/v) polyoxyethlene (0.5%) Sigma, USA 
EDTANa2 Sigma, USA 
Ethidium Bromide 
MgCl2 Sigma, USA 
NaCl BDH, UK 
N-Lauroyl sarcosine (Sarkosy NL30) Sigma, USA 
Sodium deoxycholate (w/v) (0.2%) Sigma, USA 
Tris Sigma, USA  
Lysostaphin Sigma, USA 
Lysozyme Sigma, USA 
Proteinase K Amersham Biosciences, USA 
Smal Amersham Biosciences, USA 
1 OX T buffer Amersham Biosciences, USA 
0.1% BSA Amersham Biosciences, USA 
X DNA — PFGE markers Amersham Biosciences, USA 
Blood agar 
McFariand Standards bioMerieux, France  
Chef Mapper BioRad, USA 
Thermal Imaging System CTI-500 Amersham Biosciences, USA 
Water bath HAAKE, USA 
BioNumerics Applied Maths, Belgium  
172 
Appendix 
(VI) Phage Typing 
Material/Reagent Source Catafog no. 
Nutrient broth (Oxoid; No.2) Oxoid，UK CM67 
NaCl 
Agar (Oxoid; No. 1) Oxoid, UK LI 1 
CaCli  
Bacteriophages Propagating Strains Source 
29 NCTC 8331 PHLS 
52 NCTC 8507 PHLS 
52A NCTC 8363 PHLS 
79 NCTC 8363 PHLS 
80 NCTC 9789 PHLS 
3A NCTC 8319 PHLS 
3C NCTC 8327 PHLS 
55 NCTC 8358 PHLS 
71 NCTC 9315 PHLS 
95 NCTC 10971 PHLS 
6 NCTC 8509 PHLS 
42E NCTC 8357 PHLS 
47 NCTC 8325 PHLS 
53 NCTC 8511 PHLS 
54 NCTC 8329 PHLS 
75 NCTC 8354 PHLS 
77 NCTC 8356 PHLS 
83A NCTC 10039 PHLS 
84 NCTC 10455 PHLS 
85 NCTC 10457 PHLS 
81 NCTC 9717 PHLS 
94 NCTC 10970 PHLS 
96 NCTC 10972 PHLS  
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(VII) Detection of genes by PCR 
SCCmec detection 
Primer Sequence Product Source 
al(F): 5'-AACCTATATCATCAATCAGTACGT-3' SCCmec I GIBCOBRL, 
pc(R): Life 
5'-ATTGCCTTGATAATAGCCITCT-3' technologies, 
a2(F): TAAAGGCATCAATGCACAAACACT SCCmec II U S A 
Pc(R)  
a3(F): 5'-AGCTCAAAAGCAAGCAATAGAAT-3' SCCmec III 
Pc(R)  
IVal(F): 5'-TTTGAATGCCCTCCATGAATAAAAT-3' SCCmecIVa 
IVa2(R): 5'-AGAAAGATAGAAGTTCGAAAGA-3‘ 
IVbl(R): 5'-AGTACATTTTATCTTTGCGTA-3' S C C騰 I V b 
IVb2(F): 5'-AGTCATCTTCAATATCGAGAAAGTA-3， 
agr detection  
Primer Sequence Product Source  
pan-agr(F): 5,-ATGCACATGGTGCACATGC -3, agr I GIBCOBRL, 
agr-I(R): 5，-GTC AC A AGTACTATAAGCTGCG AT-3 ’ Life 
pan-agr(F) agr II technologies, 
agr-II(R): 5'-GTATTACTAATTGAAAAGTGCCATAGC-3， U S A 
pan-agr(F) agr III 
agr-m(R): 5'-CTGTTGAAAAAGTCAACTAAAAGCTC-3' 
pan-agr(F) agr IV 
agr-IV(R): 5'-CGATAATGCCGTAATACCCG-3'  
Pyrogenic toxin detection  
a) sea-see  
Primer Sequence Product Source  
SEA(F)i: 5'-CCTTTGGAAACGGTTAAAACG-3‘ sea GIBCOBRL, 
SEA(R)i: 5‘-TCTGAACCTTCCCATCAAAAA-3‘ Life 
SEB(F)i: 5'-TCGCATCAAACTGACAAACG-3' seb technologies, 
SEB(R)i: 5'-GCAGGTACTCTATAAGTGCCTGC-3' U S A 
SEC(F)i: 5'-CTCAAGAACTAGACATAAAAGCTAGG-3' sec 
SEC(R)i: 5'-TCAAAATCGGATTAACATTATCC-3'  




SEE(F): 5'-CAGTACCTATAGATAAAGTTAAAACAAGC-3' see 
SEE(R): 5‘-TAACTTACCGTGGACCCTTC-3‘ 
b) seg-sej  
Primer Sequence Product Source 
SEG(F): 5'-CGTCTCCACCTGTTGAAGG-3' seg GIBCOBRL, 
SEG(R): 5'-CCAAGTGATTGTCTATTGTCG-3' Life 
SEH(F): 5'-CAACTGCTGATTTAGCTCAG-3' seh technologies, 
SEH(R): 5，-GTCGAATGAGTAATCTCTAGG-3 ’ U S A 
SEI(F): 5'-CAACTCGAATTTTCAACAGGTAC-3' sei 
SEI(R): 5'-CAGGCAGTCCATCTCCTG-3' 
SEJ(F): 5'-CATCAGAACTGTTGTTCCGCTAG-3 ’ sej 
SEJ(R): 5'-CTGAATTTTACCATCAAAGGTAC-3'  
c) tsst-l/eta/etb  
Primer Sequence Product Source  
Tsst-l(F): 5‘-AAGCCCTTTGTTGCTTGCG-3‘ tsst-1 GIBCOBRL, 
Tsst-1 (R): 5，-ATCGAACTTTGGCCCATACTTT-3 ’ Life 
eta(F): 5，-CTAGTGCATTTGTTATTCAAGACG-3, eta technologies, 
eta(R): 5'-TGCATTGACACCATAGTATTATTC-3‘ U S A 
etb(F): 5'-ACGGCTATATACATTCAATTCAATG-3， etb 
etb(R): 5'-AAGTTATTCATTTAATGCACTGTCTC-3'  
Adhesin/toxin genes  
Primer Sequence Product Source 
lukE(F): 5'-GACTGATTGCACCTTTAGC-3' lukE GIBCOBRL, 
lukE(R): 5，-GCAATTGATGAAGCAACTGATG-3 ’ Life 
cna(F): 5‘-AAGCATTTGCAGCACGAG-3 ‘ cna technologies, 
cna(R): 5,-ATATGACCCATAGCCTTGTGG-3， U S A 
fib(F): 5'-AACATTAGCGGCAATAGG-3' fib 
fib(R): 5,-ATTCGCTCTTGTAAGACC-3, 
icaD(F): 5, - ATGGTC AAGCCC AG AC AG AG-3 ’ icaD 
icaD(R): '-CGTGTTTTCAACATTTAATGCAA-3, 
fiibA(F): 5'-CACAAACTGCACAACCAGC-3' fnbA GIBCOBRL, 
fiibA(R): 5 ‘ -GGATTTGATTCCTCAGAGGAC-3 ‘ Life 
hlb(F): 5'-AGTTGGTGCACTTACTGAC-3' hlb technologies, 
hlb(R): 5,-TACTATAGGCTTTGATTGGG-3, USA 
fiibB(F): 5,-GCTCAACCAAGTAACGTCTC-3 ’ fnbB 
fiibB(R): 5,-TTGCTAACCGTAGTCTCACC-3,  
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hla(F): 5，-AATTGGCGGCCTTATTGGTG-3, hla 
hla(R): 5‘-CTGTAGCGAAGTCTGGTGAA-3 ‘ 
icaA(F): 5'-TCTCTTGCAGGAGCAATCAA-3， icaA 
icaA(R): 5，-TCAGGCACTAACATCCAGCA-3 ’ 
Material/Reagent Source 
Taq DNA polyermase Qiagen, USA 
IPX PCR buffer Qiagen, USA  
DNA polymerization mix (20mM/dNTP) Amersham Biosciences, USA 
Seakem LE Agarose BMA, USA  
0-174 DNA/Hae III Marker Promega, USA 
GeneAmp PCR System 9700 Perkin Elmer, Applied Biosystem, USA 
Thermal Imaging System CTI-500 Amersham Biosciences, USA 
Gel Electrophoresis Tank Amersham Biosciences, USA 
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(VIII) coa sequencing typing 
Material/Reagent Source 
coa(F): 5‘-TATAGAGATGCTGGTACAGG-3‘ GIBCOBRL, Life technologies,  
coa(R): 5'-CTGTATGTCTWTGGATAGAG-3' GIBCOBRL, Life technologies, 
USA  
Taq DNA polyermase Qiagen, USA 
IPX PCR buffer Qiagen, USA  
DNA polymerization mix (20mM/dNTP) Amersham Biosciences, USA 
Seakem LE Agarose BMA, USA 
O-174 DNA/Hae III Marker Promega，USA 
GeneAmp PCR System 9700 Perkin Elmer, Applied 
Biosystem, USA 
Thermal Imaging System CTI-500 Amersham Biosciences, USA 
Gel Electrophoresis Tank Amersham Biosciences, USA 
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Appendix II (A2) - Reagents Formula 
1. Buffers 
a) SE Buffer (pH=7.5; autoclaved; kept at 4^C) 
NaCl (75mM) 4.38 g 
EDTA(25mM) 9.3 g 
Distilled H2O Top up to 1 L 
b) Lysis Buffer 
1) Gram-positive Lysis Buffer (pH-7.5; kept at 4^C) 
Tris (6mM) 0.36 g 
EDTANai (lOOmM) 18.6 g 
NaCl (IM) 29.2 g 
Brij 58 (w/v) polyoxyethylene (0.5%) 2.5 g 
Sodium deoxycholate (w/v) (0.2%) 1.0 g 
N-Lauroyl sarcosine (Sarkosy NL30) 8.25 ml 
MgCl2 (ImM) 0.5 ml (1 M) 
Distilled H2O Top up to 500 ml 
2) Gram-negative Lysis Buffer (pH=9.5; kept at 4^C) 
N-Lauroyl sarcosine (Sarkosy NL30) 5 g/16.5 ml 
EDTANai (0.5M) 93 g 
Distilled H2O Top up to 500 ml 
c) TE Buffer (pH=7.5; autoclaved; kept at 4®C) 
Tris (lOmM) 1.21 g 
EDTANa^ 3.72 g 
Distilled H2O Top up to 1 L 
d) TBE Buffer (lOx) (kept at 4°C) 
Tris 108 g 
EDTANa2 7.44 g 
Boric Acid 55.65 g 




a) Low-melting agarose gel (2%) 
Agarose 1 g 
SE Buffer 10 ml 
b) PFGE-agarose gel (1%) 
Agarose 1 g 
TBE Buffer (Ix) 100 ml 
3. Media Plate 
s e e plate: Oxoid nutrient broth no.2 20g 
NaCl 5 g 
Oxoid agar no. 1 7 g 
Distilled H2O 1 L 
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Appendix III (A3) 一 coa sequence alignment 







175_PFGE_I ACGATGGMCATTTGGATATGMGCGAGACCMGATTCMTMGCCATCAGMACAAATG 60 




































175—PFGE—I CATATMCGTMCMCACATGCAAACGGCCAAGTATCATACGGAGCTCGCCCAACACAAA 120 
176_PFGE_I CATATMCGTMCMCACATGCAMCGGCCMGTATCATACGGAGCTCGCCCMCACMA 120 
IBERIAN  
Brazilian ACGATGGAACATTTGGATAT~GAAGCGAGACCAAGTTCT- 38 
PFGE_Bla ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
132—PFGE—H ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
150—PFGE—H ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
PFGE—Ala ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
PFGE_Cla ACGATGGMCATTTGGATAT-~GMGCGAGACCMGATrCA 39 
PFGE_D1 ACGATGGA-CATTTGGATAT—GAAGCTAGACCAAGATTCA 38 
PFGE—A2a ACGATGGA-CATTTGGATAT—GAANCGAGACCAAGATTCA 38 
PFGE_E ACCGATGGA-CATITGGATAT—GAAGCCAGACCAAGATTCA 39 
EMRSA—7 CAGMTACMCGTGGMCAmGGATATTTGAAGCGAGAC-AAGATTCA 48 
EMRSA—1 CAGA 4 
EMRSA_4 CAGGGATTGAAGCTAGACAAGATTCA 26 
234_PFGE_G ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
238JPFGE_G ACGATGGAACATTTGGATAT--GAAGCGAGACCAAGATTCA 39 
EMRSA_11 CAGTTTGGATAT—GAAGCGAGAC-AAGATTCA 30 
36—PFGE—F ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
61_PFGE_F ACGATGGAACATTTGGATAT—GAAGCGAGACCAAGATTCA 39 
227_PFGE_F ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
71—PFGE_F ACGATGGAACATTTGGATAT—GMGCGAGACCAAGATTCA 39 
NY-Japan ACGATGGAACAnTGGATAT—GAATCGAGACCAAGATTCA 39 
Paediatric ACGATGGA-CATTTGGATAT—GAACATCGACCAAGAT-CA 37 
EMRSA_3 CAGGGATAT—GAAGCGAGACCAAGGC--- 25 
EMRSA_14 T—ACAGCAAGATCAA 14 
EMRSA一 13 CAG-TGAATCGAGAC-MGAT-CA 21 
EMRSA_15 CAG-TGMGT-AGAC-MGAT-CA 20 
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EMRSA_9 CAGGATTACTGTTGTAAAGAGACCAA-ATGTT 31 
EMSA_2 CAGTGGTACAGGTATCCGTGA-ATACAACGATGGMCATTTGG 42 
EMRSA—12 CAGTGGTACAGGTATCCGTGA-ATACAACGATGGAACATTTGG 42 
EMRSA_5 CAG-ATAACACGAAGGA-CATCTGG 23 
EMRSA_10 CAG~TACMCGATGGAACATTrGG 23 
EMRSA—6 CAGGTGGTACAGGTATCCGTGA-ATACMCGATGGMCATTTGG 43 
EMRSA_16  
175_PFGE_I ACAAGCCAAGTG-AAACAAATG-CATACAACGTAACAACAAATCAAGATGGCACAGTATC 178 
176_PFGE_I ACAAGCCAAGTG-AAACAAATG-CATACAACGTAACAACAAATCAAGATGGCACAGTATC 178 
IBERIAN ACGATGGAACATTTGG 16 
Brazilian -CAAGCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCATGATGGCACAGTATC 95 
PFGE_Bla ACAAGCCAAGCG-AAACAAATG-CATACMCGTAACGACAAATCAAGATGGCACAGTATC 97 
132_PFGE_H ACM(XCMGCG-AAACAAATG-CATACAACGTAACGACAAATCMGATGGCACAGTATC 97 
150一PFGE—H ACM(XCMGCG-AMCAMTG-CATACMCGTMCGACAAATCAAGATGGCACAGTATC 97 
PFGE—Ala ACAAGCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
PFGE.Cla ACAAGCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCMGATGGCACAGTATC 97 
PFGEJ)1 ACAAGCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 96 
PFGE_A2a CMGCCMGCG-TMCAAATG-CATACAAAATMCGACAAATCMGATGGCACAGTATC 96 
PFGE_E ACAAGCCAAGCG-TAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
EMRSA—7 ACACCCCAAGCG-AAACAAATG-CATACAACGTAACGACAMTCAAGATGGCACAGTATC 106 
EMRSA—1 ACAAGCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 62 
EMRSA—4 ACACCCCAAGCG-AAACAAATG-CATACAACGTAACGACAAATCMGATGGCACAGTATC 84 
234_PFGE_G ATMGCCATCAG-AAACAAATGGCATACAACGTAACGACAAATCAAGATGGCACAGTATC 98 
238_PFGE_G ATAAGCCATCAG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
EMRSA—11 ACAAGCCATCAG-AAACAAACG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 88 
36_PFGE_F ACAAGCCAAGTG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
61_PFGE_F ACMGCCAAGTG-AAACAMTG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
227—PFGE—F ACMGCCAAGTG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
71_PFGE_F ACAAGCCAAGTG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
NY-Japan ACM(XCMGTG-AMCAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 97 
Paediatric ACAAGCCAAGTGTAAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 96 
EMRSA—3 CCAAGCCAAGTG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 83 
EMRSA_14 -CAACCCAAGTG-AAACAAATG-CATACAACGTAACGACAAATCAAGATGGCACAGTATC 71 
EMRSA_13 ATACCAGATCAG-AMCAMCG-CATACMCGTMCGACAMTCAAGATGGCACAGTMC 79 
EMRSA—15 AGACCCCATCC—AAACAAACG-CATACAACGTAACGACAAATCAAGATGGCACAGTAAC 77 
EMRSA—9 TAGTATTGACTGTATGTCTATG-GATAGAGT-TATAMCmTTTTGTTACTCTAGGACC 89 
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EMRSA—2 ATATGAAGC-GAGACCAAGAT-CAATACCCC-ATCAGAAACAAATGCATATAACGTAACA 99 
EMRSA—12 ATATGAAGCCGAGACCAAGATTCAATACCCCCATCAGAAACAAATGCATATAACGTAACA 102 
EMRS/LS ATATGMGC-GAGACCMGATTCAATACGCC-ATCAGAAACAAATGCATATAACGTAACA 81 
EMRSA_10 ATATGMGC-GAGACCMGATTCMTAAGCC-TTCAGAAACAAATGCATATAACGTAACA 81 
EMRSA_6 ATATGAAGC-GAGACCAAGATTCAATACCCC-ATCAGAMCAAATGCATATAACGTAACA 101 
EMRSA—16 CAGAAGCCAAGC-GAAACAAATGCATACAACGTAACG 36 
175_PFGE—I ATATGGCGC-TCGCCCGACACAAAACAAGCCAAGC-AAAACAAACGCATATAACGTAACA 236 
176_PFGE_I ATATGGCGC-TCGCCCGACACAAAACAAGCCAAGC-AAAACAAACGCATATAACGTAACA 236 
IBERIAN ATATGMGC-GAGACCMGATTCAATAAGCCATCA-GAAACAAATGCATATAACGTAACA 74 
Brazilian ATATGGCGC-TCGCCCGACACAAAACAMCCMGC-GAMCAMTGCATACMCGTMCA 153 
PFGE_Bla ATATGGCGC-TCGCCCGACACAAMCMACCMGOGAMCAAATGCATACMCGTMCA 155 
132—PFGE—H ATATGGCGC-TCGCCCGACACAAMCAMCCMGC-GMACMATGCATACMCGTMCA 155 
150_PFGE_H ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTMCA 155 
PFGE_Ala ATATC^CGC-TCGCCCGACACAAMCAMCCAAGC-GAAACAAATGCATACAACGTAACA 155 
PFGE_Cla ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTAACA 155 
PFGE_D1 ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTAACA 154 
PFGE_A2a ATATGGCGC-TCGCCCGACACAAAACMGCCAAGC-GAAACAAATGCATACAACGTAACA 154 
PFGE—E ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTAACA 155 
EMRSA_7 ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTAACA 164 
EMRSA—1 ATATGGCGC-TCGCCCGACACAAAACAAACCAAGC-GAAACAAATGCATACAACGTAACA 120 
EMRSA_4 ATATGGCGC-TCGCCCGACACAAMCMACCMGC-GMACMATGCATACMCGTMCA 142 
234_PFGE_G ATATGGCGC-TCGTCCGACACAAAAGAAGCCAAGT-GAAACAAATGCATATAACGTAACA 156 
238_PFGE_G ATATGGCGC-TCGTCCGACACAAAAGAAGCCAAGT-GAAACAAATGCATATAACGTAACA 155 
EMRSA—11 ATATGGa^C-TCGCCCAACACAAAACAAGCCAAGC-AAAACAAATGCATATAACGTAACA 146 
36—PFGE—F ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 155 
61—PFGE—F ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 155 
227_PFGE_F ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 155 
71—PFGE—F ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 155 
NY-Japan ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTMCA 155 
Paediatric ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 154 
EMRSA—3 ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAAACGCATATAACGTAACA 141 
EMRSA_14 ATACGGAGC-TCGCCCAACACAAAACAAGCCAAGT-GAAACAMCGCATATAACGTAACA 129 
EMRSA—13 ATATGGCGC-TCGTCCAACACAAAACAAGCCAAGC-AAAACAAACGCATATAACGTAACA 137 
EMRSA—15 ATATGGCGC-TCGTCCAACACAAAACAAGCCAAGC-AAAACAAACGCATATAACGTAACA 135 
EMRSA_9 ATATGTCGCAGTACCATCTGCATGTGTTGmCATTGTATGCATTTGnTTMCTTGGCT 149 
氺 氺 本 氺木氺 ^ 氺 
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EMRSA^2 ACACATGGAAA 110 
EMRSA_12 ACACATGCAMTGGTCMGTATCATACGGAGCTCGTCCGACATACAAGMGCCM-GCGA 161 
EMRSA_5 ACACATGCAAATGGTCMGTATCATACGGAGCTCGTCCGACATACMGMGCCM-GCGA 140 
EMRSA_10 ACACATGCMATGGTCMGTATCATACGGAGCTCGTCCGACATACMGMGCCM-GCGA 140 
EMRSA—6 ACACATGCAMTGGTCMGTATCATACGGAGCTCGTCCGACATACMGMGCCM-GCGA 160 
EMRSA_16 ACAAATCAAGA 47 
175—PFGE—I ACACATGCMATGGTCMGTGTCATACGGAGCTCGTCCGACATACMCMGCCM-GCGA 295 
176—PFGE_I ACACATGCAMTGGTCMGTGTCATACGGAGCTCGTCCGACATACMCM(XCM-GCGA 295 
IBERIAN ACACATGCAAATGGTCAAGTATCATACGGAGCTCGTCCGACATACAAGAAGCCAA-GCGA 133 
Brazilian ACACATGCAAACGGCCAAGTATCATATGGCGCCCGCCC 191 
PFGE—Bla ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 214 
132—PFGE—H ACACATGCAAACGGCCAAGTATCATATGGCGCCCGCCCAACATACAAGAAGCCAA-GCGA 214 
150_PFGEJ1 ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 214 
PFGE—Ala ACACATGCMACGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 214 
PFGE—Cla ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCAA-GCGA 214 
PFGE_D1 ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGAAGCCM-GCGA 213 
PFGE_A2a ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 213 
PFGE—E ACACATGCAMCGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 214 
EMRSA_7 ACACATGCAAACGGCCAAGTATCATATGGCGCCCGCCCAACATACAAGAAGCCAA-GCGA 223 
EMRSA—1 ACACATGCAAACGGCCMGTATCATATGGCGCCCGCCCMCATACMGMGCCM-GCGA 179 
EMRSA—4 ACACATGCAAACGGCCAAGTATCATATGGCGCCCGCCCAACATACAAGAAGCCAA-GCGA 201 
234_PFGE_G ACACATGCAAACGGCCMGTATCATACGGAGCTCGTCCGACATACMCMGCCM-GTM 215 
238_PFGE_G ACACATGCAMCGGCCAAGTATCATACGGAGCTCGTCCGACATACMCMGCCM-GTM 214 
EMRSA—11 ACACATGCMACGGCCMGTATCATATGGCGCTCGCCCGACATACMCMGCCM-GTGA 205 
36_PFGE_F ACACATGCMATGGTCMGTATCATACGGTGCTCGCCCMCACAAMAMGCCM-GCM 214 
61—PFGE_F ACACATGCAMTGGTCAAGTATCATACGGTGCTCGCCCMCACAAAMAAGCCM-GCM 214 
227_PFGE_F ACACATGCAMTGGTCMGTATCATAC(^TGCTCGCCCAACACAAAAAAAGCCAA-GCM 214 
71—PFGE—F ACACATGCMATGGTCMGTATCATACGGTGCTCGCCCMCACAMAMAGCCM-GCM 214 
NY-Japan ACACATGCMATGGTCMGTATCATACGGTGCTCGCCCMCACAAAAAMGCCM-GCM 214 
Paediatric ACACATGCMATGGTCMGTATCATACGGTGCTCGCCCMCACMMCMGTCM-GCM 213 
EMRSA—3 ACACATGCAAATGGTCAAGTATCATACGGAGCTCGCCCGACATACAAG—GCCAA-GCGA 198 
EMRSA—14 ACACATGCAMTGGTCMGTATCATACGGAGCTCGCCCGACATACMGMGCCM-GCGA 188 
EMRSA_13 ACACATGCAMCGGTCMGTATCATACGGAGCTCGTCCGACATACMGMGCCM-GCGA 196 
EMRSA_15 ACACATG-AMCGGTCAAGTATCATACGGAGCTCGTCCGACATACAAGAAGCCAA-GCGA 193 




EMRSA_2 CGGCCAAGTATCATATGGCGCTCGC 135 
EMRSA—12 MCGMTG—CATACAATGTMCMCACATGCAMCGGCCMGTATCATACGGAGCTCGT 219 
EMRSA—5 AACGAATG—CATACAATGTAACAACACATGCAAACGGCCAAGTATCATACGGAGCTCGT 198 
EMRSA—10 MCGMTG—CATACMTGTMCMCACATGCAMCGGCCMGTATCATACGGAGCTCGT 198 
EMRSA—6 MCGMTG--CATACMTGTMCMCACATGCAMCGGCCMGTATCATACGGAGCTCGT 218 
EMRSA_16 TGGCACAGTATCATA-GGCGCTCGC 71 
175_PFGE_I MCAAATGG-CATATMCGTMCMCACATGCAMCGGGCMGTATCATACGGAGCTCGT 354 
176—PFGE—I MCAAATGG-CATATMCGTMCMCACATGCAAACGGGCMGTATCATACGGAGCTCGT 354 
IBERIAN MCGMTG—CATACMTGTMCMCACATGCAAACGGCCMGTATCATACGGAGCTCGT 191 
Brazilian  
PFGE—Bla AACAAACG—CATACAACGTAACGACAAATCAAGATGGCACAGTATCATATGGCGCTCGC 272 
132_PFGE_H AACAAACG--CATACAACGTAACGACAAATCAAGATGGCACAGTATCATATGGCGCTCGC 272 
150—PFGE—H AACAAACG—CATACAACGTAACGACAMTCAAGATGGCACAGTATCATATGGCGCTCGC 272 
PFGE_Ala AACAAACG--CATACAACGTAACGACAAATCAAGATGGCACAGTATCATATGGCGCTCGC 272 
PFGE—Cla AACAAACG—CATACMCGTMCGACAMTCMGATGGCACAGTATCATATGGCGCTCGC 272 
PFGE_D1 AACAAACG—CATACMCGTMCGACAMTCMGATGGCACAGTATCATATGGCGCTCGC 271 
PFGE—A2a MCAMCG--CATACMCGTMCGACAAATCAAGATGGCACAGTATCATATGGCGCTCGC 271 
PFGE—E AACAAACG—CATACMCGTMCGACAMTCMGATGGCACAGTATCATATGGCGCTCGC 272 
EMRSA_7 AACAAACG—CATACMCGTMCGACAAATCMGATGGCACAGTATCATATGGCGCTCGC 281 
EMRSA—1 AACAAACG—CATACAACGTAACGACAAATCAAGATGGCACAGTATCATATGGCGCTCGC 237 
EMRSA_4 MCAAACG—CATACMCGTMCGACAMTCMGATGGCACAGTATCATATGGCGCTCGC 259 
234—PFGE—G MCAAATGG-CATATMCGTMCMCACATGCAAACGGCCMGTATCATATGGCGCTCGC 274 
238_PFGE_G MCAAATG—CATATMCGTMCMCACATGCAAACGGCCMGTATCATATGGCGCTCGC 272 
EMRSA—11 MCAAATG—CATACMCGTMCGACAMTCGAGATGGCACAGTATCATATGGCGCTCGC 263 
36_PFGE_F MCAAATG—CATACMCGTMCMCACATGCAAATGGTCMGTATCATATGGCGCTCGC 272 
61_PFGE_F MCAAATG—CATACAACGTMCMCACATGCMATGGTCMGTATCATATGGCGCTCGC 272 
227_PFGE_F MCAMTG—CATACMCGTMCMCACATGCAMTGGTCMGTATCATATGGCGCTCGC 272 
71_PFGE_F MCAAATG—CATACMCGTMCMCACATGCAMTGGTCMGTATCATATGGCGCTCGC 272 
NY-Japan MCAAATG—CATACMCGTMCMCACATGCMATGGTCMGTATCATATGGCGCTCGC 272 
Paediatric MCAAATG—CATACMCGTMCMCACATGCMATGGTCMGTATCATATGGCGCTCGC 271 
EMRSA—3 MCAAATG—CATACMCGTMCMCACATGCAMTGGTCMGTATCATATGGCGCTCGC 256 
EMRSA_14 MCAAATG—CATACMCGTMCMCACATGCAMTGGTCMGTATCATATGGCGCTCGC 246 
EMRSA—13 MCGMTG—CATATMCGTMCMCACATGCAAACGGTCMGTATCATATGGCGCTCGT 254 
EMRSiLlS MCGMTG—CATATMCGTMCMCACATGCAMCGGTCMGTATCATATGGCGCTCGT 251 
EMRSA—9 TATATGCGTTCGTTTCGCTTGGCT-TGTTTTGTGTCGGACGAGCTCCGTATGATACTTGG 267 
EMRSA—2 CCMC-ACAAAACAAGCCAAGCAAAACAAACG-CATATAACGTAACAAC--ACATGGAAA 191 
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EMRSA—12 CCGAC-ACAAMCAAGCCAAGCAAAACAAACG-CATATAACGTAACAAC--ACATGGAAA 275 
EMRSA—5 CCGAC-ACAAMCM(XCAAGCAAAACAMCG-CATATAACGTAACAAC--ACATGGAAA 254 
EMRSA—10 CCGAC-ACAAMCMGCCMGCAAAACAAACG-CATATAACGTAACAAC--ACATGGAAA 254 
EMRSA_6 CCGAC-ACAAMCMGCCAAGCAAAACAAACG-CATATAACGTAACAAC--ACATGGAAA 274 
EMRSA—16 CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 127 
175—PFGE_I CCGAC-ATACAAGAAACCAAGCGAAACGAACGGCATATAACGTAACAAC—ACATGCAAA 411 
176_PFGE_I CCGAC-ATACAAGAAACCAAGCGAAACGAACGGCATATAACGTAACAAC--ACATGCAAA 411 
IBERIAN CCGAC-ACAAAACAAGCCAAGCAAAACAAACG-CATATAACGTAACAAC--ACATGGAAA 247 
Brazilian —GAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 245 
PFGE_Bla CCGAC-ACAAMCMGCCMGCGMACMACG-CATATMCGTMCMC--ACATGCAAA 328 
132—PFGE—H CCGAC-ACAAAACMGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 328 
150—PFGE—H CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 328 
PFGE—Ala CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 328 
PFGE_Cla CCGAC-ACMMCMGCCMGCGAMCAMCG-CATATMCGTMCMC--ACATGCAAA 328 
PFGE—D1 CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 327 
PFGE_A2a CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC~ACATGCAAA 327 
PFGE—E CCGAC-ACMAACMGCCMGCGAAACAMCG-CATATAACGTMCMC—ACATGCAAA 328 
EMRSA—7 CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 337 
EMRSA—1 CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 293 
EMRSA_4 CCGAC-ACAAMCAAGCCAAGCGAAACAAACG-CATATAACGTAACAACC-ACATGCAAA 316 
234_PFGE_G CCGAC-ACAAAACAAGCCAAGCGAAACAAACGGCATATAACGTAACAAC—ACATGCAAA 331 
238_PFGE_G CCGAC-ACAAAACAAGCCAAGCGAAACAAACG-CATATAACGTAACAAC—ACATGCAAA 328 
EMRSA一11 CCGAC-ACAAAACAAGCCAAGCGAAACGAATG-CATATAACGTAACAAC—ACACGGAAA 319 
36_PFGE_F CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 328 
61_PFGE_F CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 328 
227_PFGE_F CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 328 
71_PFGE—F CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATMCGTAACAAC—ACATGCAAA 328 
NY-Japan CCGAC-ACMAMMGCCMGCAMACMATG-CATATMCGTMCMC—ACATGCAAA 328 
Paediatric CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 327 
EMRSA—3 CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 312 
EMRSA—14 CCGAC-ACAAAAAAAGCCAAGCAAAACAAATG-CATATAACGTAACAAC—ACATGCAAA 302 
EMRSA—13 CCGAC-ACAAAACAAGGCAAGCGAAACAAATG-CATACAACGTAACAAC—ACATGCAAA 310 
EMRSA_15 CCGAC-ACAAAACAAGGCAAGCGAAACAAATG-CATACAACGTAACAAC—ACATGCAAA 307 
EMRSA—9 CCGTTTGCATGTGTTGCCTTACGTTATATGCG-TTTGTTTCGCTTCGGCTTGTnTGTGT 326 
氺 氺 氺 氺 氺 氺 木 氺 氺 氺 
EMRSA_2 CGGCCAAGTATCATATGGCGCTCGCCCAACACMAACAAGCCMGCAAMCAAATG-CAT 250 
EMRSA_12 CGGCCAAGTATCATATGGCGCTCGCCCMCACAAAACMGCCMGCAAAACAAATG-CAT 334 
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E M R S O CGGCCAAGTATCATATGGCGCTCGCCCMCACAAMCAAGCCMGCMMCAMTG-CAT 313 
EMRSA^IO CGGCCMGTATCATATGGCGCTCGCCCMCACAAAACMGCCMGCAAMCAAATG-CAT 313 
EMRSA—6 CGGCCAAGTATCATATGGCGCTCGCCCMCACAAMCMGCCMGCAAMCAMTG-CAT 333 
EMRSA_16 CGGCCAAGTATCATACGGAGCTCGTCCGACACAAAACMGCCAAGCGAAACGMCG-CAT 186 
175_PFGE_I CGGCCMGTATCATATGGCGCTCGCCCMCACAAMCMGCCMGTAAMCAMTGGCAT 471 
176_PFGE_I CGGCCMGTATCATATGGCGCTCGCCCAACACAAAACMGCCMGTMAACAAATGGCAT 471 
IBERIAN CGGCCAAGTATCATATGGCGCTCGCCCAACACAAAACAAGCCAAGCAAAACAAATG-CAT 306 
Brazilian CGGCCMGTATCATACGGAGCTCGTCCGACACAAMCMGCCMGCGAMCGMCG-CAT 304 
PFGE_Bla CGGCCMGTATCATACGGAGCTCGTCCGACACAAAACMGCCMGCGMACGMCG-CAT 387 
132—PFGE—H CGGCCAAGTATCATACGGAGCTCGTCCGACACAAMCMGCCMGCGAMCGMCG-CAT 387 
150—PFGE—H CGGCCMGTATCATACGGAGCTCGTCCGACACAAAACMGCCMGCGAMCGMCG-CAT 387 
PFGE_Ala CGGCCMGTATCATACGGAGCTCGTCCGACACAAMCMGCCMGCGAMCGMCG-CAT 387 
PFGE_Cla CGGCCMGTATCATACGGAGCTCGTCCGACACAMACMGCCMGCGMACGMCG-CAT 387 
PFGE_D1 CGGCCAAGTATCATACGGAGCTCGTCCGACACAAAACAAGCCAAGCGAAACGAACG-CAT 386 
PFGE—A2a CGGCCMGTATCATACGGAGCTCGTCCGACACAMACMGCCMGCGAMCGMCG-CAT 386 
PFGE—E CGGCCMGTATCATACGGAGCTCGTCCGACACMMCMGCCMGCGAMCGMCG-CAT 387 
EMRSA—7 CGGCCAAGTATCATACGGAGCTCGTCCGACACAAAACAAGCCAAGCGAAACGAACG-CAT 396 
EMRSA.l CGGCCMGTATCATACGGAGCTCGTCCGACACAMACMGCCMGCGAMCGMCG-CAT 352 
EMRS1_4 CGGCCMGTATCATACGGAGCTCGTCCGACACAAMCMGCCMGCGMACGMCG-CAT 375 
234_PFGE_G CGGCCMGTATCATATGGCGCTCGCCCGACACAAMCMGCCMGCGMACMAGG-CAT 390 
238—PFGE—G CGGCCAAGTATCATATGGCGCTCGCCCGACACAAAACMGCCAAGCGAAACAAACG-CAT 387 
EMRSA—11 TGGCCAAGTATCATATGGCGCTCGTCCGACACAMAGMGCCMGCAMACAMTG-CAT 378 
36_PFGE_F TGGTCAAGTATCATACGGAGCTCGCCCGACATACAAGAAGCCAAGCGAAACAAATG-CAT 387 
61_PFGE_F TGGTCAAGTATCATACGGAGCTCGCCCGACATACAAGAAGCCAAGCGAAACAAATG-CAT 387 
227—PFGE—F TGGTCAAGTATCATACGGAGCTCGCCCGACATACMGAAGCCAAGCGAAACAMTG-CAT 387 
71—PFGE_F TGGTCMGTATCATACGGAGCTCGCCCGACATACMGMGCCMGCGAMCAMTG-CAT 387 
NY-Japan TGGTCMGTATCATACGGAGCTCGCCCGACATACMGMGCCMGCGMACAMTG-CAT 387 
Paediatric TGGTCAAGTATCATACGGAGCTCGCCCGACATACAAGAAGCCAAGCGAAACAAATG-CAT 386 
EMRSA—3 TGGTCAAGTATCATACGGAGCTCGCCCGACATACAAGMGCCAAGCGAAACAAATG-CAT 371 
EMRSA_14 TGGTCMGTATCATACGGAGCTCGCCCGACA-ACMGMGCCMGCGAMCMATG-CAT 360 
EMRSA—13 TGGTCMGTATCATATGGCGCTCGTCCGACACMMCMGCCMGCAMACAMCG-CAT 369 
EMRSA—15 TGGTCMGTATCATATCGCGCTCGTCCGACACMMCMGCCMGCMMCAMCG-CAT 366 
EMRSA_9 CGGGCGAGCGCCATATGATACTGTGCCATCTTGATTCTGTCGTTACGTTGTATGCG-TTT 385 
氺 本 本 氺 本 氺 氺 术 本本 氺 氺 ： 本 ^ ^ 
EMRSA_2 ACMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCGACATACM 308 
EMRSA—12 ACMCGTMCMC-ACATGCAAAC-GGTCMGTGTCATACGGAGCTCGCCCGACATACM 392 
EMRSA_5 ACMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCGACATACM 371 
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E M R S U O ACMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCGACA-ACM 370 
EMRSA—6 ACMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCGACATACM 391 
EMRS/L16 ATMCGTMCMC-ACATGCAMC-raCMGTGTCATACGGAGCTCGCCCMCACAm 244 
175—PFGE_I ATAACGTAACAAC-ACATGCAAAT-GGTCAAGTGTCATACGGTGCTCGTCCGACATACAA 529 
176—PFGE—I ATAACGTAACMC-ACATGCAAAT-GGTCAAGTGTCATACGGTGCTCGTCCGACATACAA 529 
IBERIAN ACMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCGACATACAA 364 
Brazilian ATMCGTMCMC-ACATGCMAC-GGTCMGTGTCATACGGAGCTCGCCCMCACMM 362 
PFGE— M a ATAACGTAACAAC-ACATGCAAAC-GGTCAAGTGTCATACGGAGCTCGCCCAACACAAAA 445 
132_PFGE_H ATMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCMCACAMA 445 
150_PFGE_H ATMCGTMCMC-ACATGCAMC-OTCMGTGTCATACGGAGCTCGCCCMCACAAM 445 
PFGE_Ala ATMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACG-AGCTCGCCCMCACAAAA 444 
PFGE_Cla ATMCGTMCMC-ACATGCAAAC-GGTCAAGTGTCATACGGAGCTCGCCCAACACAAAA 445 
PFGE—D1 ATAACGTAACAAC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCAACACAAAA 444 
PFGE_A2a ATAACGTAACAAC-ACATGCAAAC-GGTCAAGTGTCATACGGAGCTCGCCCAACACAAAA 444 
PFGE—E ATMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCMCACMM 445 
EMRSA_7 ATMCGTMCMC-ACATGCAMC-GGTCMGTGTCATACGGAGCTCGCCCMCACAMA 454 
EMRSA—1 ATMCGTMCMC-ACATGCMAC-GGTCMGTGTCATACGGAGCTCGCCCMCACAAM 410 
EMRSA_4 ATMCGTMCACC-ACATGCAMC-GGTCAAGTGTCATACGGAGCTCGCCCAACACAAM 433 
234_PFGE_G ATAACGTAACAAC-ACATGCAAAC-GGCCAAGTATCATACGGAGCTCGTCCAACACAAAA 448 
238_PFGE_G ATMCGTMCMC-ACATGCAMC-GGCCMGTATCATACGGAGCTCGTCCMCACAMA 445 
EMRSA_11 ATMCGTMCACC-ACATGCAAAC-GGCCMGTATCATATGGCGCTCGTCCGACATACM 436 
36_PFGE_F ACMCGTAACAAC-ACATGCAAAT-GGTCMGTATCATATGGCGCTCGCCCGACACAAAA 445 
61—PFGE—F ACAACGTAACAAC-ACATGCAAAT-GGTCMGTATCATATGGCGCTCGCCCGACACAAAA 445 
227_PFGE_F ACAACGTAACAAC-ACATGCAAAT-GGTCAAGTATCATATGGCGCTCGCCCGACACAAAA 445 
71_PFGE—F ACMCGTMCMC-ACATCCAAAT-GGTCMGTATCATATGGCGCTCGCCCGACACMM 445 
NY-J apan ACAACGTAACAAC-ACATGCAAAT-GGTCAAGTATCATATGGCGCTCGCCCGACACAAAA 445 
Paediatr ic ACMCGTMCMC-ACATGCAMT-GGTCMGTATCATATGGCGCTCGCCCGACACMM 444 
EMRSA—3 ACAACGTMCAACCACATGCAAAT-GGTCAAGTATCATATGGCGCTCGCCCGACACAAAA 430 
EMRSA—14 ACAACGTAACAAC-ACATGCAAAT-GGTCCAGTATCATATGG-GCCTCCCCGACACAAAA 417 
EMRSA—13 ATMCGTMCMC-ACACGGMAT-GGCCMGTATCATACGGAGCTCGCCCGACATACM 427 
EMRSA_15 ATMCGTMCMC-ACACG-MAT-GGCCMGTATCATACGGAGCTCGCCCGACATACM 423 
EMRSA—9 GTTTCGCTTCGGCTTCTTGTATGTTGGGCGGGCGCCATATGATACTTGGCCGTTT——G 441 
氺氺 氺 禾 氺 氺 氺 ^ ^ ^ ^ 本 氺 氺 氺 本 氺 氺木 
EMRSA—2 GMGCCMGT-AAMCAMTG-CATACAATGTAACMC-ACATGCAGATGGTACTGCGAC 365 
EMRSA—12 GAAGCCAAGT-AAMCAMTG-CATACAATGTMCAAC-ACATGCAGATGGTACTGCGAC 449 
EMRSA—5 GMGCCMGT-AMACMATG-CATACMTGTMCAAC-ACATGCAGATGGTACTGCGAC 428 
EMRSA—10 GAAGCCAAGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 427 
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EMRSA—6 GMGCCMGT-AAMCMATG-CATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 448 
EMRSA—16 CAAGCCAAGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 301 
175—PFGE—I GAAGCCAAGC-GAAACAAATGGCATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 587 
176_PFGE_I GAAGCCAAGC-GAMCAAATGGCATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 587 
IBERIAN GMGCCMGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 421 
Brazilian CMGCCMGT-AMACAMTG-CATACAATGTMCMC-ACATGCAGATGGTACTGCGAC 419 
PFGE_Bla CMGCCMGT-MMCAMTG-CATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 502 
132_PFGE_H CMGCCMGT-AAMCAMTG-CATACMTGTAACAAC-ACATGCAGATGGTACTGCGAC 502 
150—PFGE_H CMGCCMGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 502 
PFGE—Ala CMGCCMGT-AAMCMATG-CATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 501 
PFGE—Cla CMGCCMGT-AAMCAMTG-CATACMTGTMCAAC-ACATGCAGATGGTACTGCGAC 502 
PFGE—D1 CMGCCMGT-AAMCAMTG-CATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 501 
PFGE_A2a CAAGCCAAGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 501 
PFGE—E CAAGCCAAGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 502 
EMRSA_7 CMGCCMGT-AAMCAMTG-CATACMTGTAACAACCACATGCAGATGGTACTGCGAC 512 
EMRSA_1 CAAGCCAAGT-AAAACAAATG-CATACMTGTAACMC-ACATGCAGATGGTACTGCGAC 467 
EMRSA一4 CAAGCCAAGnAAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 491 
234—PFGE—G CMGCCMGT-MMCGMTGGCATATMTGTMCMC-ACATGCAGATGGTACTGCGAC 506 
238_PFGE_G CMGCCMGT-AAMCGMTGGCATATMTGTMCMC-ACATGCAGATGGTACTGCGAC 503 
EMRSA_11 CAAGCCAAGT-AAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 493 
36_PFGE_F AAAGCCMGC-GAAACAAACG-CATATMCGTMCMC-ACATGCAGATGGTACTGCGAC 502 
61_PFGE_F MAGCCMGC-GMACAMCG-CATATMCGTMCMC-ACATGCAGATGGTACTGCGAC 502 
227_PFGE_F M A G C C M G C - G A A A C M A C G - C A T A T M C G T M C M C - A C A T G C A G A T G G T A C T G C G A C 502 
71_PFGE_F MAGCCMGC-GMACAMCG-CATATMCGTMCMC-ACATGCAGATGGTACTGCGAC 502 
NY-Japan A A A G C C A A G C - G A A A C A A A C G - C A T A T M C G T A A C A A C - A C A T G C A G A T G G T A C T G C G A C 502 
Paediatric MAGCCMGC-GAAACAMCG-CATATMCGTMCMC-ACATGCAGATGGTACTGCGAC 501 
EMRSA—3 MAGCCMGC-GAMCAAACG-CATATMCGTMCMC-ACATGCAGATGGTACTGCGAC 487 
EMRSA—M M A G C C M G C - G M A C A A A C G - C A T A T M C G T M C M C C A C A T G C A G A T G G T A C T G C G A C 475 
EMRSA_13 GMGCCMGC-GMACAMTG-CATACMTGTMCMC-ACATGCAGATGGTACTGCGAC 484 
EMRSA_15 GAAGCCMGC-GAAACAAATG-CATACAATGTAACAAC-ACATGCAGATGGTACTGCGAC 480 
EMRSA_9 CATGTGTTGT—-TACGTATG-TATGCATTGTTGTTrC-GCTTGCAGTTTGTTTTGTGTC 496 
氺 氺 氺 氺 氺 泳 氺 木本 氺 氺 木 氺 木 氺 木 氺 氺 氺 氺 ； i ； 氺 木 乐 氺 
EMRSA_2 ATATGGGCCTAGAGTMCAAMTMGTTTGTMCTC--TATCCAMGACATACAGTCMT 423 
EMRSA—12 ATATGGGCCTAGAGTMCAAMTMGTTTGTMCTC--TATCCAMGACATACAGTCMT 507 
EMRSA—5 ATATGGGCCTAGAGTMCMAATMGTTTGTMCTC—TATCCAMGACATACAGTCMT 486 
EMRSA.IO ATATGGGCCTAGAGTMCAAMTMGTTTGTMCTC--TATCCAMGACATACAGTCMT 485 
EMRSA—6 ATATGGGCCTAGAGTMCAAMTMGTTTGTMCTC—TATCCMAGACATACAGTCTAT 506 
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EMRSA^ie ATATGGTCCTAGAGTMCAMATMGTTTATMCTC--TATCCATAGACATACAGTCMT 359 
175—PFGE—I ATATGGTCCTAGAGTMCAMATMGTTTATA-CTC--TATC 626 
176—PFGE—I ATATGGTCCTAGAGTMCAAAATAAGTrTATA-CTC——ATC 625 
IBERIAN ATATGGGCCTAGAGTMCMMTMGTTTGTMCTC--TATC 461 
Brazilian ATATGGTCCTAGAGTAACAAAATAAGnTATAACTC 455 
PFGE.Bla ATATGGTCCTAGAGTAACAAAATAAGTTTATAACTC 538 
132_PFGE_H ATATGGTCCrAGAGTAACAAAATMGTTTATA-CTC—ATCG 541 
150_PFGE_H ATATGGTCCTAGAGTAACAAAATAAGTTTATA-CTC—ATC 540 
PFGE.Ala ATATGGTCCTAGAGTAACAAAATAAGTTTATAACTC 537 
PFGE—Cla ATATGGTCCTAGAGTAACAAAATAAGTTTATAACTC 538 
PFGE_D1 ATATGGTCCTAGAGTAACAAAATMGnTATAACTC 537 
PFGE—A2a ATATGGTCCTAGAGTAACAAAATAAGTTTATAACTC 537 
PFGEJE ATATGGTCCTAGAGTAACAAAATAAGTTTATAACTC 538 
EMRSA_7 ATATGGTCCTAGAGTMCAAAATMGTTTATMCTC—TATCCATAGACATACAGTCMT 570 
EMRSA—1 ATATGGTCCTAGAGTMCMMTMGTTTATMCTC—TATCCATAGACATACAGTCMT 525 
EMRSA—4 ATATGGTCCTAGAGTMCAAMTMGTTTATMCTC—TATCCATAGACATACAGTCMT 549 
234—PFGE—G ATAIGGGCCTAGAGTAACAAAATAAATTrATA—CT—CATC 544 
238_PFGE_G ATATGGGCCTAGAGTMCAMATMATTTATMCTC—TATC 543 
EMRSA—11 ATATGGTCCTAGAGTMCMMTMGTTTATMCTC—TATCCATAGACATACAGTCMT 551 
36_PFGE—F ATATGGGCCTAGAGTAACAAAATAAATTTATAACTC—TATC 542 
61—PFGE_F ATATGGGCCTAGAGTMCAMATMATTTATMCTC—TATC 542 
227_PFGE_F ATATGGGCCTAGAGTAACAAAATAAATTTATAACTC--TATC 542 
71—PFGE—F ATATGGGCCTAGAGTMCMMTAAATTTATMCTC--TATC 542 
NY-Japan ATATGGGCCTAGAGTAACAAAATAAATTTATAACTC 538 
Paed iatric ATATCGGCCTAGAGTMCAMATMATTTATATTC 536 
EMRSA—3 ATATGGGCCTAGAGTMCMAATMmTATMCTC--TATCCAAAGACATACAGTCMT 545 
EMRSA_14 ATATGGGCCTAGAGTMCMAATAAATTTATMCTC—TATCCAAAGACATACAGTCMT 533 
EMRSA—13 ATATGGGCCTAGAGTMCAMATMGTTTGTMCTC—TATCCMAGATATACAGTCMT 542 
EMRSA_15 ATATGGGCCTAGAGTAACAAAATMGTTTGTMCTC--TATCCAMGATATACAGTCTTT 538 
EMRSA—9 GGGCGAGCGCCATATGATACTGTGCCATCTTGATTTGTCGmCGTTGTATGCATTTGrr 556 
；Jc 氺 本 氺 氺 氺 氺 乐 
EMRSA—2 ACMAA-CATTACGTATCTTTACMCAGTMTCATGCATTCTATGATGCrrCTMCTGM 482 
EMRSA—12 ACAMA-CATTACGTATCnTACMCAGTMTCATGCATTCTATGATGCTTCTMCTGM 566 
EMRSA_5 ACMAMCATTACGTATCTTTACMCAGTMTCATGCATTCTATGATGCTTCTMCTGM 546 
EMRSA—10 ACMAA-CATTACGTATCTTTACMCAGTMTCATGCATTCTATGATGCTTCTMCTGM 544 
EMRSA—6 ACAAAA-CGGTACGT-TCTTTACAACAGTAT 535 















EMRSA—7 A C M 574 
EMRSA—1 ACAAAA-CAmiGT-TCTTTACAACAGT 552 
EMRSA_4 ACAM--CGTTATGTATCTTTACAACAGTA-- 577 
234_PFGE_G  
238—PFGEjG  







EMRSA-3 ACAAAG-MTTATGTATCTATACAACAGT 573 
EMRSA—14 ACA 536 
EMRSA_13 ACAAM-CA 550 
EMRSA_15 A 539 
EMRSA—9 TCGCTTGGCTTGGGA 571 
EMRSA—2 TTAAAGCATCGAACAATCGG 502 
EMRSA_12 TTAAAGCATCGMCAA——582 
EMRSA—5 TTAAAGCATCGA 558 
EMRSA—10 TTAAAGCATCGAACAAT561 
EMRSA_6  


































Appendix IV (A4) - Typing patterns and Characteristics 
of reference isolates 
PFGE+Te-C 
PFGE(m«in>^«nti-B PPGE PFGEfrnaln)4artl-B S^ ay SEA-SEE TSST SEG-SEJ 
o o 曰 f ， f 二 ^ ^ ^ ® ^^  ^ ^ ^ ^ ^ ^ ^ ^^ 
fi ！III iiiiiiiti ssssssssssssi a J _ 丨丨旧 nil Mini • • • • • • • • • • • • • • 
r— I I I I I nil I Mill iiiiiiiiiiiii m • 
r H Z II I lillll mill I l l l l l i l l l l l l H i 
J 1 1 II I II iiiiii ! ! ! ! ! ! ! ! ! ! ! ! ! 國 
� [ II I IN I Mill ! ! • ! ! ! ! ! ! ! ! ! ! ™ • r III I I III Mini • • !••• !•• !•• ! S 9 
_ n II11 I III I MlII • • • • • • • • • • • • • • _ L II I I III I Mill • • l l l l i l l l l l l • • 
f III Hi iiiiii ! ! ! ! ! ! ! ! ! ! ! ! ! B • 
_ n — III III IIIIII ! ! ! ! ! ! ! ! ! ! ! ! ! S 圓 —— I III III Ml • • l l l l i l l l l l l Hi • , _ I nil • • l l l l i l l l l l l • • 
jCZ I 丨丨丨丨 j I iiiiiii IIIIII m • � � I 'ii 丨 I III' II III ••••••••••••• • 
I II nil III III • • • • • • • • • • • • • • • 
L I III II 11 II nil I I I I I I I I I I I I I 丨 丨 II III III n nil wm m , I II I Mill i i i l l l i l l l l l l • 
[ jCZZ II I I nil 
I Ml Hill II i i l l l i l l l l l l l m • • • �I I III i II i nil • • • 
^ ii III I II 1111 2 ! ! ! ! ! ! ! ! ! ! ! ! • 
r — I I ！ I III IIIIII • • • • • • • • • n i l 
I I M l I Hill • • l l l l i l l l l l l • 
[ t “ 'i',,|f,i', S i l S S S i i S S S S ! s s • 
丨 11 丨丨丨 mil I i l l l i l l l l l l l • I I 
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:G-SEJ Adhedns &toxlns Phaga Typing  
0 UJ 5 3 C JD -p £ -p 
75 (fi (/) 」 o ^ •»= X： c： X： C M i o i o r - o o c O c o i o r - r o c D T } - ^ i o u ^ h - r * - c o c o c o c o O T a > 
n _ _ • m U I I I F2436 2000 FWH PWH Pattern A2 
__ I • H I I F4027 1999 PWH PWH Patern Ola 
• • • I • • • F1602 1999 FWH PWH Patern A1 
• • • • • • • • • •圃 F8ig0 1994 PWH PWH Patern A1 
HmH • • • I • • F0060 1993 PWH PWH Patern A2 
• • • • • • • • • • • F0556 1998 PWH PWH Patern D1 
• • • • • • • • • F5406 1997 PWH PWH Patern E 
m H • • • • • — • • • • F0750 1995 PWH PWH Patern E 
H I m • F0771 1997 PWH PWH Patern Clb 
• • • • • I • • — • • • ••画 F1063 2000 PWH PWH Patern B 
n m m I I 漏• | |__il__ • F51 龙 1995 PWH PWH Pattern B 
• • 歴 • •懕••___••• F8015 1996 PWH PWH Patern B 
I I _ « • 一 ^ 
• • • • • eMFSArS 
I I I • • I I I I I 
• I • • • _ • I . _ i 一 
• • • • I I 11 • • • • • • 11 I I I I I H I 菌 • • • n _ I I I • • ！ I m 
• • • • • ••••！ eMRSA^a 
• • • • I • • • • • eMRS^. • I n I I I • • • • • I I I eMRs/vs I I I • • I I I 1 • ! • • • B-an 
I I I III! I I NY/Jap. 
• • • • • eMRSA-3 
• • • • • Iberian 
• • H I I I I I I e叫. I I H I • • • • • • • • • • Pediatric RTD1000. 
I II III e瞧. 
• • • • eMFSA-. 
Key 
PFGE(main)+anti-B SCCmec SEA-SEE, TSST-1, . 
5议 type Phage typing 
=antibiogram type SEG-SEJ, Adhesins&Toxins  
_墓 resistant 1 1 ~ P r e s e n c e of a geneUp^J^^^i^^^^J^n 
Colour and intermediate 2 2 ^^J weak reaction 
implication " J ^susceptible W 3 • 3 Inhibition 




Appendix V (A5) 一 Miscellaneous 
Table 1 Antibiotic resistance profile in PFGE type A isolates 
No. of isolates Antibiotic resistance , 八^、 
(n=99) 
T E D G To a 71 
2 T E D G To Ci M 5 
3 T E D G To Ci F 4 
4 T E G To Ci 4 
5 T E D G To Ci N 2 
6 G To Ci 2 
7 T E D G To 2 
S T E D G T o C i N M 1 
9 E D Ci M F R 1 
10 E D G To Ci 1 
11 T E G To Ci N S 1 
12 T E G To Ci M C 1 
13 T E D Ci 1 
14 T E Ci 1 
15 E G To Ci 1 
16 T E D G To R 1 
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Table 2 Antibiotic resistance profile in PFGE type F isolates 
A .1. . . No. of isolates 
Antibiotic resistance , 
(n:35) 
1 " ~ T E G l b C i 22 
2 T E D G To Ci 4 
3 T E G To Ci M 2 
4 T E G To Ci M C 1 
5 G To Ci 1 
6 E To Ci 1 
7 T E G To 1 
8 T E D G To Ci R 1 
9 T E Ci 1 
10 T E To Ci 1 
Table 3 Antibiotic resistance profile in PFGE type G isolates 
No. of isolates 
Antibiotic resistance , … 
(n=26) 
T E C T 16 
2 Ci 3 
3 T E D G To Ci 2 
4 To Ci 2 
5 T Ci 1 
6 T E D Ci 1 
7 E To Ci 1 
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Table 4 Unique Antibiotic resistance profile 
Antibiotic Sample no. Stock no. Date Source 
Profiles 
1 EDCMFR #29 1782 17/05/01 PWH 
2 E #233 PYNEH 
3 TEDGToCiNM #24 123 09/01/00 PWH 
4 TEGToCiC #28 20 02/01/00 PWH 
5 TEGTo #31 639 19/02/01 PWH 
6 TEGToCiNM #149 01MB002360 08/03/01 PMH 
7 EGToCi #40 1287 10/04/01 PWH 
8 EDGToCi #209 PYNEH 
9 ECi #19 3725 07/10/00 PWH  
10 TCi #11 3554 11/09/00 PWH 
11 TEDToCi #79 A9142 PYNEH 
12 TEToCi #237 PYNEH 
13 TEGToCiNMS #140 01MB000779 27/01/01 PMH  
14 TEGToCiMS #221 PYNEH 
15 TEGToCiNF #26 1853 11/06/01 pPWH 
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Table 5 Genetic characteristics of remaining 11 PFGE type A isolates 
SEA-SEE TSST+et SEG-SEJ Adhesins & toxins 
泛 S 袋 LuiuiSS 
« W 1- COOTWW 
m m 026 1853 11/06/01 PWH A2 
i m • • 040 1287 10/04/01 PWH A2 
I m H 058 261 04/11/01 PWH A2 
• ^ ^ 096 00MB 007950 22/07/00 PMH A2 
m H ^ ^ g • • • • 106 OOMB 010127 17/09/00 PMH A2 
V H 111 OOMB 011021 18/10/00 PMH A2 
114 OOMB 011388 27/10/00 PMH A2 
141 01MB 000838 29/01/01 PMH A2 
L ^ M 172 T-128 TKOH A 
• 173 T-129 TKOH A2 
232 PYNEH A2 
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Tab le 6 P h a g e p a t t e r n in all P F G E type isolates 
a ) P F G E t y p e A isolates 
PMfl* PtiaOBl^g 
• . ^RbSSBAiierS.^ bsss^BiSBSSS 
'"二 t ' • " • • 170 T-S3 TK)H A3 叫 — • • • • • • 012 3656 ia090�PV^  « C0«5«A , • • 003 3221 31咖0 PWi « A1471964 I I • 184 01MB054SQ 22iOMi PMH « I • • 激 4 10/1000 P 州 to. B2flS7707 im UMBO 09617 taoaoo Phtn « 113 0QMe0125« Z/IQOO ？ « 11S 0CMB01643 PfcH « |> I 235 P^NBI « I . • 211 ？ 細 « JLJ 1 I 214 P 郷 « 
II ~ • P 100 OCMBOOSag? 2Bj08(00 ptiti « ri' 141 O1M8OOOS30 20101 P»1 « _ • • • 172 T-12B TtOH A • m • _ H 122 0mB01230t 2Sfl1/0Q PMi « H • • • • 171 T^S TtOH « 
I • 105 OCMB01061 1D£9Q0 PV« « 
I I • 202 P^B^ « 
_ U — L — • • 1« OlMeO 02339 ITiOOl « T • 0GMe0183e OMIiOO PfcH « • 051 4 01 £>1/01 P 州 n 0698 0«2 • 210 P^EH n • • • 110 0CMB010r2B OMOO PfcH K2 « • • • • • I 143 01MB0170 CB£t2!D1 PhU « J t m JM • I 033 0(MB073SB lOCTAJO PfcW « 
1 ••• gl^l I log o0MB0ia58B aw 000 pm K 
_ _ _ _ _ Bip • • 075 PVJai « 
警 •• _ 圔^^ • •画 • • 啦 棚。 P利出 位 
• • • • • • I I 144 01MB0013S3 13jD2(01 PhW « 
• M • • 015 4426 3tW1/00 P 州 A2 02«S181 
• “ " V " •• • = = = : 
• • 032 1775 aSiWOI PW « B1«SCe4 
H M ••• • • I 068 鄉 6 « 
• ^ • • • • • • 18S3 1C&01 PVH « A10eS199 
J I 027 1901 2a0S01 PWH A2 A22D3726 Jl • 02S 22S3 SaOOOl PW1 « AOflaO? 
P • 145 01MD0 01644 17)02101 PVH « 
n • 1S2 CHMBOOam 034D901 PfiW A [i B 115 OaiB011514 aM1«0 PhU « r M • m i33 01MB0CO42 12j01/D1 PMH A2 • • • 165 01MB0 05463 2li»01 PWH fl2 
010 3917 15/1000 PW « B3735B1 
f L H 208 p 消田 « 
"1 • • • • 102 OCMBO 09539 OlDSOO PWW A2 • IbIh 03D 110 05£rifl1 PVSH n ASOBSSaj 
• 画 • 203 P>NB1 « 
rHZZZZZ •• I 001 B?28e P^NW « 
, “ • •• • • • • •Ilii p 明田 « 
• • • • • • 040 12B7 100401 PW « B3932546 • • "B^ t^a • • 1 田 oiMSOoesra laoeoi pfcw AZ • • • • • mm • MM 奴 ZJOWM P 州 « B3Q216A 
ZZ^^ H H • • • I I I I I 039 1069 25D301 PV«  « B39MSZ7 
^ • • • • • 021 4704 10/1200 M ©8061725 
i I I I I M • • 016 4054 aWODO PWi « 0345 0068 L • • • • • • � oCfi 4297 OMI/OO P 州 « BS3W2S  
ri •画 I I H h ra 17B2 17CMH PWH « 4^367 0*8 
L • • • • • H IIIb 041 160 24WCI1 P 州 « 05896 SBA I ™ • • • • I OSB 281 W/11/01 PW1 « H0634249 • 2 082 B70T1 P ^NW « 
r j H • • M B H • 114 0CMe0113a8 27/100 0 PhU « 106 0CMB01O12r 17090 0 PMH « • • • • 彻 3878 laoaoo PVH A C40t4837 
ppj 一 * * * • 022 42BS 0M1fl� PW A2 H34S9 952 
H I • 129 OOilB013666 Q2iM«1 Pl*1 « • • I 217 « • 239 p VJ&t A • 02 3927 OB/JQCO PW « KM90a» • 213 P 糊 « L I 215 « I • 23B PW^  « • • • • 006 4433 27fl1/0 0 PWH K 82912^2 • § 095 B754 7 P 水 EH « 
iPl |B CFTO 畑 9 p 糊 AJ 
r CZZZ^I • 111 awBOira 1WW3 0 pm n 
• • 222 P^BI A 
r* 2Z P^eh « • • • •进 awsooawa ircaoo pm n • bI 060 1SB CWQ01 PYH A2 K3Z»2U 
J—* • • •• I • • • 062 «S2 P^EH A2 
M • • • • 095 awBO_ 1灣0 PhU « • • • • l ^ l OCM 4675 17/120� P州 KL A93279 pi n I I 054 1863 22J0SC1 PWH « £003180 
I • “ S \ 
nln 130 OlMBOOOOaB OMMfl 1 Pm K • • • • • • • • • • • 074 «!28 « • • OS  1812 10XJ901 P 州 « £0330759 fJ 一 • • _••• I 077 畑0 PVJBI « "1 I 1 •• in T-1 芯 兑 M mM (HB CKMB0e»4 16^80 0 PWH « I • • • m^^  I'm 103 (XMe0953B WXJ90 0 PMi « 
. m • • g J I • • • I o» 123 auyino PW « amsstoo A ~ • • • • • 09B MWBOCTOSO 2 2 j 0 7 « �« •H I • • 154 01MB0 03670 210301 « • • • • • OSB 2272 2«a01 PVV1 « £1603385 I • • • • • • 1CB OCMBOIBS :&09DO « 1 • • •画 Oe 67202 P^ ^ « 
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f) PFGE type F isolates 
Phage "Typing 
• • • • • • • • 1 4 9 0 1 M B 0 0 2 3 6 0 0 8 / 0 3 / 0 1 P M H B 
c) PFGE type C isolates 
Peasoncord^on 
PtiageTypng Phafle Typing 
o c n c N S & > o < b ih ^ Ih - W r- c b - n o r - ^ ^ w ^ S X Q 9 g a ocN«o»or-aocncr) loior-f^ -aacotDCD mm J ‘ if _ _ • _ • • • 220 PYNEH C 
i - • • • ••••圔•••_•• _ • 048 2 96 OSO測 PWH 
•醒 __• •霧 _ • 1�1 0_ 009496 0 209/00 PMH C 
d) PFGE type D isolates 
Peaistn cor del on 
Phafl«Typftig Phag6 T y p h g 
‘ ‘ H H • UU • 092 OOM曰 007244 06/07/00 PMH D1 I • • IhHhH I 166 01MB 006159 07/0&01 PMH D1 
• • ••趣 • • 017 3617 24/0細 PWH D1 
p- H • • • • • OIM曰 000502 22/01/01 PMH D1 
I • m m • • • m m i ^ o o i m b 000779 27/01/01 p m h d i L I • • • • • 053 965 01/0e/01 PWH D1 
I • • • H^ 161 01MB 004771 03/05/01 PMH DI 
• • • • • • • • • • • • • • • m 076 A8981 PYNEH D1 
• • g 160 01MB 004198 18/04/01 PMH DI 
e) PFGE type E isolates 
Pea ism ccird^tft 
PhagcTyphfl Ptiag» Typing 
S o 3 o 
• 丄 , • 甲 . , • H I 155 01 MB 002742 14/03/01 PMH E jH • • 2 3 � PYNEH E I m I 81 • HI MM B7611 PYNEH E 
• I I I m m 131 01 MB 000304 12/01/01 PMH E 
1 一 ! ! • • 152 01 MB 002655 14/03/01 PMH E 
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f) PFGE type F isolates 
PaBfscn corded on 
Pfi8«TVph8 Phage Typhg 
_ _ < _ _ . - . . Oj ；£ Q CT> CN c^  ov o < O -- ib - CN r«- to ^ « r- -- 3 • .尹• i o CN m m f^  00 « CO ifj r-» oS (p co CD <D oa en O) 
I • • • • 087 07264 PYNEH F I““I • • • • • 223 PYNEH F \ H Qj I I H B B 072 B7129 PYNEH F 
I • • • • • 071 A9212 PYNEH F 
I f i H 061 186 4 0 9 ^ 6 0 1 PWH F ^H 圔 229 PYNEH F 
• H I • • • • • 123 00MB 012624 04/1 沈0 P M H F 
I H H • • • 12 8 00MB 013462 29/12^)0 PMH F R T D 1000 
i H • • _ _ • • 036 929 UJ02J01 PWH F 
I I • • • • • 00 7 4646 20^200 PWH F 
- • • • 120 0(>/1B 011957 15/11XD0 PMH F 
I H 205 P YNEH F 
8 1 • fl 107 00MB 010235 02^0900 P M H F 
• • 227 P Y N E H F 
I 1 • • • 228 PYNEH F 
• 03 1 639 19A)201 PWH F R T D 1000 
「 fl 历2 125 8 31>03t)1 PWH F 
• 204 P Y N E H F 
• 224 P Y N E H F 
• 11 00 9 3934 09/100 0 PWH F 
I • m 136 01MB 000455 ^ 7 / 0 W ^ P M H F CZIZ^ ^ • |g 237 PYNEH F 
, BIB mmmm ••••«!••••••附• pwh f H • fil 231 PYNEH F 
" i m H H H • • 208 PYNEH F R T D 1000 
• • •••• Hill III 咖 16 06謂 1 PVWH F H • • • • • • • • • H I 09 7 0MB 008868 15^0800 PMH F ri • H MM _ 013 4343 16/11/00 PWH F 
I HI B • • 047 128 3 09 ^4^1 PWH F 
r l • • • B H H B 678 04)01 幻 1 PWH F 
• • • 134 01MB 000368 13幻 PMH F II • • • • "147 01MB 001797 21 幻201 PMH F 
L _ • 127 00MB 013272 22/1200 PMH F 
* 1 • H I B i W t M H 157 01MB 003931 12幻4/31 PMH F 
• • 225 P Y N E H F 
g) PFGE type G isolates 
Pearsm careldfon 
Phag•Typhg Phage T y p h g 
> _ Qj _ . 这 - - - - -
^ ‘ ‘ — ^ fi • H n 094 00MB 007466 KVOTjTO PMH G 
H S B I B H M U H 158 01M曰 004(^9 16^04^1 PMH G 
124 OOMB 012988 15^2伪 PMH G 
A 169 T-5 TKOH G 
J ~ | • 142 01MB 001162 08/02/01 PMH G 
• 146 01M曰 001645 20^02-01 PMH G 
r 163 01MB 005121 12/'05^)1 PMH G 
I 212 PYNEH G 
m • • • 116 0MB 011607 06/11 PMH G 
H B H 139 01MB 000640 22/01 >01 PMH G 
m m • 033 1 318 19/04^1 PWH G 日 2419152 r H • m 201 PYNEH G 
I • • • • mUll 圓•圔 090 B 7606 PYNEH G 
HIMfl 159 01MB 006911 25'06A)1 PMH G 
J——I mmm • • 麗_ 111 舰 八_ g [•'~I mmm • • o89 sim pyneh g 
126 00MB 013190 2CV12优 PMH G * _ • • • m 00 ‘  4341 25mj00 PWH G A0419853 
[ — I • I I I • • 002 4271 laniyOO PWH G A1132906 _•• • ••—•••M__ H 011 3554 11/09^00 PWH G B9671108 
059 968 29/04.01 PWH G H38711S2 1 • • •_ • ••画 078 A 9240 PYNEH G 
• • 119 00MB 011850 11/11XX3 PMH G RTD 1000 
• 238 PYNEH G 
• 234 PYNEH G 
• • • 091 B 7331 PYNEH G 
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f) PFGE type F isolates 
Pnrecn cordtfon 
ptiafl«TVphg Phage Typhg 
• . < . ^ . ^ _ - Qj. - tfif^m' ib" ‘ io 
m H I • • • • • • flfl 04 5 2284 18/06^)1 PWH H C0186056 
I I I 151 01MB 002660 13/03^)1 PMH H 
_ • I I • 043 2279 28/064D1 PWH H B7492648 
H n m • I I 150 OIM日 002577 15^03^1 PMH H 
\ mm • •••_• I 132 01M日 000333 15/01A)1 PMH H 
P • 國 • _ • • • • • • _ • • • _ • _ 4062 25/^0/00 PWH H GO 284156 
_ • H B B I B I I H • • 048 1301 15/04)01 PWH H C1188303 
I • I 153 01M日 002696 15/03^)1 PMH H 
i) PFGE type I isolates 
Poatwr coTdtfion 
Phag«Typho Phag» Typhfi 
g o a 8 s K I S S ^ ^ S "；： ffi ^  ^ s S fc i S S 5 S S 
’ • • • 仍 T-235 TKOH I 
H • 醒 • • • 176 T-252 TKOH I 
• 177 T-399 TKOH I 
Key: I Strong reaction ^ weak reaction y inhibtion 
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j) Reference strains  
Lytic group I H EI V 
29 52 52A 79 80 3A 3C 55 71 95 6 42E 47 53 54 75 77 83A 84 85 81 94 95 Sample 
I eMRSA 1 
eMRSA 2 
• • eMRSA 3 
I m ^ = 
藝 ’ eMRSA 6 
I n ^ M H eMRSA 7 
^ J j r j H eMRSA 8 
• eMRSA 9 
H eMRSA 10 
I m • m j f ^ H H eMRSA 11 
I m M F ' X J H eMRSA 12 
• H H ^ H l l l j j ^ H l ^ a H eMRSA 
eMRSA 14 
eMRSA 15 
I H _ J H I eMRSA 
m • s i r ^ _ B — 
^ H Iberian 
K ^ m • _ 
Paediatric 
Key: • Strong reaction _ weak reaction 國 inhibtion 
*done at RTD xlOOO 
The dendrograms (a) - (i) were drawn at UPGMA 
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Appendix VI (A6) 一 Typing Patterns and Characteristics 
of PFGE type isolates* 
1) PFGE type A & C isolates 
_PES WGEMO‘B soon., SEASE TSSr, 
I , s g I 
v：'.' (I'i'i l i i r I S • 
J ；'Mlill l i s 
^ I丨丨丨丨丨丨丨丨丨I'.i. i.lVi I I I -H III ill I I II I • • — Mill Ml. I I II . • • ^ HS 
I I I I _ • • 翻 • , amBBB � J 圜 S 
II I I II 11 IIII s n s 
- ^ E 丨 丨 I V . 丨 丨 丨 丨 丨 丨 丨 丨 丨 丨 二 丨 ! § = 
•⑴（ UVI!').'： 隱 S 
I I I I ' I i l l h ' M 靈 S 
II 'I ill i j i ' i I I a 
11 I E 
iiinii'； i i E 
IM•丨丨 ！：‘二丨！丨 l i i • 
I M j i I l l i 
/ Eg! “ = 
I 1 I I _ _ 醒 
i 冊 iiii' mi I I 1 
h r 丨 丨 ( V I丨丨 i i ^ i 
•d I, IN 1 i i i i I s ― • _ I 
- I f I i i : ” 
1!丨丨 I, lii :iK i -
k ! iV S i r . . ^ I 
4 ‘ h I P i 
^ i丨I丨丨丨 | |:i;?i丨 醒 • • 
P I , ！ ！ i i r i 
� _ H I I i l l 屬 I H _ 111 I I 11 | | i i 鹤 
m M M l i i I • 
fe I 1:1,11'lii t r • i 
： ^ iii'i liiI'lVl,'' f f ' I 
H ： 芸 I'M'' • 
I I I III I III II •醒鼸H細睡 snag 
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Appendix 
2) PFGE type B, D & E isolates 
PFGE (main) ^ sntLB SCCnn agr SEA-SEE 
PFGE ‘ 一 
I - gs 8 I 
… … j 'I "111 1(11! B I T I I B B 
^ i I _ s 
^ ~ ‘ I ‘ Si ^ mm _ wm • r rC i',' I II i a MM 5S . 
厂 W i l l i i i v l i i s 
r - ( — ^ I I 丨丨 im 1 = s 


































































































































































































f) PFGE type F isolates 
PF6E(fnBlQ)>an«8 PFGE PR5E(fn8irt»»artlB SCCmw agr S 
H LU ^ O K O Z ^ l ^ 5 K o O 
O o o v <-io6i>ifOOo<S ® ^ < 
\ 11 III, 11 丨 1,1,1 i n i p i i i i — i s ‘ 「 驪關 J 圓 s 
厂 I I I ij 11 1111 •麵鼸i醺减醒••翻IS wm r4— V I I i i i l l 棚 , • M _ 厂一 I I I III ••圔豔『，譯盼璽^ ：] wwm 
I I I 11 I I I 園匾•園画 mm mm � �I 丨丨 im 
r - r f 丨丨•丨 |丨 丨丨丨"Vli'i SS SIS ISKS S 3 I S 
— I J I i i i _ 卵教irilH•臛翻  I II I I 關趣關通 � I I I II II II •• | i i • • J I S 
r f c 1 1 : 1 ! , i l l i d S S 
� f H'' fliiii'f'i" l l i l i i I I I III III1111 ！i ' i i lfSiiS! S S 1 9 I— — ‘―t— I I I 丨丨丨丨 • 臛 i i 臞 M l t wm 
I , , ' 11 1 SNIS ^ H I S b s 
�~ ~ ^ 'I 1' , I (I IVi'i 鼸靈麗 = 
� ^ - c z j I I '1,1 ii 翻 1 翻 5 5 S 
厂 J " " “ I I I ••釅黼 
I—T I il III 5 � • 
J I II II I Ii nil ！屋«/『】！，• 
Lp 丨 I,丨丨丨 III 1,1' I'll SiJSS IihSS 錢 = 




B 二 s S o S 
r SEA-SE TSST+e SEG-SEJ Adhertis&toxlnB Ph^ e Typing X/1 口 Q X/1 Ph CX 
S 爱 t S S 民歪=g e I f ^ a a K g k ffi fc K U ffi s K ^ ^ s s s s s 
• • • m i l l HH • • •• • 120 00MB 011957 1311/00 PMH • HHH ^ H • • JH 134 01MB 000368 13/01/01 PMH HI WM • • • • • m ^ 136 01MB 0CM5 17AD1/01 PMH 
mm ^ H • • • • fl K b • 157 01MB 003931 12/0布01 PMH 
• • ^H • • K|H| ^UpB f^cjjjP • 013 4343 1 6/11/00 FWH 
• ^ m m m i ^ H I • fl H B ^ ^ H • 128 00MB 013462 2^12/00 PMH RTD 1000 
• ^H • • TB m 009 3934 0 9M(VQ0 FWH 
• • mill ^H I • • ^ipi _ • 071 A9212 FYNEH •Hm • • • • • 107 OMB 010235 0 2/0Si'00 PMH F 
• • • Pt'NEH 
• • H^H ^H • • on • mm • • •••[• 036 929 i4d3/oi fwh 
s I s l I I “ V ; ™ 
—mi ^H • • • • M M • • 123 OMB 012624 04/12/00 PMH S • ^^B • • • 031 639 19/02/01 PWH F RTD 100 
5 b s b I I I I •••醒 J B二 = ； 
• • 丨 ^ a mm H b | | H HB^I 097 ooMBoosaee 1508/00 pmh f S • •••n^^Hl ^HlhHl^HHHH 1768 19IOSm FWH ^H • 061 1864 0906/01 PWH S Hj S^S ^H • BB HI 2^7 OMB 013272 2 2/12/00 PMH F 
S • ^ ^ S • | | B | J k m 147 OIM日 001797 2 1 ^ 0 1 PMH S • ^^S I ^^m ^m • 1258 31/D3/01 FWH I_ ^^E • • • HHHI • • • HI 047 1283 0 904/01 FWH ^^S ^H • HH^^ |hI||H 049 678 04D1/Q1 FWH 
• . b I i t • H I h • 。 額 = H ； S • m^ m H • • m 231 FYNEH S • • • H 內neh 
• _ • • • 丨 a n • 228 FYNEH 
• ^ H H • • • 圔 226 FYNEH F 
S • ^ ^ ^ • Bj 224 FYNEH S • •mM Hjl H • • • I FYNEH 
= ^ ^ • i M I • 007 4646 2(yi2/00 PWH 
I 237 P^NEH F 
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Appendix 
f) PFGE type F isolates 
PFGE PFGE(n«"+anti"B SCCm*. agr SEA-SEE 
h-. m O O h- Q 3； 5 li. CE OT V. Q 
ooy 00009 00009 S. >_ jg <_> 
—^ ？ I I I) 111] I imiifis^iiii^i wmm mm “ 
_ _ H = I I I II I ril l 
I I I I 1111 III I • 驟 • 
~~CZ '1 mii iHii i i f l m 吻..s � 1' I IIIII I miMfl i i im mm m&M I ‘ II I I II III II I •••••••••剛 g^ H • i 
‘ I I I I I ••酬••丨丨• •••鄉痛 fH I I I I I I I I 11 • • � _ • • • • • : , I III III _ • • • • • • • _ � 
H I I I III III I • • 驅 • 國 S 1 
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f) PFGE type F isolates 
PFGE+Te-C 
PFGE^n£*t>+and-B PFGE P F G E ( m a i n ) + a i t i - B S C C a g - S E A - S E E 1 
… … nnmmm " 径 
"" ' " " ' "^ j - i II III nil _ • • • • • • • _ • 
pCZ I i mil 
~ , I i nil i___瑪••••••t豳國 
f - I I III IIII ! ! ! ! ! ! ! ! ! ! ! ^ l 9 
丨 II i i i n i i i i 




£E TSST SEG-SEJ Adiesins & toxins Phage Typing ^ O D jCJ 
rv d O PM U 
^ ^ ^ a I I s O S 
H H H I • I HHIj • 132 ^B 000333 "/01/01 PMH H 
^ ^ H ^ B I • 150 01 MB 002577 15/03/01 PMH H 
^ ^ H ^ H I I ^ 151 01MB 002660 1 3/03/01 PMH H 
^ ^ H ^ H • • I I I 153 01 MB 002696 15/03/01 PMH H 
^ ^ H ^ ^ • • • ril 。43 2279 28/06/01 PWH 
^ ^ H I H ^ n g r a • • 045 2284 18/06/01 PWH H 
H m ^ ^ B H l m " ^ m m H ^ H 048 1 301 15/04/01 PWH H 
i ^ B n ^ ^ H i p m ^ m K i m • oi8 4062 25/10/00 PWH H 
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f) PFGE type F isolates 
PFGE+Te-C 
PFGEOm*iHand-B PFGE PR5E(maiii)+anti-B SCC 
0606066660660 9 
H H J; I I I j I IIIIII i i i i i i i i i M••圓 




S 6 <i> . a 
^ « S S g 
s e e agr SEA-SEE TSS' SEG-SEJ Adhesins & toxins Phage Typing C W cS O kj 
h GO H-) P-^  
m I • • • • • 176 T-252 TKOH 1 
m m • I • _ _ 謹 I 177 T-399 TKOH I 
m I • _ I I 仍丁-235TK0H 1 
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7) PFGE unique pattern isolates 
PFGE PFGEOTiair^*anti-B ^ agr SEASEI TSST+a SEG-SEJ 
^ _ CD „ „ Q. H ra 
① X 
h - u j Q O h - D z S i i - i r w o o OOOOOOOOOOOOO ^ <r o W ff> _ I 
<Dd><D®<l>6®<D<D<fc<I><J>a> O) LU LU CO LU LU LU LU 
CO W CO h- W W W W 
11 I I I I IIIIIII ! ! ! ! ! ! ! ! ! ! ! ! 5  
I I I I III MM • • • • • • • • • • • • • S �S • • 
ill I II II IIIIII ! • ! • ! ! ! ! ! ! ! ! ! ? ! H _ • • • 
iiMii I ii II Hill ! ! ! ! ! ! ! ! ! ! ! ! ! LI H S S 9B 
I I I III II III B i i i i i i i i i i i i m m • n 
I III III I mill ! ! ! ! ! ! ! ! ! ! ! ! ! " — 





iSEJ AdheeSre&toxins Phage Typing ^ ^ P 
g ^ -
C/3 H-1 P ^ 
CO (0 < N i o l o r - c o c J i c o m r - o S c o - ^ t ^ l o i o r ^ h - o o c o c o c o o ^ 
• • • • • • • • • • H • • • 019 3725 07/10/00 PVVH 
• _ • 0功 20 02ClyD0 PVWH 
• • i • • mmm • • • _ • • mm 042 112 。&/0湖 
• • • 079 A9142 PYNEH 
• • _ _ _ • • _ 080 A9022 PYNEH 
• • • • B • 2 0 6 PWEH 
• B ffl H ffi • E H 207 PYNEH 
• • • • • • • • 國 • • • 2 1 9 PYNEH 
• • • • • • 221 PYNEH 
• • • 233 PYNEH 
• • • • • • • • • • 240 PYNEH 
Key 
PFGE(main)+anti-B SCCmec SEA-SEE, TSST-1, 
縱 type Phage typing 
二 antibiogram type SEG-SEJ, Adhesins&Toxins 
resistant 1 1 W j ^ P r e s e n c e of a gene 
Colour and intermediate 2 2 ^ H weak reaction 
implication susceptible _ 3 ^ J 3 H j Inhibition 
, 4 4 
*Cluster analysis by composite data of PFGE pattern and antibiogram (3: 1); 
dendrogram generated by UPGMA 
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